The O
fluoroquinolones B-GROUP
for O
urinary O
tract O
infections O
: O
a O
review O
. O
The O
fluoroquinolones B-GROUP
are O
a O
rapidly O
growing O
class O
of O
antibiotics B-GROUP
with O
a O
broad O
spectrum O
of O
activity O
against O
gram O
- O
negative O
and O
some O
gram O
- O
positive O
aerobic O
bacteria O
. O
These O
agents O
, O
including O
norfloxacin B-DRUG
, O
ciprofloxacin B-DRUG
, O
ofloxacin B-DRUG
, O
enoxacin B-DRUG
, O
and O
lomefloxacin B-DRUG
, O
have O
been O
extensively O
studied O
and O
have O
demonstrated O
efficacy O
and O
safety O
profiles O
comparable O
to O
those O
of O
other O
traditional O
agents O
for O
the O
treatment O
of O
complicated O
or O
uncomplicated O
urinary O
tract O
infections O
and O
prostatitis O
. O
Advantages O
offered O
by O
this O
class O
of O
antibiotics B-GROUP
include O
optimal O
pharmacokinetics O
, O
effectiveness O
against O
multidrug O
- O
resistant O
organisms O
, O
and O
oral O
administration O
even O
when O
parenteral O
antibiotics B-DRUG
are O
generally O
used O
. O
The O
fluoroquinolones B-GROUP
are O
also O
extensively O
used O
in O
urologic O
surgery O
. O

Progestin O
- O
only O
oral O
contraception O
: O
a O
comprehensive O
review O
. O
In O
order O
to O
provide O
information O
for O
the O
appropriate O
package O
insert O
labeling O
of O
progestin B-GROUP
- I-GROUP
only I-GROUP
oral I-GROUP
contraceptives I-GROUP
( O
POC B-GROUP
) O
in O
the O
US O
, O
a O
comprehensive O
review O
was O
made O
of O
norgestrel B-DRUG
( O
0 O
. O
075 O
mg O
) O
and O
norethindrone B-DRUG
( O
0 O
. O
35 O
mg O
) O
, O
with O
the O
clinical O
differences O
indicated O
where O
applicable O
. O
The O
goal O
of O
this O
review O
was O
to O
cite O
primary O
sources O
for O
virtually O
all O
research O
specific O
to O
POPs O
since O
1975 O
. O
Conclusions O
and O
the O
types O
of O
studies O
which O
support O
these O
conclusions O
are O
given O
for O
each O
major O
section O
. O
The O
introductory O
chapter O
discusses O
the O
advantages O
and O
disadvantages O
of O
POCs B-GROUP
and O
the O
magnitude O
and O
prevalence O
of O
their O
use O
. O
Future O
trends O
are O
also O
predicted O
. O
Chapter O
2 O
considers O
the O
mode O
of O
action O
, O
including O
ovulation O
prevention O
; O
suppression O
of O
midcycle O
gonadotropin O
peaks O
; O
changes O
in O
cervical O
mucus O
, O
the O
endometrium O
, O
and O
the O
fallopian O
tubes O
; O
and O
clinical O
implications O
. O
Chapter O
3 O
covers O
pharmacology O
( O
pharmacokinetics O
, O
pharmacodynamics O
and O
potency O
, O
and O
clinical O
implications O
) O
. O
The O
next O
chapter O
presents O
information O
on O
efficacy O
and O
pregnancy O
outcomes O
in O
terms O
of O
pregnancy O
rates O
, O
compliance O
and O
efficacy O
, O
ectopic O
pregnancies O
, O
the O
outcome O
of O
pregnancies O
conceived O
while O
using O
POCs B-GROUP
, O
and O
fertility O
following O
discontinuation O
. O
Chapter O
5 O
focuses O
on O
metabolic O
effects O
, O
specifically O
lipid O
metabolism O
, O
carbohydrate O
metabolism O
and O
diabetes O
, O
coagulation O
factors O
, O
and O
blood O
pressure O
. O
Cardiovascular O
disease O
is O
considered O
in O
the O
next O
chapter O
, O
and O
chapter O
7 O
presents O
findings O
on O
endometrial O
, O
ovarian O
, O
cervical O
, O
breast O
, O
and O
other O
cancers O
. O
A O
host O
of O
other O
medical O
considerations O
are O
discussed O
in O
chapter O
8 O
, O
including O
persistent O
ovarian O
follicles O
; O
reproductive O
tract O
infections O
; O
abnormal O
vaginal O
bleeding O
; O
uterine O
fibroids O
; O
gestational O
trophoblastic O
disease O
; O
benign O
breast O
disease O
; O
diseases O
of O
the O
liver O
, O
gallbladder O
, O
and O
bowel O
; O
endocrine O
dysfunction O
; O
epilepsy O
; O
bone O
density O
; O
sickle O
cell O
disease O
; O
ocular O
effects O
; O
surgery O
; O
and O
overdose O
. O
The O
last O
4 O
chapters O
cover O
interactions O
with O
drugs O
and O
laboratory O
tests O
, O
common O
side O
effects O
, O
breast O
feeding O
, O
and O
effective O
use O
of O
POCs B-GROUP
. O
Information O
on O
precautions O
and O
contraindications O
, O
indications O
, O
use O
instructions O
, O
and O
instructions O
for O
appropriate O
actions O
after O
missing O
a O
pill O
is O
appended O
. O

Antimicrobial O
activity O
of O
Ganoderma B-DRUG_N
lucidum I-DRUG_N
extract I-DRUG_N
alone O
and O
in O
combination O
with O
some O
antibiotics B-GROUP
. O
Antimicrobial O
activity O
of O
GL B-DRUG_N
( O
the O
aqueous O
extract O
from O
the O
carpophores O
of O
Ganoderma O
lucidum O
( O
FR O
) O
KARST O
) O
was O
tested O
in O
vitro O
against O
Gram O
positive O
and O
Gram O
negative O
bacteria O
by O
serial O
broth O
dilution O
method O
, O
and O
the O
antimicrobial O
activity O
was O
expressed O
by O
minimal O
inhibitory O
concentration O
( O
MIC O
) O
. O
Among O
fifteen O
species O
of O
bacteria O
tested O
, O
the O
antimicrobial O
activity O
of O
GL B-DRUG_N
was O
the O
most O
potent O
against O
Micrococcus O
luteus O
( O
MIC O
, O
0 O
. O
75 O
mg O
/ O
ml O
) O
. O
To O
investigate O
the O
effects O
of O
antimicrobial O
combinations O
of O
GL B-DRUG_N
with O
four O
kinds O
of O
antibiotics B-GROUP
( O
ampicillin B-DRUG
, O
cefazolin B-DRUG
, O
oxytetracycline B-DRUG
and O
chloramphenicol B-DRUG
) O
, O
the O
fractional O
inhibitory O
concentration O
index O
( O
FICI O
) O
was O
determined O
by O
checkerboard O
assay O
for O
each O
strain O
. O
The O
antimicrobial O
combinations O
of O
GL B-DRUG_N
with O
four O
antibiotics B-GROUP
resulted O
in O
additive O
effect O
in O
most O
instances O
, O
synergism O
in O
two O
instances O
, O
and O
antagonism O
in O
two O
instances O
. O
Synergism O
was O
observed O
when O
GL B-DRUG_N
was O
combined O
with O
cefazolin B-DRUG
against O
Bacillus O
subtilis O
and O
Klebsiella O
oxytoca O
. O

Death O
in O
amphetamine B-DRUG
users O
: O
causes O
and O
rates O
. O
The O
world O
medical O
literature O
contains O
43 O
reports O
of O
deaths O
associated O
with O
amphetamines B-DRUG
in O
a O
35 O
- O
year O
period O
. O
These O
included O
seven O
cerebrovascular O
accidents O
, O
six O
sudden O
cardiac O
deaths O
, O
three O
cases O
of O
hyperpyrexia O
, O
eight O
poisonings O
of O
uncertain O
mechanism O
and O
seven O
cases O
of O
medical O
complications O
of O
intravenous O
injection O
; O
the O
remainder O
were O
of O
uncertain O
cause O
. O
In O
contrast O
, O
in O
Ontario O
alone O
, O
in O
1972 O
and O
1973 O
there O
were O
26 O
deaths O
in O
amphetamine B-DRUG
users O
, O
of O
which O
16 O
were O
due O
to O
accident O
suicide O
or O
homicide O
. O
Of O
the O
remaining O
cases O
, O
two O
were O
cardiac O
, O
two O
hepatic O
and O
the O
rest O
were O
mixed O
drug O
overdose O
. O
Pulmonary O
granulomata O
, O
subacute O
hepatitis O
and O
other O
lesions O
resulting O
from O
intravenous O
drug O
use O
were O
common O
findings O
at O
autopsy O
. O
On O
the O
basis O
of O
the O
estimated O
number O
of O
regular O
users O
of O
intravenous O
amphetamine B-DRUG
in O
Ontario O
, O
the O
mortality O
rate O
in O
such O
users O
is O
at O
least O
four O
times O
as O
high O
as O
in O
the O
general O
population O
of O
the O
same O
age O
, O
and O
is O
comparable O
to O
that O
in O
alcoholics O
and O
heroin B-DRUG_N
addicts O
. O
However O
, O
the O
absolute O
number O
of O
alcohol B-DRUG
- O
related O
deaths O
is O
far O
greater O
than O
the O
number O
of O
deaths O
in O
amphetamine B-DRUG
or O
heroin B-DRUG_N
users O
. O

Ascorbic B-DRUG
acid I-DRUG
and O
the O
common O
cold O
. O
Evaluation O
of O
its O
efficacy O
and O
toxicity O
. O
We O
reviewed O
the O
clinical O
data O
relating O
to O
the O
efficacy O
and O
safety O
of O
pharmacologic O
doses O
of O
ascorbic B-DRUG
acid I-DRUG
in O
the O
prevention O
and O
treatment O
of O
the O
common O
cold O
. O
Although O
one O
study O
tentatively O
supports O
the O
hypothesis O
that O
such O
doses O
of O
ascorbic B-DRUG
acid I-DRUG
may O
be O
efficacious O
, O
a O
second O
study O
by O
the O
same O
group O
did O
not O
confirm O
the O
significant O
findings O
, O
and O
no O
clear O
, O
reproducible O
pattern O
of O
efficacy O
has O
emerged O
from O
the O
review O
of O
all O
the O
evidence O
. O
Similarly O
, O
there O
is O
currently O
little O
adequate O
evidence O
on O
either O
the O
presence O
or O
the O
absence O
of O
serious O
adverse O
reactions O
to O
such O
doses O
of O
ascorbic B-DRUG
acid I-DRUG
, O
although O
many O
such O
reactions O
have O
been O
hypothesized O
. O
The O
unrestricted O
use O
of O
ascorbic B-DRUG
acid I-DRUG
for O
these O
purposes O
cannot O
be O
advocated O
on O
the O
basis O
of O
the O
evidence O
currently O
available O
. O

Optimal O
designs O
for O
the O
individual O
and O
joint O
exposure O
general O
logistic O
regression O
models O
. O
Interest O
in O
administering O
compounds O
in O
combination O
lies O
both O
in O
enhancing O
efficacious O
effects O
and O
in O
limiting O
adverse O
effects O
. O
Although O
much O
statistical O
work O
has O
focused O
on O
developing O
mathematical O
functions O
to O
model O
the O
joint O
dose O
- O
response O
curves O
, O
relatively O
little O
work O
exists O
in O
regard O
to O
designing O
experiments O
for O
assessing O
joint O
action O
. O
A O
variety O
of O
parametric O
dose O
- O
response O
models O
based O
on O
either O
the O
normal O
or O
logistic O
probability O
distribution O
have O
been O
proposed O
in O
the O
literature O
. O
These O
models O
are O
typically O
nonlinear O
in O
the O
parameters O
, O
and O
as O
such O
, O
a O
nonlinear O
weighted O
least O
squares O
approach O
can O
be O
employed O
for O
the O
purpose O
of O
designing O
experiments O
. O
The O
approach O
is O
applicable O
across O
a O
wide O
variety O
of O
settings O
commonly O
associated O
with O
joint O
action O
data O
, O
including O
continuous O
and O
discrete O
responses O
, O
alternative O
error O
structures O
, O
and O
nonzero O
background O
response O
. O
Further O
, O
designs O
can O
be O
expressed O
in O
terms O
of O
proportionate O
responses O
associated O
with O
the O
individual O
compounds O
rather O
than O
dose O
levels O
, O
thereby O
providing O
for O
results O
that O
are O
applicable O
across O
compounds O
. O
As O
a O
precursor O
to O
this O
effort O
, O
optimal O
and O
minimal O
experimental O
designs O
for O
the O
case O
in O
which O
a O
single O
compound O
is O
administered O
have O
also O
been O
developed O
. O
Although O
the O
proposed O
methodology O
for O
deriving O
experimental O
designs O
can O
be O
applied O
to O
any O
nonlinear O
regression O
model O
, O
primary O
focus O
is O
given O
to O
the O
additive O
and O
nonadditive O
independent O
joint O
action O
( O
IJA O
) O
models O
for O
individual O
and O
combined O
exposures O
proposed O
by O
Barton O
, O
Braunberg O
, O
and O
Friedman O
( O
1 O
) O
. O

Differential O
regulation O
of O
tyrosine O
phosphorylation O
in O
tumor O
cells O
by O
contortrostatin B-DRUG_N
, O
a O
homodimeric O
disintegrin O
, O
and O
monomeric O
disintegrins O
echistatin B-DRUG_N
and O
flavoridin B-DRUG_N
. O
The O
homodimeric O
disintegrin O
contortrostatin B-DRUG_N
was O
compared O
directly O
to O
the O
monomeric O
disintegrins O
echistatin B-DRUG_N
and O
flavoridin B-DRUG_N
for O
the O
ability O
to O
affect O
protein O
tyrosine O
phosphorylation O
in O
tumor O
cells O
. O
It O
was O
observed O
that O
contortrostatin B-DRUG_N
had O
a O
dramatic O
effect O
on O
the O
tyrosine O
phosphorylation O
status O
of O
several O
proteins O
in O
T24 O
human O
bladder O
cancer O
cells O
, O
including O
robust O
induction O
of O
phosphorylation O
of O
proteins O
in O
the O
range O
of O
120 O
- O
140 O
kDa O
. O
Echistatin B-DRUG_N
alone O
had O
no O
effect O
on O
tyrosine O
phosphorylation O
in O
T24 O
cells O
, O
but O
dose O
- O
dependently O
inhibits O
the O
effects O
of O
contortrostatin B-DRUG_N
when O
both O
are O
added O
simultaneously O
. O
Among O
the O
proteins O
that O
undergo O
tyrosine O
phosphorylation O
in O
response O
to O
contortrostatin B-DRUG_N
treatment O
is O
CAS O
, O
a O
130 O
kDa O
adapter O
protein O
involved O
in O
integrin O
signaling O
. O
Flavoridin B-DRUG_N
alone O
was O
found O
to O
have O
no O
effect O
on O
CAS O
, O
but O
can O
completely O
block O
contortrostatin B-DRUG_N
- O
induced O
phosphorylation O
of O
this O
protein O
in O
MDA O
- O
MB O
- O
435 O
cells O
. O
These O
observations O
strongly O
suggest O
that O
the O
homodimeric O
structure O
of O
contortrostatin B-DRUG_N
functionally O
distinguishes O
it O
from O
other O
monomeric O
members O
of O
the O
disintegrin O
family O
. O

Modification O
of O
surface O
histidine O
residues O
abolishes O
the O
cytotoxic O
activity O
of O
Clostridium B-DRUG_N
difficile I-DRUG_N
toxin I-DRUG_N
A I-DRUG_N
. O
Clostridium B-DRUG_N
difficile I-DRUG_N
toxin I-DRUG_N
A I-DRUG_N
displays O
both O
cytotoxic O
and O
enterotoxic O
activities O
. O
It O
has O
recently O
been O
demonstrated O
that O
toxin B-DRUG_N
A I-DRUG_N
exerts O
its O
cytotoxic O
effect O
by O
the O
glucosylation O
of O
the O
small O
GTP O
- O
binding O
proteins O
of O
the O
Rho O
family O
. O
Diethyl B-DRUG_N
pyrocarbonate I-DRUG_N
, O
at O
pH O
7 O
. O
0 O
, O
was O
used O
to O
chemically O
modify O
exposed O
histidine O
residues O
on O
toxin B-DRUG_N
A I-DRUG_N
. O
Modification O
of O
toxin B-DRUG_N
A I-DRUG_N
with O
diethyl B-DRUG_N
pyrocarbonate I-DRUG_N
abolished O
both O
its O
cytotoxic O
activity O
and O
the O
ability O
of O
the O
toxin O
to O
bind O
Zn O
- O
Sepharose O
gel O
. O
Treatment O
of O
toxin B-DRUG_N
A I-DRUG_N
with O
[ O
( O
14 O
) O
C O
] O
- O
diethyl B-DRUG_N
pyrocarbonate I-DRUG_N
revealed O
concentration O
dependent O
labelling O
of O
histidine O
residues O
on O
the O
toxin O
molecules O
. O
The O
effects O
of O
diethyl B-DRUG_N
pyrocarbonate I-DRUG_N
could O
be O
reversed O
by O
hydroxylamine B-DRUG_N
treatment O
. O
These O
data O
suggest O
the O
modified O
histidine O
residues O
on O
toxin B-DRUG_N
A I-DRUG_N
are O
critical O
to O
its O
cytotoxic O
activity O
. O
Histidine O
modification O
had O
no O
effect O
on O
the O
glucosyl O
transferase O
enzyme O
activity O
of O
toxin B-DRUG_N
A I-DRUG_N
. O
However O
, O
modification O
abolished O
the O
' O
cold O
' O
binding O
of O
toxin O
to O
bovine O
thyroglobulin O
in O
an O
ELISA O
and O
reduced O
ligand O
binding O
activity O
in O
a O
rabbit O
erythrocyte O
haemagglutination O
assay O
. O
The O
data O
suggest O
that O
the O
histidine O
residues O
may O
be O
crucial O
to O
the O
receptor O
- O
binding O
activity O
of O
toxin B-DRUG_N
A I-DRUG_N
. O
Exposed O
histidines O
on O
toxin B-DRUG_N
A I-DRUG_N
are O
available O
for O
zinc B-DRUG
chelation O
, O
and O
these O
have O
been O
exploited O
in O
the O
development O
of O
a O
novel O
purification O
protocol O
for O
toxin B-DRUG_N
A I-DRUG_N
using O
zinc B-DRUG
- O
chelating O
chromatography O
. O

Note O
: O
dissolution O
of O
aerosol O
particles O
of O
budesonide B-DRUG
in O
Survanta B-BRAND
, O
a O
model O
lung B-GROUP
surfactant I-GROUP
. O
The O
effect O
of O
a O
pulmonary B-GROUP
surfactant I-GROUP
extract O
from O
bovine O
lung O
, O
Survanta B-BRAND
, O
on O
the O
dissolution O
rate O
of O
aerosol O
particles O
of O
budesonide B-DRUG
was O
determined O
. O
Aerosol O
particles O
of O
budesonide B-DRUG
were O
generated O
from O
an O
ethanol B-DRUG
solution O
, O
dried O
, O
and O
collected O
by O
a O
cascade O
impactor O
for O
characterization O
or O
by O
a O
liquid O
impinger O
for O
dissolution O
experiments O
. O
Powder O
x O
- O
ray O
diffraction O
, O
differential O
scanning O
calorimetry O
, O
differential O
thermal O
analysis O
, O
and O
scanning O
electron O
microscopy O
were O
used O
to O
characterize O
the O
aerosol O
particles O
and O
starting O
material O
. O
No O
change O
in O
phase O
was O
detected O
, O
although O
the O
aerosol O
particles O
appeared O
to O
contain O
residual O
solvent B-GROUP
. O
The O
dissolution O
rate O
of O
the O
aerosol O
particles O
in O
saline O
was O
low O
and O
variable O
. O
Survanta B-BRAND
increased O
the O
extent O
of O
dissolution O
of O
budesonide B-DRUG
in O
proportion O
to O
the O
added O
concentration O
, O
which O
was O
also O
verified O
by O
equilibrium O
solubilization O
studies O
. O
Survanta B-BRAND
also O
increased O
rate O
of O
dissolution O
, O
in O
a O
manner O
similar O
to O
sodium B-DRUG_N
dodecyl I-DRUG_N
sulfate I-DRUG_N
. O
Analysis O
of O
the O
concentration O
of O
budesonide B-DRUG
following O
ultracentrifugation O
indicated O
that O
there O
is O
rapid O
equilibration O
of O
budesonide B-DRUG
between O
the O
Survanta B-BRAND
and O
aqueous O
phase O
. O
These O
results O
show O
that O
lung B-GROUP
surfactant I-GROUP
has O
the O
potential O
of O
enhancing O
the O
rate O
and O
extent O
of O
dissolution O
of O
drugs O
administered O
to O
the O
lung O
. O

Activation O
of O
an O
effector O
immediate O
- O
early O
gene O
arc O
by O
methamphetamine B-DRUG
. O
As O
immediate O
- O
early O
genes O
( O
IEGs O
) O
are O
thought O
to O
play O
a O
critical O
role O
in O
mediating O
stimulus O
- O
induced O
neural O
plasticity O
, O
IEG O
response O
induced O
by O
methamphetamine B-DRUG
( O
METH B-DRUG
) O
has O
been O
characterized O
to O
define O
the O
changes O
in O
gene O
expression O
that O
may O
underlie O
its O
long O
- O
lasting O
behavioral O
effects O
. O
Although O
activation O
of O
several O
transcription O
factor O
IEGs O
has O
been O
described O
, O
little O
is O
known O
about O
effector O
IEGs O
. O
Here O
, O
we O
have O
examined O
whether O
METH B-DRUG
administration O
affects O
expression O
of O
an O
effector O
IEG O
arc O
( O
activity O
- O
regulated O
, O
cytoskeleton O
- O
associated O
) O
that O
encodes O
a O
protein O
with O
homology O
to O
spectrin O
. O
Using O
in O
situ O
hybridization O
, O
we O
observed O
that O
METH B-DRUG
caused O
a O
rapid O
and O
transient O
dose O
- O
dependent O
increase O
in O
arc O
mRNA O
level O
in O
the O
striatum O
and O
cortex O
that O
was O
abolished O
by O
pretreatment O
with O
the O
specific O
dopamine O
D1 O
receptor O
antagonist O
SCH B-DRUG_N
- I-DRUG_N
23390 I-DRUG_N
but O
not O
by O
an O
atypical B-GROUP
neuroleptic I-GROUP
clozapine B-DRUG
. O
METH B-DRUG
induced O
arc O
mRNA O
in O
layers O
IV O
and O
VI O
of O
the O
cortex O
which O
dopamine O
receptor O
are O
localized O
to O
. O
These O
results O
suggest O
that O
D1 O
receptors O
are O
coupled O
to O
activation O
of O
arc O
gene O
, O
which O
may O
be O
involved O
in O
functional O
or O
structural O
alterations O
underlying O
neural O
plasticity O
triggered O
by O
METH B-DRUG
. O

The O
effects O
of O
DCG B-DRUG_N
- I-DRUG_N
IV I-DRUG_N
and O
L B-DRUG_N
- I-DRUG_N
CCG I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
upon O
phencyclidine B-DRUG_N
( O
PCP B-DRUG_N
) O
- O
induced O
locomotion O
and O
behavioral O
changes O
in O
mice O
. O
The O
behavioral O
changes O
of O
mice O
induced O
by O
acute O
and O
repeated O
i O
. O
p O
. O
injection O
of O
phencyclidine B-DRUG_N
( O
PCP B-DRUG_N
) O
were O
observed O
by O
measuring O
locomotor O
activity O
and O
stereotyped O
behavior O
. O
Then O
, O
the O
effects O
of O
metabotropic O
glutamate O
receptor O
( O
mGluR O
) O
agonists O
, O
DCG B-DRUG_N
- I-DRUG_N
IV I-DRUG_N
and O
L B-DRUG_N
- I-DRUG_N
CCG I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, O
on O
the O
above O
behavioral O
changes O
induced O
by O
PCP B-DRUG_N
were O
found O
. O
The O
effects O
of O
DCG B-DRUG_N
- I-DRUG_N
IV I-DRUG_N
were O
very O
strong O
and O
completely O
depressed O
the O
PCP B-DRUG_N
- O
induced O
hyperlocomotion O
. O
The O
effects O
of O
L B-DRUG_N
- I-DRUG_N
CCG I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
were O
not O
so O
strong O
. O
Repeated O
injection O
of O
PCP B-DRUG_N
for O
20 O
days O
into O
mice O
induced O
lower O
locomotor O
activity O
than O
that O
in O
acutely O
injected O
mice O
. O
These O
behavioral O
changes O
may O
be O
related O
with O
the O
negative O
symptoms O
of O
schizophrenia O
. O
In O
order O
to O
examine O
some O
molecular O
mechanisms O
of O
PCP B-DRUG_N
- O
induced O
behavioral O
changes O
, O
Northern O
blot O
analysis O
of O
total O
RNA O
from O
prefrontal O
cortical O
tissues O
of O
mice O
treated O
with O
PCP B-DRUG_N
, O
DCG B-DRUG_N
- I-DRUG_N
IV I-DRUG_N
, O
and O
L B-DRUG_N
- I-DRUG_N
CCG I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
was O
carried O
out O
. O

Behavioral O
responses O
to O
repeated O
cocaine B-DRUG
exposure O
in O
mice O
selectively O
bred O
for O
differential O
sensitivity O
to O
pentobarbital B-DRUG
. O
Mice O
from O
the O
20th O
generation O
of O
three O
lines O
divergently O
selected O
for O
response O
to O
pentobarbital B-DRUG
- O
induced O
sedation O
times O
[ O
long O
- O
sedation O
time O
( O
LST O
) O
, O
short O
sedation O
time O
( O
SST O
) O
, O
and O
randomly O
bred O
control O
( O
RBC O
) O
] O
were O
used O
to O
study O
cocaine B-DRUG
- O
induced O
behavioral O
sensitization O
. O
These O
lines O
showed O
variable O
degrees O
of O
locomotor O
activities O
in O
response O
to O
cocaine B-DRUG
. O
At O
a O
low O
cocaine B-DRUG
dose O
and O
long O
withdrawal O
period O
( O
10 O
mg O
/ O
kg O
, O
twice O
a O
day O
for O
5 O
days O
followed O
by O
a O
14 O
- O
day O
withdrawal O
) O
, O
the O
LST O
mice O
showed O
tolerance O
development O
. O
In O
response O
to O
cocaine B-DRUG
, O
the O
locomotor O
activities O
of O
the O
SST O
were O
not O
significantly O
different O
from O
the O
RBC O
group O
. O
At O
a O
higher O
dose O
and O
a O
shorter O
withdrawal O
period O
( O
20 O
mg O
/ O
kg O
, O
daily O
for O
7 O
days O
followed O
by O
a O
3 O
- O
day O
withdrawal O
) O
, O
the O
SST O
mice O
showed O
behavioral O
sensitization O
similar O
to O
the O
RBC O
mice O
, O
but O
the O
LST O
mice O
did O
not O
develop O
sensitization O
. O
The O
different O
responses O
in O
locomotor O
activity O
induced O
by O
cocaine B-DRUG
suggest O
that O
genetic O
factors O
may O
play O
a O
role O
in O
determining O
the O
magnitude O
of O
response O
to O
this O
drug O
. O
Dopamine O
( O
DA O
) O
levels O
did O
not O
differ O
significantly O
in O
either O
striatum O
( O
STR O
) O
or O
nucleus O
accumbens O
( O
NAC O
) O
for O
the O
cocaine B-DRUG
- O
treated O
animals O
to O
their O
corresponding O
saline O
- O
treated O
controls O
. O
The O
affinity O
( O
Kd O
) O
of O
D2 O
in O
the O
NAC O
decreased O
significantly O
, O
without O
changes O
in O
density O
( O
Bmax O
) O
, O
in O
the O
cocaine B-DRUG
- O
treated O
SST O
and O
RBC O
mice O
. O
On O
the O
other O
hand O
, O
the O
density O
of O
D2 O
binding O
sites O
in O
the O
SST O
and O
the O
RBC O
mice O
in O
the O
STR O
was O
significantly O
increased O
in O
cocaine B-DRUG
- O
treated O
groups O
without O
change O
in O
Kd O
. O
The O
LST O
mice O
did O
not O
show O
any O
changes O
in O
the O
Kd O
and O
Bmax O
in O
either O
the O
STR O
or O
the O
NAC O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
the O
changes O
in O
the O
Kd O
of O
D2 O
in O
the O
NAC O
and O
the O
Bmax O
of O
D2 O
in O
the O
STR O
may O
contribute O
to O
the O
differences O
in O
locomotor O
responses O
to O
cocaine B-DRUG
exposure O
in O
these O
mouse O
lines O
. O

18 B-DRUG_N
- I-DRUG_N
Methoxycoronaridine I-DRUG_N
( O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
) O
and O
ibogaine B-DRUG_N
: O
comparison O
of O
antiaddictive O
efficacy O
, O
toxicity O
, O
and O
mechanisms O
of O
action O
. O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
, O
a O
novel O
iboga O
alkaloid O
congener O
, O
is O
being O
developed O
as O
a O
potential O
treatment O
for O
multiple O
forms O
of O
drug O
abuse O
. O
Like O
ibogaine B-DRUG_N
( O
40 O
mg O
/ O
kg O
) O
, O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
( O
40 O
mg O
/ O
kg O
) O
decreases O
the O
intravenous O
self O
- O
administration O
of O
morphine B-DRUG
and O
cocaine B-DRUG
and O
the O
oral O
self O
- O
administration O
of O
ethanol B-DRUG
and O
nicotine B-DRUG
in O
rats O
; O
unlike O
ibogaine B-DRUG_N
, O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
does O
not O
affect O
responding O
for O
a O
nondrug O
reinforcer O
( O
water O
) O
. O
Both O
ibogaine B-DRUG_N
and O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
ameliorate O
opioid B-GROUP
withdrawal O
signs O
. O
Both O
ibogaine B-DRUG_N
and O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
decrease O
extracellular O
levels O
of O
dopamine O
in O
the O
nucleus O
accumbens O
, O
but O
only O
ibogaine B-DRUG_N
increases O
extracellular O
levels O
of O
serotonin O
in O
the O
nucleus O
accumbens O
. O
Both O
ibogaine B-DRUG_N
and O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
block O
morphine B-DRUG
- O
induced O
and O
nicotine B-DRUG
- O
induced O
dopamine O
release O
in O
the O
nucleus O
accumbens O
; O
only O
ibogaine B-DRUG_N
enhances O
cocaine B-DRUG
- O
induced O
increases O
in O
accumbal O
dopamine O
. O
Both O
ibogaine B-DRUG_N
and O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
enhance O
the O
locomotor O
and O
/ O
or O
stereotypic O
effects O
of O
stimulants O
. O
Ibogaine B-DRUG_N
attenuates O
, O
but O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
potentiates O
, O
the O
acute O
locomotor O
effects O
of O
morphine B-DRUG
; O
both O
compounds O
attenuate O
morphine B-DRUG
- O
induced O
locomotion O
in O
morphine B-DRUG
- O
experienced O
rats O
. O
Ibogaine B-DRUG_N
produces O
whole O
body O
tremors O
and O
, O
at O
high O
doses O
( O
> O
or O
= O
100 O
mg O
/ O
kg O
) O
, O
cerebellar O
damage O
; O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
does O
not O
produce O
these O
effects O
. O
Ibogaine B-DRUG_N
, O
but O
not O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
, O
decreases O
heart O
rate O
at O
high O
doses O
. O
While O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
and O
ibogaine B-DRUG_N
have O
similar O
affinities O
for O
kappa O
opioid O
and O
possibly O
nicotinic O
receptors O
, O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
has O
much O
lower O
affinities O
than O
ibogaine B-DRUG_N
for O
NMDA O
and O
sigma O
- O
2 O
receptors O
, O
sodium O
channels O
, O
and O
the O
5 O
- O
HT O
transporter O
. O
Both O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
and O
ibogaine B-DRUG_N
are O
sequestered O
in O
fat O
and O
, O
like O
ibogaine B-DRUG_N
, O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
probably O
has O
an O
active O
metabolite O
. O
The O
data O
suggest O
that O
18 B-DRUG_N
- I-DRUG_N
MC I-DRUG_N
has O
a O
narrower O
spectrum O
of O

actions O
and O
will O
have O
a O
substantially O
greater O
therapeutic O
index O
than O
ibogaine B-DRUG_N
. O

Clinical O
implications O
of O
warfarin B-DRUG
interactions O
with O
five O
sedatives B-GROUP
. O
The O
intensity O
, O
uniformity O
and O
time O
course O
of O
anticoagulant B-GROUP
interference O
by O
phenobarbital B-DRUG
, O
secobarbital B-DRUG
, O
glutethimide B-DRUG
, O
chloral B-DRUG
hydrate I-DRUG
and O
methaqualone B-DRUG
were O
systematically O
investigated O
in O
16 O
patients O
receiving O
coumarin B-GROUP
therapy O
. O
Each O
subject O
received O
an O
individualized O
fixed O
daily O
dose O
of O
warfarin B-DRUG
and O
served O
as O
his O
own O
pre O
- O
and O
postsedative O
treatment O
control O
. O
Prothrombin O
times O
were O
measured O
four O
times O
weekly O
during O
five O
long O
- O
term O
experiments O
. O
Anticoagulant O
inhibition O
was O
observed O
during O
the O
administration O
of O
phenobarbital B-DRUG
, O
secobarbital B-DRUG
and O
glutethimide B-DRUG
; O
there O
was O
no O
significant O
change O
in O
prothrombin O
test O
results O
during O
the O
trials O
of O
chloral B-DRUG
hydrate I-DRUG
and O
methaqualone B-DRUG
. O
Barbiturates B-GROUP
and O
glutethimide B-DRUG
should O
not O
be O
administered O
to O
patients O
receiving O
coumarin B-GROUP
drugs I-GROUP
. O
The O
concurrent O
use O
of O
drugs O
from O
these O
groups O
is O
decreasing O
according O
to O
a O
survey O
of O
200 O
hospital O
medical O
records O
. O
Chloral B-DRUG
hydrate I-DRUG
and O
methaqualone B-DRUG
interact O
pharmacologically O
with O
orally O
administered O
anticoagulant B-GROUP
agents I-GROUP
, O
but O
the O
effect O
is O
not O
clinically O
significant O
. O
It O
is O
concluded O
that O
chloral B-DRUG
hydrate I-DRUG
and O
methaqualone B-DRUG
may O
be O
administered O
safely O
without O
additional O
caution O
in O
prothrombin O
test O
monitoring O
during O
oral O
anticoagulant B-GROUP
therapy O
. O

Effects O
of O
low O
temperatures O
on O
microtubules O
in O
the O
non O
- O
myelinated O
axons O
of O
post O
- O
ganglionic O
sympathetic O
nerves O
. O
The O
effect O
of O
temperature O
changes O
on O
the O
number O
of O
microtubules O
in O
non O
- O
myelinated O
axons O
has O
been O
studied O
in O
cat O
inferior O
mesenteric O
ganglion O
/ O
hypogastric O
nerve O
preparations O
incubated O
at O
various O
temperatures O
in O
Eagles O
minimal O
essential O
tissue O
culture O
medium O
in O
vitro O
. O
At O
37 O
degrees O
C O
the O
non O
- O
myelinated O
axons O
contained O
28 O
. O
4 O
plus O
or O
minus O
0 O
. O
8 O
S O
. O
E O
. O
M O
. O
( O
54 O
) O
microtubules O
per O
axon O
. O
After O
incubation O
at O
0 O
degrees O
C O
for O
4 O
h O
this O
number O
fell O
to O
2 O
. O
3 O
plus O
or O
minus O
0 O
. O
1 O
S O
. O
E O
. O
M O
. O
( O
41 O
) O
but O
returned O
to O
normal O
levels O
when O
the O
nerves O
were O
rewarmed O
. O
This O
loss O
of O
microtubules O
on O
cooling O
the O
nerves O
and O
their O
reappearance O
on O
rewarming O
was O
a O
rapid O
process O
; O
it O
was O
independent O
of O
the O
influence O
of O
the O
nueronal O
cell O
body O
and O
of O
protein O
synthesis O
within O
the O
axon O
. O
The O
preservation O
of O
the O
microtubules O
was O
improved O
when O
D2O O
was O
present O
in O
the O
incubation O
medium O
. O
Reformed O
microtubules O
appeared O
to O
function O
normally O
with O
respect O
to O
their O
possible O
role O
in O
the O
transport O
of O
noradrenaline O
storage O
vesicles O
along O
the O
axons O
. O

Serum O
digoxin B-DRUG
levels O
using O
an O
125I O
- O
labelled O
antigen O
: O
Validation O
of O
method O
and O
observations O
on O
cardiac O
patients O
. O
1 O
. O
Determinations O
of O
serum O
digoxin B-DRUG
levels O
utilizing O
commercially O
available O
kits O
with O
an O
125I O
- O
labelled O
antigen O
were O
precise O
and O
not O
materially O
different O
from O
results O
obtained O
with O
a O
3H O
- O
labelled O
antigen O
. O
2 O
. O
In O
order O
to O
approximate O
the O
steady O
state O
level O
, O
serum O
digoxin B-DRUG
levels O
should O
be O
drawn O
either O
before O
or O
at O
least O
six O
hours O
following O
the O
administration O
of O
an O
oral O
tablet O
. O
3 O
. O
Concomitantly O
given O
thiazide B-GROUP
diuretics I-GROUP
did O
not O
interfere O
with O
the O
absorption O
of O
a O
tablet O
of O
digoxin B-DRUG
. O
4 O
. O
In O
the O
digitalized O
patient O
, O
slow O
alterations O
in O
serum O
levels O
after O
oral O
administration O
appeared O
well O
correlated O
with O
, O
at O
least O
, O
the O
negative O
chronotropic O
effects O
of O
the O
drug O
. O
5 O
. O
Maximal O
exercise O
testing O
, O
a O
maneuver O
often O
applied O
to O
cardiac O
patients O
, O
does O
not O
significantly O
alter O
the O
serum O
digoxin B-DRUG
level O
. O

Combinations O
of O
clozapine B-DRUG
and O
phencyclidine B-DRUG_N
: O
effects O
on O
drug O
discrimination O
and O
behavioral O
inhibition O
in O
rats O
. O
Phencyclidine B-DRUG_N
( O
PCP B-DRUG_N
) O
produces O
psychotomimetic O
effects O
in O
humans O
that O
resemble O
schizophrenia O
symptoms O
. O
In O
an O
effort O
to O
screen O
compounds O
for O
antipsychotic O
activity O
, O
preclinical O
researchers O
have O
investigated O
whether O
these O
compounds O
block O
PCP B-DRUG_N
- O
induced O
behaviors O
in O
animals O
. O
In O
the O
present O
study O
, O
the O
atypical B-GROUP
antipsychotic I-GROUP
clozapine B-DRUG
was O
tested O
in O
combination O
with O
an O
active O
dose O
of O
PCP B-DRUG_N
in O
two O
- O
lever O
drug O
discrimination O
and O
mixed O
signalled O
- O
unsignalled O
differential O
- O
reinforcement O
- O
of O
- O
low O
- O
rates O
( O
DRL O
) O
procedures O
. O
PCP B-DRUG_N
produced O
distinctive O
effects O
in O
each O
task O
: O
it O
substituted O
for O
the O
training O
dose O
in O
PCP B-DRUG_N
discrimination O
and O
it O
increased O
the O
number O
of O
responses O
with O
short O
( O
< O
3 O
s O
) O
interresponse O
times O
as O
well O
as O
increasing O
overall O
response O
rates O
in O
the O
DRL O
schedule O
. O
Acute O
dosing O
with O
clozapine B-DRUG
failed O
to O
alter O
the O
behavioral O
effects O
of O
PCP B-DRUG_N
in O
either O
procedure O
even O
when O
tested O
up O
to O
doses O
that O
produced O
pharmacological O
effects O
alone O
. O
These O
results O
suggest O
that O
acute O
dosing O
with O
clozapine B-DRUG
would O
not O
affect O
behaviors O
most O
closely O
associated O
with O
PCP B-DRUG_N
intoxication O
. O
Further O
, O
they O
bring O
into O
question O
the O
utility O
of O
using O
PCP B-DRUG_N
combination O
procedures O
in O
animals O
to O
screen O
for O
antipsychotic O
potential O
. O
Since O
chronic O
dosing O
is O
required O
for O
therapeutic O
efficacy O
of O
antipsychotics B-GROUP
, O
future O
studies O
should O
focus O
on O
investigation O
of O
chronic O
dosing O
effects O
of O
these O
drugs O
in O
combination O
with O
PCP B-DRUG_N
. O

The O
mechanism O
of O
resveratrol B-DRUG_N
- O
induced O
vasorelaxation O
differs O
in O
the O
mesenteric O
resistance O
arteries O
of O
lean O
and O
obese O
rats O
. O
Resveratrol B-DRUG_N
has O
been O
shown O
to O
induce O
vasorelaxation O
. O
In O
this O
study O
, O
we O
investigated O
the O
mechanism O
( O
s O
) O
of O
resveratrol B-DRUG_N
- O
induced O
vasorelaxation O
in O
resistance O
mesenteric O
arteries O
from O
male O
lean O
and O
dietary O
- O
induced O
obese O
rats O
. O
Compared O
with O
lean O
rats O
, O
arteries O
from O
dietary O
- O
obese O
rats O
showed O
significant O
( O
P O
< O
0 O
. O
001 O
) O
endothelial O
dysfunction O
, O
as O
indicated O
by O
a O
decrease O
( O
> O
20 O
% O
) O
in O
maximal O
acetylcholine O
- O
induced O
vasorelaxation O
. O
Resveratrol B-DRUG_N
( O
5 O
- O
35 O
micromol O
/ O
l O
) O
induced O
concentration O
- O
dependent O
relaxation O
of O
mesenteric O
arteries O
preconstricted O
with O
noradrenaline B-DRUG
( O
8 O
micromol O
/ O
l O
) O
or O
KCl B-DRUG
( O
125 O
mmol O
/ O
l O
) O
from O
both O
lean O
and O
dietary O
- O
obese O
rats O
. O
There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
, O
achieving O
a O
maximum O
relaxation O
of O
> O
95 O
% O
at O
a O
concentration O
of O
35 O
micromol O
/ O
l O
. O
However O
, O
L B-DRUG_N
- I-DRUG_N
NAME I-DRUG_N
( O
100 O
and O
300 O
micromol O
/ O
l O
) O
did O
not O
alter O
the O
effects O
of O
reseveratrol B-DRUG_N
on O
arteries O
from O
dietary O
- O
obese O
rats O
, O
giving O
superimposed O
concentration O
- O
responses O
curves O
. O
Indomethacin B-DRUG
was O
also O
ineffective O
in O
altering O
resveratrol B-DRUG_N
activity O
in O
arteries O
from O
both O
lean O
and O
dietary O
- O
obese O
rats O
. O
In O
noradrenaline B-DRUG
- O
precontracted O
arteries O
from O
dietary O
- O
obese O
rats O
, O
responses O
to O
resveratrol B-DRUG_N
were O
not O
attenuated O
by O
endothelial O
denudation O
, O
indicating O
an O
action O
independent O
of O
the O
endothelium O
. O
This O
study O
indicates O
that O
: O
( O
a O
) O
the O
maximal O
effects O
of O
resveratrol B-DRUG_N
on O
resistance O
arteries O
from O
lean O
and O
dietary O
- O
obese O
rats O
are O
not O
effected O
by O
endothelial O
dysfunction O
, O
and O
( O
b O
) O
the O
effects O
of O
resveratrol B-DRUG_N
in O
lean O
animals O
( O
where O
endothelial O
function O
is O
not O
impaired O
) O
, O
but O
not O
in O
dietary O
- O
obese O
rats O
, O
are O
mediated O
via O
NO O
. O

If O
taken O
1 O
hour O
before O
indinavir B-DRUG
( O
IDV B-DRUG
) O
, O
didanosine B-DRUG
does O
not O
affect O
IDV B-DRUG
exposure O
, O
despite O
persistent O
buffering O
effects O
. O
Concurrent O
administration O
of O
indinavir B-DRUG
and O
didanosine B-DRUG
significantly O
reduces O
the O
level O
of O
exposure O
to O
indinavir B-DRUG
, O
but O
it O
is O
unclear O
how O
soon O
after O
didanosine B-DRUG
administration O
indinavir B-DRUG
may O
be O
given O
safely O
. O
We O
compared O
indinavir B-DRUG
pharmacokinetics O
and O
gastric O
pH O
in O
12 O
human O
immunodeficiency O
virus O
- O
positive O
patients O
by O
use O
of O
800 O
mg O
of O
indinavir B-DRUG
alone O
versus O
800 O
mg O
of O
indinavir B-DRUG
administered O
1 O
h O
after O
didanosine B-DRUG
administration O
. O
Median O
gastric O
pH O
was O
significantly O
higher O
when O
indinavir B-DRUG
was O
taken O
after O
didanosine B-DRUG
administration O
; O
however O
, O
no O
significant O
difference O
in O
the O
maximum O
concentration O
in O
plasma O
or O
the O
area O
under O
the O
concentration O
- O
time O
curve O
from O
time O
zero O
to O
8 O
h O
was O
observed O
. O
Indinavir B-DRUG
may O
be O
taken O
with O
a O
light O
meal O
1 O
h O
following O
the O
administration O
of O
400 O
mg O
of O
didanosine B-DRUG
. O

A O
proposed O
mechanism O
for O
the O
potentiation O
of O
cAMP O
- O
mediated O
acid O
secretion O
by O
carbachol B-DRUG
. O
Acid O
secretion O
in O
isolated O
rabbit O
gastric O
glands O
was O
monitored O
by O
the O
accumulation O
of O
[ O
( O
14 O
) O
C O
] O
aminopyrine B-DRUG
. O
Stimulation O
of O
the O
glands O
with O
carbachol B-DRUG
synergistically O
augmented O
the O
response O
to O
dibutyryl O
cAMP O
. O
The O
augmentation O
persisted O
even O
after O
carbachol B-DRUG
was O
washed O
out O
and O
was O
resistant O
to O
chelated O
extracellular O
Ca O
( O
2 O
+ O
) O
and O
to O
inhibitors O
of O
either O
protein O
kinase O
C O
or O
calmodulin O
kinase O
II O
. O
Cytochalasin B-DRUG_N
D I-DRUG_N
at O
10 O
microM O
preferentially O
blocked O
the O
secretory O
effect O
of O
carbachol B-DRUG
and O
its O
synergism O
with O
cAMP O
, O
whereas O
it O
had O
no O
effect O
on O
histamine O
- O
or O
cAMP O
- O
stimulated O
acid O
secretion O
within O
15 O
min O
. O
Cytochalasin B-DRUG_N
D I-DRUG_N
inhibited O
the O
carbachol B-DRUG
- O
stimulated O
intracellular O
Ca O
( O
2 O
+ O
) O
concentration O
( O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
) O
increase O
due O
to O
release O
from O
the O
Ca O
( O
2 O
+ O
) O
store O
. O
Treatment O
of O
the O
glands O
with O
cytochalasin B-DRUG_N
D I-DRUG_N
redistributed O
type O
3 O
inositol O
1 O
, O
4 O
, O
5 O
- O
trisphosphate O
receptor O
( O
the O
major O
subtype O
in O
the O
parietal O
cell O
) O
from O
the O
fraction O
containing O
membranes O
of O
large O
size O
to O
the O
microsomal O
fraction O
, O
suggesting O
a O
dissociation O
of O
the O
store O
from O
the O
plasma O
membrane O
. O
These O
findings O
suggest O
that O
intracellular O
Ca O
( O
2 O
+ O
) O
release O
by O
cholinergic O
stimulation O
is O
critical O
for O
determining O
synergism O
with O
cAMP O
in O
parietal O
cell O
activation O
and O
that O
functional O
coupling O
between O
the O
Ca O
( O
2 O
+ O
) O
store O
and O
the O
receptor O
is O
maintained O
by O
actin O
microfilaments O
. O

Interference O
of O
biocytin O
with O
opioid B-GROUP
- O
evoked O
hyperpolarization O
and O
membrane O
properties O
of O
rat O
spinal O
substantia O
gelatinosa O
neurons O
. O
In O
our O
laboratory O
, O
preliminary O
whole O
- O
cell O
, O
tight O
seal O
recordings O
of O
rat O
spinal O
substantia O
gelatinosa O
neurons O
including O
biocytin O
in O
the O
patch O
pipette O
yielded O
a O
significantly O
smaller O
proportion O
of O
neurons O
hyperpolarized O
by O
selective B-GROUP
opioid I-GROUP
agonists I-GROUP
compared O
with O
recordings O
without O
biocytin O
. O
Therefore O
, O
we O
investigated O
the O
effects O
of O
biocytin O
inclusion O
on O
opioid B-GROUP
responses O
and O
other O
membrane O
properties O
during O
whole O
- O
cell O
, O
tight O
seal O
recordings O
of O
these O
neurons O
. O
The O
percentage O
of O
neurons O
hyperpolarized O
by O
mu B-GROUP
- I-GROUP
, I-GROUP
delta I-GROUP
( I-GROUP
1 I-GROUP
) I-GROUP
- I-GROUP
, I-GROUP
and I-GROUP
kappa I-GROUP
- I-GROUP
selective I-GROUP
opioids I-GROUP
was O
significantly O
reduced O
when O
1 O
% O
but O
not O
< O
or O
= O
0 O
. O
2 O
% O
biocytin O
was O
included O
in O
the O
recording O
pipette O
, O
compared O
with O
neurons O
recorded O
without O
biocytin O
. O
However O
, O
a O
significantly O
higher O
proportion O
of O
neurons O
fired O
spontaneous O
action O
potentials O
with O
either O
0 O
. O
05 O
- O
0 O
. O
2 O
or O
1 O
% O
biocytin O
compared O
to O
no O
biocytin O
. O
Resting O
membrane O
potential O
, O
input O
impedance O
and O
the O
proportion O
of O
neurons O
displaying O
transient O
outward O
rectification O
were O
each O
significantly O
altered O
for O
neurons O
recorded O
with O
1 O
% O
but O
not O
0 O
. O
05 O
- O
0 O
. O
2 O
% O
biocytin O
. O
These O
effects O
may O
be O
due O
to O
a O
relatively O
specific O
blockade O
of O
diverse O
potassium O
channel O
types O
. O
Because O
efficient O
labeling O
can O
be O
achieved O
with O
0 O
. O
1 O
% O
biocytin O
with O
whole O
- O
cell O
recording O
, O
higher O
concentrations O
are O
contraindicated O
. O

Increased O
stability O
of O
nucleophosmin O
/ O
B23 O
in O
anti O
- O
apoptotic O
effect O
of O
ras O
during O
serum O
deprivation O
. O
We O
obtained O
evidence O
that O
increased O
stability O
of O
nucleophosmin O
/ O
B23 O
is O
involved O
in O
antiapoptotic O
effect O
of O
ras O
during O
serum O
deprivation O
. O
Nucleophosmin O
/ O
B23 O
in O
serum O
- O
deprived O
( O
0 O
% O
serum O
) O
NIH O
- O
3T3 O
cells O
was O
found O
to O
be O
highly O
unstable O
with O
a O
half O
- O
life O
less O
than O
4 O
h O
. O
In O
contrast O
, O
nucleophosmin O
/ O
B23 O
in O
serum O
- O
deprived O
ras O
- O
transformed O
( O
RAS O
- O
3T3 O
) O
cells O
was O
as O
stable O
as O
that O
in O
serum O
- O
supplemented O
NIH O
- O
3T3 O
or O
RAS O
- O
3T3 O
cells O
. O
Treatment O
of O
RAS O
- O
3T3 O
cells O
with O
nucleophosmin O
/ O
B23 O
antisense O
oligomer O
significantly O
potentiated O
the O
apoptosis O
induced O
by O
serum O
deprivation O
. O
Much O
less O
caspase O
- O
3 O
activity O
was O
noted O
in O
the O
lysate O
derived O
from O
serum O
- O
deprived O
RAS O
- O
3T3 O
cells O
compared O
with O
that O
in O
the O
lysate O
of O
serum O
- O
deprived O
NIH O
- O
3T3 O
cells O
. O
Cell O
permeable O
caspase O
- O
3 O
inhibitor O
added O
in O
the O
medium O
blocked O
the O
decrease O
of O
nucleophosmin O
/ O
B23 O
and O
apoptosis O
induced O
by O
serum O
deprivation O
in O
NIH O
- O
3T3 O
cells O
. O
The O
inhibitor O
, O
on O
the O
other O
hand O
, O
promoted O
significant O
decrease O
of O
nucleolin O
/ O
C23 O
in O
NIH O
- O
3T3 O
cells O
during O
serum O
deprivation O
. O
Unlike O
nucleolin O
/ O
C23 O
, O
down O
- O
regulation O
of O
nucleophosmin O
/ O
B23 O
was O
thus O
not O
proliferation O
- O
dependent O
but O
caspase O
- O
3 O
- O
and O
apoptosis O
- O
dependent O
. O
Our O
results O
indicate O
important O
relationships O
among O
ras O
, O
nucleophosmin O
/ O
B23 O
, O
activation O
of O
caspase O
- O
3 O
, O
and O
induction O
of O
apoptosis O
. O

Suppression O
by O
verapamil B-DRUG
of O
bombesin B-DRUG_N
- O
enhanced O
peritoneal O
metastasis O
of O
intestinal O
adenocarcinomas O
induced O
by O
azoxymethane B-DRUG_N
in O
wistar O
rats O
. O
BACKGROUND O
: O
The O
effects O
of O
combined O
administration O
of O
bombesin B-DRUG_N
and O
verapamil B-DRUG
hydrochloride I-DRUG
( O
verapamil B-DRUG
) O
, O
a O
calcium B-GROUP
channel I-GROUP
blocker I-GROUP
, O
on O
the O
incidence O
of O
peritoneal O
metastasis O
of O
intestinal O
adenocarcinomas O
induced O
by O
azoxymethane B-DRUG_N
( O
AOM B-DRUG_N
) O
and O
the O
labeling O
index O
of O
intestinal O
cancers O
were O
investigated O
in O
male O
Wistar O
rats O
. O
METHODS O
: O
From O
the O
beginning O
of O
the O
experiment O
, O
rats O
were O
given O
10 O
weekly O
subcutaneous O
injections O
of O
AOM B-DRUG_N
( O
7 O
. O
4 O
mg O
/ O
kg O
body O
weight O
) O
and O
subcutaneous O
injections O
of O
bombesin B-DRUG_N
( O
40 O
microg O
/ O
kg O
body O
weight O
) O
every O
other O
day O
, O
and O
from O
week O
16 O
, O
intraperitoneal O
injections O
of O
verapamil B-DRUG
( O
10 O
or O
20 O
mg O
/ O
kg O
body O
weight O
) O
every O
other O
day O
until O
the O
end O
fo O
the O
experiment O
in O
week O
45 O
. O
RESULTS O
: O
Bombesin B-DRUG_N
significantly O
increased O
the O
incidence O
of O
intestinal O
tumors O
and O
cancer O
metastasis O
to O
the O
peritoneum O
. O
Although O
verapamil B-DRUG
administered O
at O
either O
dose O
had O
little O
or O
no O
effect O
on O
the O
enhancement O
of O
intestinal O
carcinogenesis O
by O
bombesin B-DRUG_N
or O
on O
the O
location O
, O
histologic O
type O
, O
depth O
of O
involvement O
, O
labeling O
index O
, O
apoptotic O
index O
or O
tumor O
vascularity O
of O
intestinal O
cancers O
, O
it O
significantly O
decreased O
the O
incidence O
of O
cancer O
metastasis O
. O
Verapamil B-DRUG
also O
significantly O
decreased O
the O
incidence O
of O
lymphatic O
invasion O
of O
adenocarcinomas O
, O
which O
was O
enhanced O
by O
bombesin B-DRUG_N
. O
CONCLUSION O
: O
These O
findings O
indicate O
that O
verapamil B-DRUG
inhibits O
cancer O
metastasis O
through O
actions O
that O
do O
not O
affect O
the O
growth O
of O
intestinal O
cancers O
. O

In O
vitro O
interaction O
of O
prostaglandin B-DRUG
F2alpha I-DRUG
and O
oxytocin B-DRUG
in O
placental O
vessels O
. O
The O
interaction O
of O
prostaglandin B-DRUG
F2alpha I-DRUG
and O
synthetic O
oxytocin B-DRUG
on O
placental O
vessels O
was O
studied O
in O
vitro O
. O
Resistance O
was O
measured O
near O
the O
placental O
margin O
after O
spontaneous O
term O
delivery O
. O
In O
seven O
experiments O
reactions O
to O
norepinephrine B-DRUG
and O
oxytocin B-DRUG
were O
PGF2alpha B-DRUG
. O
PGF2alpha B-DRUG
produced O
significantly O
increased O
vasoconstriction O
after O
a O
single O
administration O
of O
oxytocin B-DRUG
. O
In O
eight O
experiments O
the O
perfusion O
medium O
contained O
oxytocin B-DRUG
. O
There O
was O
no O
change O
after O
a O
single O
dose O
of O
PGF2alpha B-DRUG
. O
The O
reaction O
after O
norepinephrine B-DRUG
remained O
the O
same O
in O
both O
groups O
of O
experiments O
. O
There O
is O
thus O
an O
enhancement O
effect O
There O
is O
thus O
an O
enhancement O
effect O
of O
PGF2alpha B-DRUG
upon O
the O
reaction O
of O
placental O
vessels O
to O
oxytocin B-DRUG
in O
vitro O
. O

Carbamazepine B-DRUG
overdose O
recognized O
by O
a O
tricyclic B-GROUP
antidepressant I-GROUP
assay O
. O
Altered O
mental O
status O
in O
an O
adolescent O
presents O
a O
diagnostic O
challenge O
, O
and O
the O
clinician O
depends O
on O
clinical O
evaluation O
and O
laboratory O
studies O
to O
determine O
therapy O
and O
prognosis O
. O
We O
report O
the O
case O
of O
an O
adolescent O
with O
altered O
consciousness O
caused O
by O
carbamazepine B-DRUG
overdose O
with O
a O
positive O
tricyclic B-GROUP
antidepressant I-GROUP
level O
to O
alert O
clinicians O
to O
the O
cross O
- O
reactivity O
of O
carbamazepine B-DRUG
with O
a O
toxicology O
screen O
for O
tricyclic B-GROUP
antidepressants I-GROUP
. O

Cypermethrin B-DRUG
- O
induced O
oxidative O
stress O
in O
rat O
brain O
and O
liver O
is O
prevented O
by O
vitamin B-DRUG
E I-DRUG
or O
allopurinol B-DRUG
. O
Considering O
that O
the O
involvement O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
has O
been O
implicated O
in O
the O
toxicity O
of O
various O
pesticides O
, O
this O
study O
was O
designed O
to O
investigate O
the O
possibility O
of O
oxidative O
stress O
induction O
by O
cypermethrin B-DRUG
, O
a O
Type B-DRUG_N
II I-DRUG_N
pyrethroid I-DRUG_N
. O
Either O
single O
( O
170 O
mg O
/ O
kg O
) O
or O
repeated O
( O
75 O
mg O
/ O
kg O
per O
day O
for O
5 O
days O
) O
oral O
administration O
of O
cypermethrin B-DRUG
was O
found O
to O
produce O
significant O
oxidative O
stress O
in O
cerebral O
and O
hepatic O
tissues O
of O
rats O
, O
as O
was O
evident O
by O
the O
elevation O
of O
the O
level O
of O
thiobarbituric O
acid O
reactive O
substances O
( O
TBARS O
) O
in O
both O
tissues O
, O
either O
4 O
or O
24 O
h O
after O
treatment O
. O
Much O
higher O
changes O
were O
observed O
in O
liver O
, O
increasing O
from O
a O
level O
of O
60 O
% O
at O
4 O
h O
up O
to O
nearly O
4 O
times O
the O
control O
at O
24 O
h O
for O
single O
dose O
. O
Reduced O
levels O
( O
up O
to O
20 O
% O
) O
of O
total O
glutathione O
( O
total O
GSH O
) O
, O
and O
elevation O
of O
conjugated O
dienes O
( O
approximately O
60 O
% O
in O
liver O
by O
single O
dose O
at O
4 O
h O
) O
also O
indicated O
the O
presence O
of O
an O
oxidative O
insult O
. O
Glutathione O
- O
S O
- O
transferase O
( O
GST O
) O
activity O
, O
however O
, O
did O
not O
differ O
from O
control O
values O
for O
any O
dose O
or O
at O
any O
time O
point O
in O
cerebral O
and O
hepatic O
tissues O
. O
Pretreatment O
of O
rats O
with O
allopurinol B-DRUG
( O
100 O
mg O
/ O
kg O
, O
ip O
) O
or O
Vitamin B-DRUG
E I-DRUG
( O
100 O
mg O
/ O
kg O
per O
day O
, O
ig O
, O
for O
3 O
days O
and O
a O
dose O
of O
40 O
mg O
/ O
kg O
on O
the O
4th O
day O
) O
provided O
significant O
protection O
against O
the O
elevation O
of O
TBARS O
levels O
in O
cerebral O
and O
hepatic O
tissues O
, O
induced O
by O
single O
high O
dose O
of O
oral O
cypermethrin B-DRUG
administration O
within O
4 O
h O
. O
Thus O
, O
the O
results O
suggest O
that O
cypermethrin B-DRUG
exposure O
of O
rats O
results O
in O
free O
radical O
- O
mediated O
tissue O
damage O
, O
as O
indicated O
by O
elevated O
cerebral O
and O
hepatic O
lipid O
peroxidation O
, O
which O
was O
prevented O
by O
allopurinol B-DRUG
and O
Vitamin B-DRUG
E I-DRUG
. O

Effect O
of O
ginsenosides B-DRUG_N
on O
voltage O
- O
dependent O
Ca O
( O
2 O
+ O
) O
channel O
subtypes O
in O
bovine O
chromaffin O
cells O
. O
In O
previous O
reports O
we O
have O
shown O
that O
ginsenosides B-DRUG_N
inhibit O
high O
threshold O
voltage O
- O
dependent O
Ca O
( O
2 O
+ O
) O
channels O
in O
neuronal O
cells O
. O
However O
, O
these O
studies O
did O
not O
show O
whether O
ginsenosides B-DRUG_N
- O
induced O
inhibition O
of O
Ca O
( O
2 O
+ O
) O
currents O
discriminates O
among O
the O
various O
Ca O
( O
2 O
+ O
) O
channel O
subtypes O
, O
although O
it O
is O
known O
that O
there O
are O
at O
least O
five O
different O
Ca O
( O
2 O
+ O
) O
channel O
subtypes O
in O
neuronal O
cells O
. O
In O
this O
study O
we O
investigated O
the O
effect O
of O
ginsenosides B-DRUG_N
on O
high O
threshold O
voltage O
- O
dependent O
Ca O
( O
2 O
+ O
) O
channel O
subtypes O
using O
their O
selective B-GROUP
Ca I-GROUP
( I-GROUP
2 I-GROUP
+ I-GROUP
) I-GROUP
channel I-GROUP
blockers I-GROUP
nimodipine B-DRUG
( O
L O
- O
type O
) O
, O
omega B-DRUG_N
- I-DRUG_N
conotoxin I-DRUG_N
GVIA I-DRUG_N
( O
N O
- O
type O
) O
, O
or O
omega B-DRUG_N
- I-DRUG_N
agatoxin I-DRUG_N
IVA I-DRUG_N
( O
P O
- O
type O
) O
in O
bovine O
chromaffin O
cells O
. O
We O
could O
observe O
that O
ginsenosides B-DRUG_N
inhibited O
high O
threshold O
voltage O
- O
dependent O
Ca O
( O
2 O
+ O
) O
currents O
in O
a O
dose O
- O
dependent O
manner O
. O
The O
IC O
( O
50 O
) O
was O
about O
120 O
microgram O
/ O
ml O
. O
Nimodipine B-DRUG
had O
no O
effect O
on O
ginsenosides B-DRUG_N
response O
. O
These O
data O
suggest O
that O
ginsenosides B-DRUG_N
are O
negatively O
coupled O
to O
three O
types O
of O
calcium O
channels O
in O
bovine O
chromaffin O
cell O
, O
including O
an O
omega B-DRUG_N
- I-DRUG_N
conotoxin I-DRUG_N
GVIA I-DRUG_N
- O
sensitive O
( O
N O
- O
type O
) O
channel O
, O
an O
omega B-DRUG_N
- I-DRUG_N
agatoxin I-DRUG_N
IVA I-DRUG_N
- O
sensitive O
( O
P O
- O
type O
) O
channel O
and O
nimodipine B-DRUG
/ O
omega B-DRUG_N
- I-DRUG_N
conotoxin I-DRUG_N
GVIA I-DRUG_N
/ O
omega B-DRUG_N
- I-DRUG_N
agatoxin I-DRUG_N
VIA I-DRUG_N
- O
resistant O
( O
presumptive O
Q O
- O
type O
) O
channel O
. O
Thus O
, O
the O
selective O
regulation O
of O
voltage O
- O
dependent O
Ca O
( O
2 O
+ O
) O
subtypes O
by O
ginsenosides B-DRUG_N
in O
bovine O
chromaffin O
cell O
could O
be O
the O
cellular O
basis O
of O
antistress O
effects O
induced O
by O
ginseng B-DRUG
. O

In O
vitro O
activity O
of O
KRM B-DRUG_N
- I-DRUG_N
1648 I-DRUG_N
, O
either O
singly O
or O
in O
combination O
with O
ofloxacin B-DRUG
, O
against O
Mycobacterium O
ulcerans O
. O
The O
antimicrobial O
effect O
of O
a O
benzoxazinorifamycin B-DRUG_N
, O
KRM B-DRUG_N
- I-DRUG_N
1648 I-DRUG_N
, O
either O
alone O
or O
in O
combination O
with O
ofloxacin B-DRUG
, O
was O
evaluated O
in O
vitro O
against O
two O
type O
strains O
and O
six O
clinical O
isolates O
of O
Mycobacterium O
ulcerans O
. O
Growth O
of O
M O
. O
ulcerans O
was O
measured O
by O
plate O
counts O
and O
the O
BACTEC O
radiometric O
method O
. O
The O
minimal O
inhibitory O
concentration O
as O
well O
as O
minimal O
bactericidal O
concentration O
of O
KRM B-DRUG_N
- I-DRUG_N
1648 I-DRUG_N
against O
M O
. O
ulcerans O
was O
between O
0 O
. O
012 O
and O
0 O
. O
025 O
mg O
/ O
l O
, O
while O
corresponding O
values O
for O
rifampicin B-DRUG
and O
rifabutin B-DRUG
were O
in O
the O
range O
of O
0 O
. O
1 O
- O
0 O
. O
8 O
mg O
/ O
l O
and O
0 O
. O
1 O
- O
0 O
. O
4 O
mg O
/ O
l O
respectively O
. O
When O
combined O
with O
ofloxacin B-DRUG
, O
KRM B-DRUG_N
- I-DRUG_N
1648 I-DRUG_N
exhibited O
strong O
synergistic O
activity O
while O
only O
additive O
effects O
were O
observed O
with O
the O
combination O
of O
rifampicin B-DRUG
( O
or O
rifabutin B-DRUG
) O
and O
ofloxacin B-DRUG
. O
These O
results O
suggest O
that O
KRM B-DRUG_N
- I-DRUG_N
1648 I-DRUG_N
has O
a O
great O
potential O
in O
the O
treatment O
of O
M O
. O
ulcerans O
infection O
. O

Inhibitory O
effects O
of O
ruthenium B-DRUG_N
red I-DRUG_N
on O
inositol O
1 O
, O
4 O
, O
5 O
- O
trisphosphate O
- O
induced O
responses O
in O
rat O
megakaryocytes O
. O
The O
effects O
of O
ruthenium B-DRUG_N
red I-DRUG_N
( O
RR B-DRUG_N
) O
on O
inositol B-DRUG_N
1 I-DRUG_N
, I-DRUG_N
4 I-DRUG_N
, I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
trisphosphate I-DRUG_N
( O
InsP B-DRUG_N
( I-DRUG_N
3 I-DRUG_N
) I-DRUG_N
) O
- O
induced O
responses O
were O
studied O
in O
rat O
bone O
marrow O
megakaryocytes O
with O
the O
patch O
- O
clamp O
whole O
- O
cell O
recording O
technique O
in O
combination O
with O
fura O
- O
2 O
microfluorometry O
. O
Internal O
application O
of O
InsP B-DRUG_N
( I-DRUG_N
3 I-DRUG_N
) I-DRUG_N
( O
100 O
microM O
) O
increased O
intracellular O
Ca O
( O
2 O
+ O
) O
concentration O
( O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
) O
and O
activated O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
K O
( O
+ O
) O
current O
. O
Administering O
InsP B-DRUG_N
( I-DRUG_N
3 I-DRUG_N
) I-DRUG_N
together O
with O
RR B-DRUG_N
( O
100 O
- O
500 O
microM O
) O
inhibited O
InsP O
( O
3 O
) O
- O
induced O
responses O
( O
both O
Ca O
( O
2 O
+ O
) O
and O
current O
responses O
) O
in O
a O
dose O
- O
dependent O
fashion O
. O
Pretreatment O
of O
megakaryocytes O
with O
extracellular O
RR B-DRUG_N
( O
50 O
microM O
) O
also O
inhibited O
InsP B-DRUG_N
( I-DRUG_N
3 I-DRUG_N
) I-DRUG_N
- O
induced O
responses O
. O
Intracellular O
and O
extracellular O
application O
of O
RR B-DRUG_N
reduced O
ADP O
- O
induced O
increases O
in O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
. O
In O
contrast O
, O
in O
isolated O
single O
pancreatic O
acinar O
cells O
, O
RR B-DRUG_N
had O
no O
effect O
on O
InsP B-DRUG_N
( I-DRUG_N
3 I-DRUG_N
) I-DRUG_N
- O
induced O
responses O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
the O
site O
of O
the O
inhibitory O
action O
of O
RR B-DRUG_N
is O
at O
the O
InsP O
( O
3 O
) O
receptor O
, O
or O
its O
closely O
associated O
proteins O
. O
In O
addition O
, O
we O
have O
shown O
that O
RR B-DRUG_N
is O
a O
useful O
pharmacological O
tool O
with O
which O
to O
examine O
the O
InsP B-DRUG_N
( I-DRUG_N
3 I-DRUG_N
) I-DRUG_N
- O
mediated O
responses O
of O
megakaryocytes O
. O

Effect O
of O
rofecoxib B-DRUG
on O
the O
pharmacokinetics O
of O
digoxin B-DRUG
in O
healthy O
volunteers O
. O
The O
authors O
examined O
the O
effect O
of O
the O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
inhibitor O
, O
rofecoxib B-DRUG
, O
at O
steady O
state O
on O
the O
pharmacokinetics O
of O
digoxin B-DRUG
following O
a O
single O
dose O
in O
healthy O
subjects O
. O
Each O
healthy O
subject O
( O
N O
= O
10 O
) O
received O
rofecoxib B-DRUG
( O
75 O
mg O
once O
daily O
) O
or O
placebo O
for O
11 O
days O
in O
a O
double O
- O
blind O
, O
randomized O
, O
balanced O
, O
two O
- O
period O
crossover O
study O
. O
A O
single O
0 O
. O
5 O
mg O
oral O
dose O
of O
digoxin B-DRUG
elixir O
was O
administered O
on O
the O
7th O
day O
of O
each O
11 O
- O
day O
period O
. O
Each O
treatment O
period O
was O
separated O
by O
14 O
to O
21 O
days O
. O
Samples O
for O
plasma O
and O
urine O
immunoreactive O
digoxin B-DRUG
concentrations O
were O
collected O
through O
120 O
hours O
following O
the O
digoxin B-DRUG
dose O
. O
No O
statistically O
significant O
differences O
between O
treatment O
groups O
were O
observed O
for O
any O
of O
the O
calculated O
digoxin B-DRUG
pharmacokinetic O
parameters O
. O
For O
digoxin B-DRUG
AUC O
( O
0 O
- O
infinity O
) O
, O
AUC O
( O
0 O
- O
24 O
) O
, O
and O
Cmax O
, O
the O
geometric O
mean O
ratios O
( O
90 O
% O
confidence O
interval O
) O
for O
( O
rofecoxib B-DRUG
+ O
digoxin B-DRUG
/ O
placebo O
+ O
digoxin B-DRUG
) O
were O
1 O
. O
04 O
( O
0 O
. O
94 O
, O
1 O
. O
14 O
) O
, O
1 O
. O
02 O
( O
0 O
. O
94 O
, O
1 O
. O
09 O
) O
, O
and O
1 O
. O
00 O
( O
0 O
. O
91 O
, O
1 O
. O
10 O
) O
, O
respectively O
. O
The O
digoxin B-DRUG
median O
tmax O
was O
0 O
. O
5 O
hours O
for O
both O
treatments O
. O
The O
harmonic O
mean O
elimination O
half O
- O
life O
was O
45 O
. O
7 O
and O
43 O
. O
4 O
hours O
for O
rofecoxib B-DRUG
+ O
digoxin B-DRUG
and O
placebo O
+ O
digoxin B-DRUG
treatments O
, O
respectively O
. O
Digoxin B-DRUG
is O
eliminated O
renally O
. O
The O
mean O
( O
SD O
) O
cumulative O
urinary O
excretion O
of O
immunoreactive O
digoxin B-DRUG
after O
concurrent O
treatment O
with O
rofecoxib B-DRUG
or O
placebo O
was O
228 O
. O
2 O
( O
+ O
/ O
- O
30 O
. O
8 O
) O
and O
235 O
. O
1 O
( O
+ O
/ O
- O
39 O
. O
1 O
) O
micrograms O
/ O
120 O
hours O
, O
respectively O
. O
Transient O
and O
minor O
adverse O
events O
occurred O
with O
similar O
frequency O
on O
placebo O
and O
rofecoxib B-DRUG
treatments O
, O
and O
no O
treatment O
- O
related O
pattern O
was O
apparent O
. O
Rofecoxib B-DRUG
did O
not O
influence O
the O
plasma O
pharmacokinetics O
or O
renal O
elimination O
of O
a O
single O
oral O
dose O
of O
digoxin B-DRUG
. O

Concomitant O
cyclophosphamide B-DRUG
, O
doxorubicin B-DRUG
, O
vincristine B-DRUG
, O
and O
prednisone B-DRUG
chemotherapy O
plus O
highly B-GROUP
active I-GROUP
antiretroviral I-GROUP
therapy O
in O
patients O
with O
human O
immunodeficiency O
virus O
- O
related O
, O
non O
- O
Hodgkin O
lymphoma O
. O
BACKGROUND O
: O
The O
feasibility O
and O
efficacy O
of O
concomitant O
chemotherapy O
and O
highly B-GROUP
active I-GROUP
antiretroviral I-GROUP
therapy O
( O
HAART O
) O
is O
still O
unknown O
in O
patients O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
- O
related O
malignancies O
. O
To O
evaluate O
the O
impact O
of O
chemotherapy O
plus O
HAART O
on O
the O
clinical O
course O
of O
patients O
with O
HIV O
- O
related O
, O
systemic O
, O
non O
- O
Hodgkin O
lymphoma O
( O
HIV O
- O
NHL O
) O
, O
the O
authors O
compared O
retrospectively O
a O
group O
of O
24 O
patients O
with O
HIV O
- O
NHL O
who O
were O
treated O
with O
the O
cyclophosphamide B-DRUG
, O
doxorubicin B-DRUG
, O
vincristine B-DRUG
, O
and O
prednisone B-DRUG
( O
CHOP O
) O
chemotherapy O
regimen O
plus O
HAART O
with O
a O
group O
of O
80 O
patients O
who O
were O
treated O
with O
CHOP O
chemotherapy O
or O
a O
CHOP O
- O
like O
regimen O
( O
i O
. O
e O
. O
, O
cyclophosphamide B-DRUG
, O
doxorubicin B-DRUG
, O
teniposide B-DRUG
, O
and O
prednisone B-DRUG
with O
vincristine B-DRUG
plus O
bleomycin B-DRUG
) O
without O
receiving O
antiretroviral B-GROUP
therapy O
. O
METHODS O
: O
All O
patients O
were O
enrolled O
in O
two O
sequential O
trials O
performed O
at O
the O
Aviano O
Cancer O
Center O
, O
Italy O
, O
from O
April O
1988 O
to O
December O
1998 O
. O
HAART O
was O
included O
with O
combination O
therapy O
from O
January O
1997 O
. O
Antiretroviral B-GROUP
regimens O
consisted O
of O
two O
reverse B-GROUP
transcriptase I-GROUP
inhibitors I-GROUP
and O
one O
protease B-GROUP
inhibitor I-GROUP
. O
RESULTS O
: O
The O
two O
treatment O
groups O
were O
well O
matched O
with O
regard O
to O
patient O
demographics O
, O
NHL O
characteristics O
, O
HIV O
status O
, O
and O
treatment O
, O
i O
. O
e O
. O
, O
the O
number O
of O
cycles O
and O
chemotherapy O
dose O
. O
The O
response O
rates O
were O
similar O
between O
the O
two O
groups O
. O
Severe O
anemia O
( O
Grade O
3 O
- O
4 O
according O
to O
the O
World O
Health O
Organization O
criteria O
) O
was O
significantly O
greater O
in O
the O
patients O
who O
received O
CHOP O
- O
HAART O
compared O
with O
the O
patients O
who O
received O
CHOP O
alone O
( O
33 O
% O
vs O
. O
7 O
% O
, O
respectively O
; O
P O
= O
0 O
. O
001 O
) O
. O
Leukopenia O
was O
similar O
between O
the O
two O
groups O
, O
but O
colony O
stimulating O
factor O
support O
was O
significantly O
greater O
in O
the O
CHOP O
- O
HAART O
group O
than O
in O
the O
control O

group O
( O
92 O
% O
vs O
. O
66 O
% O
, O
respectively O
; O
P O
= O
0 O
. O
03 O
) O
. O
Seventeen O
percent O
of O
CHOP O
- O
HAART O
patients O
developed O
severe O
autonomic O
neurotoxicity O
, O
whereas O
none O
of O
the O
CHOP O
patients O
developed O
neurotoxicity O
( O
P O
= O
0 O
. O
002 O
) O
. O
At O
similar O
median O
follow O
- O
up O
, O
opportunistic O
infection O
( O
OI O
) O
rates O
and O
mortality O
were O
significantly O
lower O
in O
the O
CHOP O
- O
HAART O
patients O
than O
in O
the O
CHOP O
patients O
( O
18 O
% O
vs O
. O
52 O
% O
, O
respectively O
; O
P O
= O
0 O
. O
05 O
; O
and O
38 O
% O
vs O
. O
85 O
% O
, O
respectively O
; O
P O
= O
0 O
. O
001 O
) O
. O
The O
median O
survival O
for O
CHOP O
- O
HAART O
patients O
was O
not O
reached O
, O
whereas O
the O
medial O
survival O
of O
CHOP O
patients O
was O
7 O
months O
( O
P O
= O
0 O
. O
03 O
) O
. O
CONCLUSIONS O
: O
The O
combination O
of O
CHOP O
plus O
HAART O
is O
feasible O
and O
may O
reduce O
the O
morbidity O
from O
OIs O
in O
HIV O
- O
NHL O
patients O
. O
However O
, O
careful O
attention O
must O
be O
directed O
to O
cross O
toxicity O
and O
possible O
pharmacokinetic O
interactions O
between O
antiretroviral B-GROUP
and I-GROUP
antineoplastic I-GROUP
drugs I-GROUP
. O
The O
impact O
of O
the O
combined O
chemotherapy O
plus O
HAART O
treatment O
on O
patient O
survival O
needs O
urgently O
to O
be O
evaluated O
in O
prospective O
studies O
. O

Acute O
effect O
of O
different O
antidepressants B-GROUP
on O
glycemia O
in O
diabetic O
and O
non O
- O
diabetic O
rats O
. O
Diabetic O
patients O
have O
a O
20 O
% O
higher O
risk O
of O
depression O
than O
the O
general O
population O
. O
Treatment O
with O
antidepressant B-GROUP
drugs I-GROUP
can O
directly O
interfere O
with O
blood O
glucose O
levels O
or O
may O
interact O
with O
hypoglycemic B-GROUP
agents I-GROUP
. O
The O
treatment O
of O
depression O
in O
diabetic O
patients O
must O
take O
into O
account O
variations O
of O
glycemic O
levels O
at O
different O
times O
and O
a O
comparison O
of O
the O
available O
antidepressant B-GROUP
agents I-GROUP
is O
important O
. O
In O
the O
present O
study O
we O
evaluated O
the O
interference O
of O
antidepressants B-GROUP
with O
blood O
glucose O
levels O
of O
diabetic O
and O
non O
- O
diabetic O
rats O
. O
In O
a O
first O
experiment O
, O
male O
adult O
Wistar O
rats O
were O
fasted O
for O
12 O
h O
. O
Imipramine B-DRUG
( O
5 O
mg O
/ O
kg O
) O
, O
moclobemide B-DRUG
( O
30 O
mg O
/ O
kg O
) O
, O
clonazepam B-DRUG
( O
0 O
. O
25 O
mg O
/ O
kg O
) O
, O
fluoxetine B-DRUG
( O
20 O
mg O
/ O
kg O
) O
sertraline B-DRUG
( O
30 O
mg O
/ O
kg O
) O
or O
vehicle O
was O
administered O
. O
After O
30 O
min O
, O
fasting O
glycemia O
was O
measured O
. O
An O
oral O
glucose B-DRUG
overload O
of O
1 O
ml O
of O
a O
50 O
% O
glucose B-DRUG
solution O
was O
given O
to O
rats O
and O
blood O
glucose O
was O
determined O
after O
30 O
, O
60 O
and O
90 O
min O
. O
Imipramine B-DRUG
and O
clonazepam B-DRUG
did O
not O
change O
fasting O
or O
overload O
glycemia O
. O
Fluoxetine B-DRUG
and O
moclobemide B-DRUG
increased O
blood O
glucose B-DRUG
at O
different O
times O
after O
the O
glucose O
overload O
. O
Sertraline B-DRUG
neutralized O
the O
increase O
of O
glycemia O
induced O
by O
oral O
glucose B-DRUG
overload O
. O
In O
the O
second O
experiment O
, O
non O
- O
diabetic O
and O
streptozotocin O
- O
induced O
diabetic O
rats O
were O
fasted O
, O
and O
the O
same O
procedures O
were O
followed O
for O
estimation O
of O
glucose B-DRUG
tolerance O
30 O
min O
after O
glucose B-DRUG
overload O
. O
Again O
, O
sertraline B-DRUG
neutralized O
the O
increase O
in O
glycemia O
after O
glucose B-DRUG
overload O
both O
in O
diabetic O
and O
non O
- O
diabetic O
rats O
. O
These O
data O
raise O
the O
question O
of O
whether O
sertraline B-DRUG
is O
the O
best O
choice O
for O
prolonged O
use O
for O
diabetic O
individuals O
, O
because O
of O
its O
antihyperglycemic O
effects O
. O
Clonazepam B-DRUG
would O
be O
useful O
in O
cases O
with O
potential O
risk O
of O
hypoglycemia O
. O

Activity O
of O
buforin B-DRUG_N
II I-DRUG_N
alone O
and O
in O
combination O
with O
azithromycin B-DRUG
and O
minocycline B-DRUG
against O
Cryptosporidium O
parvum O
in O
cell O
culture O
. O
The O
in O
vitro O
anti O
- O
cryptosporidial O
activity O
of O
buforin B-DRUG_N
II I-DRUG_N
alone O
and O
in O
combination O
with O
azithromycin B-DRUG
and O
minocycline B-DRUG
was O
investigated O
. O
Buforin B-DRUG_N
II I-DRUG_N
showed O
moderate O
activity O
, O
which O
increased O
with O
increasing O
concentration O
to O
55 O
. O
7 O
% O
suppression O
of O
growth O
at O
20 O
microM O
. O
Moreover O
, O
its O
activity O
was O
enhanced O
when O
it O
was O
combined O
with O
either O
azithromycin B-DRUG
or O
minocycline B-DRUG
with O
90 O
% O
parasite O
reduction O
at O
the O
highest O
concentration O
tested O
. O
Buforin B-DRUG_N
II I-DRUG_N
may O
be O
active O
in O
inhibiting O
Cryptosporidium O
parvum O
growth O
in O
vitro O
upon O
combination O
with O
either O
azithromycin B-DRUG
or O
minocycline B-DRUG
. O

Effect O
of O
dofetillide B-DRUG
on O
the O
pharmacokinetics O
of O
digoxin B-DRUG
. O
The O
effect O
of O
dofetilide B-DRUG
on O
the O
steady O
- O
state O
pharmacokinetics O
of O
digoxin B-DRUG
was O
evaluated O
in O
a O
randomized O
, O
double O
- O
blind O
study O
. O
Five O
days O
of O
dofetilide B-DRUG
treatment O
did O
not O
significantly O
affect O
steady O
- O
state O
pharmacokinetic O
variables O
of O
digoxin B-DRUG
compared O
with O
placebo O
; O
therefore O
, O
the O
use O
of O
dofetilide B-DRUG
does O
not O
necessitate O
an O
adjustment O
in O
digoxin B-DRUG
dose O
to O
maintain O
therapeutic O
digoxin O
levels O
. O

Anaesthesia O
and O
the O
epileptic O
pateint O
. O
A O
review O
. O
A O
review O
is O
presented O
of O
some O
of O
the O
problems O
that O
may O
arise O
in O
association O
with O
anaesthesia O
for O
epileptic O
patients O
. O
There O
is O
the O
possibility O
of O
precipitating O
anticonvulsant O
drug O
toxicity O
. O
Numerous O
drug O
interactions O
are O
possible O
with O
some O
anticonvulsant B-GROUP
agents I-GROUP
, O
such O
as O
phenobarbitone B-DRUG
and O
phenytoin B-DRUG
, O
which O
affect O
hepatic O
microsomal O
enzyme O
systems O
. O
There O
is O
the O
risk O
of O
convulsions O
occurring O
in O
susceptible O
patients O
following O
the O
use O
of O
the O
new O
anaesthetic B-GROUP
agents I-GROUP
which O
are O
capable O
of O
inducing O
CNS O
excitability O
. O

Interaction O
of O
ketamine B-DRUG
and O
halothane B-DRUG
in O
rats O
. O
The O
interaction O
of O
intramuscularly O
injected O
ketamine B-DRUG
and O
its O
N O
- O
demethylated O
metabolite O
( O
metabolite O
I O
) O
with O
halothane B-DRUG
was O
evaluated O
in O
rats O
. O
Five O
, O
10 O
, O
20 O
, O
or O
50 O
mg O
/ O
kg O
of O
ketamine B-DRUG
alone O
or O
20 O
, O
50 O
, O
or O
100 O
mg O
/ O
kg O
of O
metabolite O
I O
alone O
produced O
less O
than O
10 O
minutes O
of O
hypnosis O
. O
However O
, O
halothane B-DRUG
anesthetic O
requirement O
( O
i O
. O
e O
. O
, O
MAC O
) O
was O
depressed O
in O
a O
dose O
- O
dependent O
fashion O
as O
much O
as O
56 O
% O
1 O
- O
2 O
hours O
and O
as O
much O
as O
14 O
% O
5 O
- O
6 O
hours O
after O
injection O
of O
ketamine B-DRUG
, O
50 O
mg O
/ O
kg O
, O
im O
. O
The O
reduction O
in O
MAC O
was O
correlated O
with O
brain O
levels O
of O
ketamine B-DRUG
or O
metabolite O
I O
, O
suggesting O
a O
ketamine B-DRUG
: O
metabolite O
I O
potency O
ration O
of O
3 O
: O
1 O
. O
The O
half O
- O
life O
of O
ketamine B-DRUG
in O
plasma O
and O
brain O
was O
longer O
in O
the O
presence O
of O
halothane B-DRUG
than O
when O
ketamine B-DRUG
was O
given O
alone O
. O
It O
is O
concluded O
that O
ketamine B-DRUG
is O
not O
a O
short O
- O
acting O
drug O
and O
that O
concomitant O
use O
with O
halothane B-DRUG
would O
be O
expected O
to O
prolong O
further O
the O
duration O
of O
its O
action O
on O
the O
central O
nervous O
system O
. O

Rifampin B-DRUG
and O
warfarin B-DRUG
: O
a O
drug O
interaction O
. O
The O
drug O
interaction O
between O
warfarin B-DRUG
and O
rifampin B-DRUG
is O
not O
well O
known O
. O
Rifampin B-DRUG
has O
been O
reported O
to O
increase O
the O
warfarin B-DRUG
requirements O
in O
human O
subjects O
ingesting O
these O
agents O
simultaneously O
. O
The O
concomitant O
administration O
of O
rifampin B-DRUG
and O
warfarin B-DRUG
resulted O
in O
the O
need O
for O
an O
unusually O
high O
maintenance O
dose O
of O
warfarin B-DRUG
( O
20 O
mg O
per O
day O
) O
in O
order O
to O
produce O
a O
therapeutic O
effect O
. O
Withdrawal O
of O
rifampin B-DRUG
decreased O
the O
warfarin B-DRUG
requirement O
by O
50 O
% O
. O
This O
effect O
may O
be O
mediated O
by O
the O
ability O
of O
rifampin B-DRUG
to O
induce O
microsomal O
enzymes O
and O
, O
thus O
, O
the O
catabolism O
of O
warfarin B-DRUG
. O
The O
effect O
of O
rifampin B-DRUG
on O
the O
warfarin B-DRUG
requirement O
of O
our O
patient O
appeared O
to O
be O
maximal O
5 O
to O
7 O
days O
after O
the O
initiation O
of O
rifampin B-DRUG
and O
extended O
a O
similar O
length O
of O
time O
after O
rifampin B-DRUG
withdrawal O
. O
This O
interaction O
appears O
to O
be O
clinically O
significant O
. O

Thiolated B-DRUG_N
carboxymethylcellulose I-DRUG_N
: O
in O
vitro O
evaluation O
of O
its O
permeation O
enhancing O
effect O
on O
peptide O
drugs O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
sodium B-DRUG_N
carboxymethylcellulose I-DRUG_N
( O
NaCMC B-DRUG_N
) O
and O
carboxymethylcellulose B-DRUG_N
- I-DRUG_N
cysteine I-DRUG_N
( O
CMC B-DRUG_N
- I-DRUG_N
Cys I-DRUG_N
) O
conjugates O
on O
the O
intestinal O
permeation O
of O
sodium B-DRUG
fluorescein I-DRUG
( O
NaFlu B-DRUG
) O
and O
model O
peptide O
drugs O
, O
bacitracin B-DRUG
and O
insulin B-DRUG
. O
Cysteine B-DRUG
was O
covalently O
linked O
to O
carbodiimide O
activated O
NaCMC B-DRUG_N
. O
Iodometric O
titration O
of O
the O
polymer O
conjugates O
was O
used O
to O
determine O
the O
extent O
of O
immobilised O
cysteine B-DRUG
. O
Permeation O
studies O
were O
performed O
on O
guinea O
pig O
small O
intestinal O
mucosa O
mounted O
in O
Ussing O
- O
type O
chamber O
. O
Unmodified O
NaCMC B-DRUG_N
( O
1 O
% O
m O
/ O
v O
) O
significantly O
improved O
the O
transport O
ratio O
( O
R O
= O
P O
( O
app O
) O
polymer O
/ O
P O
( O
app O
) O
control O
) O
of O
NaFlu B-DRUG
to O
1 O
. O
3 O
and O
1 O
% O
( O
m O
/ O
v O
) O
NaCMC B-DRUG_N
conjugated O
with O
cysteine B-DRUG
further O
enhanced O
the O
permeation O
. O
Cysteine B-DRUG
conjugation O
at O
3 O
. O
6 O
, O
5 O
. O
3 O
and O
7 O
. O
3 O
% O
( O
m O
/ O
m O
) O
resulted O
in O
R O
- O
values O
of O
1 O
. O
4 O
, O
1 O
. O
7 O
and O
1 O
. O
8 O
, O
respectively O
. O
Decreasing O
the O
concentration O
of O
CMC B-DRUG_N
- I-DRUG_N
Cys I-DRUG_N
, O
exhibiting O
7 O
. O
3 O
% O
( O
m O
/ O
m O
) O
of O
immobilised O
cysteine B-DRUG
( O
CMC O
- O
Cys7 O
. O
3 O
) O
from O
1 O
% O
( O
m O
/ O
v O
) O
to O
0 O
. O
5 O
% O
( O
m O
/ O
v O
) O
decreased O
the O
R O
- O
value O
of O
NaFlu B-DRUG
from O
1 O
. O
8 O
to O
1 O
. O
2 O
. O
NaCMC B-DRUG_N
at O
1 O
% O
( O
m O
/ O
v O
) O
in O
the O
presence O
of O
free O
cysteine B-DRUG
had O
no O
significant O
effect O
on O
the O
R O
- O
value O
of O
NaFlu B-DRUG
compared O
to O
NaCMC B-DRUG_N
alone O
. O
Formulation O
of O
fluorescence O
labelled O
bacitracin B-DRUG
and O
insulin B-DRUG
in O
unconjugated O
NaCMC B-DRUG_N
( O
1 O
% O
m O
/ O
v O
) O
did O
not O
significantly O
improve O
the O
permeation O
, O
however O
in O
the O
presence O
of O
1 O
% O
( O
m O
/ O
v O
) O
CMC B-DRUG_N
- I-DRUG_N
Cys7 I-DRUG_N
. O
3 O
a O
significantly O
improved O
permeation O
was O
observed O
( O
R O
= O
1 O
. O
3 O
) O
. O
Conjugation O
at O
NaCMC B-DRUG_N
with O
cysteine B-DRUG
moieties O
significantly O
improves O
the O

intestinal O
permeation O
of O
the O
hydrophilic O
molecule O
NaFlu B-DRUG
and O
the O
model O
peptide O
drugs O
bacitracin B-DRUG
and O
insulin B-DRUG
in O
vitro O
, O
therefore O
this O
conjugated O
system O
maybe O
useful O
for O
peroral O
administration O
of O
peptide O
drugs O
in O
the O
future O
. O

Systemic O
antibiotic B-GROUP
agents I-GROUP
. O
Understanding O
the O
breadth O
of O
systemic O
antimicrobial B-GROUP
agents I-GROUP
available O
for O
use O
by O
the O
dermatologist O
and O
their O
associated O
side O
- O
effect O
profiles O
and O
drug O
interactions O
allows O
the O
clinician O
to O
offer O
patients O
optimal O
care O
in O
the O
management O
of O
cutaneous O
infectious O
disease O
. O

Drug O
interactions O
: O
How O
to O
identify O
them O
. O
Interactions O
between O
theraputic O
agents O
have O
been O
recognized O
as O
increasingly O
important O
causes O
of O
drug O
at O
their O
usual O
recommended O
dose O
may O
, O
under O
certain O
conditions O
, O
produce O
toxicity O
of O
life O
- O
endangering O
proportions O
. O
While O
the O
recognition O
of O
drug O
toxicity O
resulting O
from O
interactions O
is O
of O
importance O
to O
all O
physciains O
, O
it O
is O
especially O
so O
for O
the O
clinician O
responsible O
for O
the O
welfare O
of O
those O
in O
the O
aerospace O
environment O
. O
This O
paper O
attempts O
to O
provide O
a O
basis O
for O
the O
understanding O
and O
identifications O
of O
important O
drug O
interactions O
. O
Guidelines O
are O
provided O
to O
assist O
the O
clinician O
in O
his O
logical O
approach O
to O
the O
identification O
of O
drug O
interactions O
when O
serious O
drug O
toxicity O
is O
encountered O
in O
a O
pateint O
. O
Only O
with O
knowledge O
of O
the O
interaction O
can O
the O
therapeutic O
regimen O
be O
altered O
so O
as O
to O
provide O
therapeutic O
levels O
of O
necessary O
drugs O
while O
avoiding O
toxicity O
. O

Pharmacokinetic O
Interaction O
between O
amprenavir B-DRUG
and O
rifabutin B-DRUG
or O
rifampin B-DRUG
in O
healthy O
males O
. O
The O
objective O
of O
this O
study O
was O
to O
determine O
if O
there O
is O
a O
pharmacokinetic O
interaction O
when O
amprenavir B-DRUG
is O
given O
with O
rifabutin B-DRUG
or O
rifampin B-DRUG
and O
to O
determine O
the O
effects O
of O
these O
drugs O
on O
the O
erythromycin O
breath O
test O
( O
ERMBT O
) O
. O
Twenty O
- O
four O
healthy O
male O
subjects O
were O
randomized O
to O
one O
of O
two O
cohorts O
. O
All O
subjects O
received O
amprenavir B-DRUG
( O
1 O
, O
200 O
mg O
twice O
a O
day O
) O
for O
4 O
days O
, O
followed O
by O
a O
7 O
- O
day O
washout O
period O
, O
followed O
by O
either O
rifabutin B-DRUG
( O
300 O
mg O
once O
a O
day O
[ O
QD O
] O
) O
( O
cohort O
1 O
) O
or O
rifampin B-DRUG
( O
600 O
mg O
QD O
) O
( O
cohort O
2 O
) O
for O
14 O
days O
. O
Cohort O
1 O
then O
received O
amprenavir B-DRUG
plus O
rifabutin B-DRUG
for O
10 O
days O
, O
and O
cohort O
2 O
received O
amprenavir B-DRUG
plus O
rifampin B-DRUG
for O
4 O
days O
. O
Serial O
plasma O
and O
urine O
samples O
for O
measurement O
of O
amprenavir B-DRUG
, O
rifabutin B-DRUG
, O
and O
rifampin B-DRUG
and O
their O
25 B-DRUG_N
- I-DRUG_N
O I-DRUG_N
- I-DRUG_N
desacetyl I-DRUG_N
metabolites I-DRUG_N
, O
were O
measured O
by O
high O
- O
performance O
liquid O
chromatography O
. O
Rifabutin B-DRUG
did O
not O
significantly O
affect O
amprenavir B-DRUG
' O
s O
pharmacokinetics O
. O
Amprenavir B-DRUG
significantly O
increased O
the O
area O
under O
the O
curve O
at O
steady O
state O
( O
AUC O
( O
ss O
) O
) O
of O
rifabutin B-DRUG
by O
2 O
. O
93 O
- O
fold O
and O
the O
AUC O
( O
ss O
) O
of O
25 B-DRUG_N
- I-DRUG_N
O I-DRUG_N
- I-DRUG_N
desacetylrifabutin I-DRUG_N
by O
13 O
. O
3 O
- O
fold O
. O
Rifampin B-DRUG
significantly O
decreased O
the O
AUC O
( O
ss O
) O
of O
amprenavir B-DRUG
by O
82 O
% O
, O
but O
amprenavir B-DRUG
had O
no O
effect O
on O
rifampin B-DRUG
pharmacokinetics O
. O
Amprenavir B-DRUG
decreased O
the O
results O
of O
the O
ERMBT O
by O
83 O
% O
. O
The O
results O
of O
the O
ERMBT O
after O
2 O
weeks O
of O
rifabutin B-DRUG
and O
rifampin B-DRUG
therapy O
were O
increased O
187 O
and O
156 O
% O
, O
respectively O
. O
Amprenavir B-DRUG
plus O
rifampin B-DRUG
was O
well O
tolerated O
. O
Amprenavir B-DRUG
plus O
rifabutin B-DRUG
was O
poorly O
tolerated O
, O
and O
5 O
of O
11 O
subjects O
discontinued O
therapy O
. O
Rifampin B-DRUG
markedly O
increases O
the O
metabolic O
clearance O
of O
amprenavir B-DRUG
, O
and O
coadministration O
is O
contraindicated O
. O

Amprenavir B-DRUG
significantly O
decreases O
clearance O
of O
rifabutin B-DRUG
and O
25 B-DRUG_N
- I-DRUG_N
O I-DRUG_N
- I-DRUG_N
desacetylrifabutin I-DRUG_N
, O
and O
the O
combination O
is O
poorly O
tolerated O
. O
Amprenavir B-DRUG
inhibits O
the O
ERMBT O
, O
and O
rifampin B-DRUG
and O
rifabutin B-DRUG
are O
equipotent O
inducers O
of O
the O
ERMBT O
. O

New O
oral O
therapies O
for O
type O
2 O
diabetes O
mellitus O
: O
The O
glitazones B-GROUP
or O
insulin O
sensitizers O
. O
Type O
2 O
diabetes O
mellitus O
is O
a O
growing O
problem O
not O
only O
in O
the O
United O
States O
but O
also O
across O
the O
world O
. O
There O
is O
now O
strong O
evidence O
that O
intensive O
control O
of O
blood O
glucose O
can O
significantly O
reduce O
and O
retard O
the O
microvascular O
complications O
of O
retinopathy O
, O
nephropathy O
, O
and O
neuropathy O
. O
Ultimately O
however O
, O
up O
to O
80 O
% O
of O
type O
2 O
diabetics O
die O
from O
macrovascular O
cardiovascular O
disease O
. O
This O
increased O
incidence O
of O
atherosclerotic O
disease O
is O
intricately O
associated O
with O
insulin O
resistance O
, O
which O
is O
a O
major O
pathophysiologic O
abnormality O
in O
type O
2 O
diabetes O
. O
There O
is O
strong O
evidence O
that O
insulin O
resistance O
is O
involved O
in O
the O
development O
of O
not O
only O
hyperglycemia O
, O
but O
also O
dyslipidemia O
, O
hypertension O
, O
hypercoagulation O
, O
vasculopathy O
, O
and O
ultimately O
atherosclerotic O
cardiovascular O
disease O
. O
This O
cluster O
of O
metabolic O
abnormalities O
has O
been O
termed O
the O
insulin O
resistance O
or O
cardiovascular O
dysmetabolic O
syndrome O
. O
The O
thiazolidinediones B-GROUP
( O
rosiglitazone B-DRUG
and O
pioglitazone B-DRUG
) O
, O
a O
new O
class O
of O
oral O
antidiabetic B-GROUP
agents I-GROUP
, O
are O
" O
insulin O
sensitizers O
" O
and O
exert O
direct O
effects O
on O
the O
mechanisms O
of O
insulin O
resistance O
. O
These O
effects O
not O
only O
improve O
insulin O
sensitivity O
and O
glycemic O
control O
with O
reduced O
insulin O
requirements O
, O
but O
also O
have O
potentially O
favorable O
effects O
on O
other O
components O
of O
the O
cardiovascular O
dysmetabolic O
syndrome O
. O
Long O
- O
term O
studies O
are O
needed O
to O
determine O
whether O
the O
insulin O
- O
sensitizing O
effects O
of O
the O
glitazones B-GROUP
can O
prevent O
or O
delay O
premature O
atherosclerotic O
cardiovascular O
disease O
, O
morbidity O
, O
and O
death O
. O

Responses O
to O
arginine B-DRUG
of O
the O
perfused O
pancreas O
of O
the O
genetically O
diabetic O
Chinese O
hamster O
. O
Nonketotic O
, O
genetically O
diabetic O
Cinese O
hamsters O
show O
subnormal O
pancreatic O
insulin O
release O
and O
impaired O
suppression O
of O
glucagon O
in O
response O
to O
glucose O
. O
To O
study O
the O
pancreatic O
effects O
of O
other O
agents O
, O
dynamic O
insulin O
and O
glucagon O
release O
was O
measured O
from O
the O
in O
vitro O
perfused O
pancreases O
of O
normal O
and O
diabetic O
Chinese O
hamsters O
in O
response O
to O
various O
combinations O
of O
arginine B-DRUG
( O
20mM O
) O
, O
glucose B-DRUG
( O
100 O
or O
150 O
mg O
. O
per O
100 O
ml O
. O
) O
, O
and O
theophylline B-DRUG
( O
10 O
mM O
) O
. O
Theophylline B-DRUG
alone O
caused O
identical O
insulin O
and O
glucagon O
release O
in O
diabetics O
and O
normals O
. O
Glucose B-DRUG
, O
alone O
and O
in O
the O
presence O
of O
theophylline B-DRUG
, O
caused O
subnormal O
insulin O
release O
and O
less O
suppression O
of O
glucagon O
release O
in O
the O
diabectics O
than O
in O
the O
normals O
. O
Arginine B-DRUG
, O
in O
the O
presence O
of O
glucose B-DRUG
and O
theophylline B-DRUG
, O
caused O
excessive O
glucagon O
release O
but O
nearly O
normal O
insulin O
release O
in O
the O
diabetics O
. O
Arginine B-DRUG
, O
in O
the O
absence O
of O
glucose B-DRUG
or O
theophylline B-DRUG
, O
caused O
excessive O
glucagon O
release O
in O
the O
diabetics O
and O
undetectable O
insulin O
release O
in O
either O
diabetics O
or O
normals O
. O
Pancreatic O
content O
after O
perfusion O
did O
not O
correlate O
with O
release O
during O
perfusion O
. O
Infusion O
of O
arginine B-DRUG
alone O
markedly O
decreased O
the O
amount O
of O
extractable O
pancreatic O
insulin O
and O
glucagon O
. O
These O
results O
indicate O
that O
the O
pancreatic O
alpha O
cell O
of O
the O
diabetic O
Chinese O
hamster O
responds O
excessively O
to O
arginine B-DRUG
, O
as O
is O
seen O
in O
the O
human O
diabetic O
. O
This O
defect O
is O
not O
related O
to O
acute O
insulin O
release O
or O
the O
presence O
of O
glucose B-DRUG
. O
Further O
, O
these O
results O
confirm O
that O
the O
diabetic O
Chinese O
hamster O
' O
s O
alpha O
and O
beta O
cells O
respond O
normally O
to O
theophylline B-DRUG
, O
but O
are O
relatively O
insensitive O
to O
glucose B-DRUG
. O

Effects O
of O
etofibrate B-DRUG
upon O
the O
metabolism O
of O
chylomicron O
- O
like O
emulsions O
in O
patients O
with O
coronary O
artery O
disease O
. O
Slow O
chylomicron O
intravascular O
catabolism O
has O
been O
associated O
with O
coronary O
artery O
disease O
and O
screening O
for O
drugs O
that O
can O
speed O
- O
up O
this O
process O
can O
be O
important O
. O
In O
this O
study O
, O
the O
effects O
of O
etofibrate B-DRUG
upon O
chylomicron O
metabolism O
was O
tested O
by O
determination O
of O
the O
plasma O
kinetics O
of O
a O
chylomicron O
- O
like O
emulsion O
model O
in O
12 O
patients O
with O
coronary O
artery O
disease O
, O
aged O
59 O
+ O
/ O
- O
11 O
years O
, O
( O
total O
cholesterol O
: O
240 O
+ O
/ O
- O
41 O
mg O
/ O
dl O
; O
triglycerides O
: O
188 O
+ O
/ O
- O
42 O
mg O
/ O
dl O
) O
submitted O
to O
a O
randomized O
, O
crossover O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
with O
administration O
of O
1 O
g O
per O
day O
etofibrate B-DRUG
or O
placebo O
for O
1 O
- O
month O
. O
A O
1 O
- O
month O
washout O
period O
was O
inserted O
between O
the O
treatment O
periods O
. O
Patients O
were O
intravenously O
injected O
a O
chylomicron O
- O
like O
emulsion O
doubly O
labeled O
with O
14C O
- O
cholesteryl O
oleate O
and O
3H O
- O
triolein O
at O
baseline O
and O
after O
treatments O
. O
After O
etofibrate B-DRUG
treatment O
, O
there O
was O
decrease O
of O
total O
cholesterol O
and O
triglyceride O
plasma O
levels O
and O
a O
trend O
to O
increase O
high O
- O
density O
lipoprotein O
cholesterol O
plasma O
levels O
. O
Etofibrate B-DRUG
elicited O
62 O
% O
enhancement O
of O
post O
- O
heparin B-DRUG
lipolytic O
activity O
and O
100 O
% O
increase O
of O
3H O
- O
triglyceride O
fractional O
clearance O
rate O
compared O
with O
placebo O
treatment O
. O
14C O
- O
cholesterol O
ester O
fractional O
clearance O
rate O
was O
260 O
% O
greater O
after O
etofibrate B-DRUG
than O
after O
placebo O
. O
Therefore O
, O
a O
potent O
effect O
of O
etofibrate B-DRUG
on O
both O
chylomicron O
lipolysis O
and O
remnant O
removal O
was O
achieved O
, O
indicating O
that O
this O
drug O
can O
be O
used O
to O
improve O
this O
metabolism O
in O
future O
prospective O
studies O
. O

The O
mode O
of O
toxic O
action O
of O
the O
pesticide O
gliftor B-DRUG_N
: O
the O
metabolism O
of O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoroacetone I-DRUG_N
to O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
erythro I-DRUG_N
- I-DRUG_N
fluorocitrate I-DRUG_N
. O
The O
biochemical O
toxicology O
of O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoroacetone I-DRUG_N
, O
a O
known O
metabolite O
of O
the O
major O
ingredient O
of O
the O
pesticide O
Gliftor B-DRUG_N
( O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoro I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
propanol I-DRUG_N
) O
, O
was O
investigated O
in O
vivo O
and O
in O
vitro O
. O
Rat O
kidney O
homogenates O
supplemented O
with O
coenzyme O
A O
, O
ATP O
, O
oxaloacetate O
, O
and O
Mg2 O
+ O
converted O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoroacetone I-DRUG_N
to O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
erythro I-DRUG_N
- I-DRUG_N
fluorocitrate I-DRUG_N
in O
vitro O
. O
Administration O
of O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoroacetone I-DRUG_N
( O
100 O
mg O
kg O
( O
- O
1 O
) O
body O
weight O
) O
to O
rats O
in O
vivo O
resulted O
in O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
erythro I-DRUG_N
- I-DRUG_N
fluorocitrate I-DRUG_N
synthesis O
in O
the O
kidney O
, O
which O
was O
preceded O
by O
an O
elevation O
in O
fluoride O
levels O
and O
followed O
by O
citrate O
accumulation O
. O
Animals O
dosed O
with O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoroacetone I-DRUG_N
did O
not O
display O
the O
2 O
- O
3 O
hour O
lag O
phase O
in O
either O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
erythro I-DRUG_N
- I-DRUG_N
fluorocitrate I-DRUG_N
synthesis O
or O
in O
citrate O
and O
fluoride O
accumulation O
characteristic O
of O
animals O
dosed O
with O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoro I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
propanol I-DRUG_N
. O
We O
demonstrate O
that O
the O
conversion O
of O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoro I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
propanol I-DRUG_N
to O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoroacetone I-DRUG_N
by O
an O
NAD O
+ O
- O
dependent O
oxidation O
is O
the O
rate O
- O
limiting O
step O
in O
the O
synthesis O
of O
the O
toxic O
product O
, O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
erythro I-DRUG_N
- I-DRUG_N
fluorocitrate I-DRUG_N
from O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoro I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
propanol I-DRUG_N
. O
Prior O
administration O
of O
4 B-DRUG
- I-DRUG
methylpyrazole I-DRUG
( O
90 O
mg O
kg O
( O
- O
1 O
) O
body O
weight O
) O
was O
shown O
to O
prevent O
the O
conversion O
of O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoro I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
propanol I-DRUG_N
( O
100 O
mg O
kg O
( O
- O
1 O
) O
body O
weight O
) O
to O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
erythro I-DRUG_N
- I-DRUG_N
fluorocitrate I-DRUG_N
in O
vivo O
and O
to O
eliminate O
the O
fluoride O
and O
citrate O
elevations O
seen O
in O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoro I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
propanol I-DRUG_N
- O
intoxicated O
animals O
. O
However O
, O
administration O
of O
4 B-DRUG
- I-DRUG
methylpyrazole I-DRUG
( O
90 O
mg O
kg O
( O
- O
1 O
) O
body O
weight O
) O
to O
rats O

2 O
hours O
prior O
to O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoroacetone I-DRUG_N
( O
100 O
mg O
kg O
( O
- O
1 O
) O
body O
weight O
) O
was O
ineffective O
in O
preventing O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
erythro I-DRUG_N
- I-DRUG_N
fluorocitrate I-DRUG_N
synthesis O
and O
did O
not O
diminish O
fluoride O
or O
citrate O
accumulation O
in O
vivo O
. O
We O
conclude O
that O
the O
prophylactic O
and O
antidotal O
properties O
of O
4 B-DRUG
- I-DRUG
methylpyrazole I-DRUG
seen O
in O
animals O
treated O
with O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoro I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
propanol I-DRUG_N
derive O
from O
its O
capacity O
to O
inhibit O
the O
NAD O
+ O
- O
dependent O
oxidation O
responsible O
for O
converting O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoro I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
propanol I-DRUG_N
to O
1 B-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
difluoroacetone I-DRUG_N
in O
the O
committed O
step O
of O
the O
toxic O
pathway O
. O

Pharmacology O
and O
pharmacotherapy O
of O
cardiovascular O
drugs O
in O
patients O
with O
chronic O
renal O
disease O
. O
Cardiovascular O
disease O
is O
a O
common O
comorbidity O
and O
a O
major O
cause O
of O
mortality O
in O
patients O
with O
chronic O
renal O
disease O
. O
Drug O
regimens O
in O
patients O
with O
cardiovascular O
disease O
are O
frequently O
complex O
and O
can O
be O
significantly O
affected O
by O
alterations O
in O
renal O
function O
. O
In O
addition O
, O
several O
cardiovascular O
drugs O
directly O
affect O
renal O
function O
and O
the O
management O
of O
patients O
with O
renal O
disease O
. O
This O
article O
reviews O
the O
impact O
of O
renal O
disease O
on O
the O
pharmacokinetics O
of O
cardiovascular O
drugs O
and O
identifies O
clinically O
important O
interactions O
between O
these O
and O
other O
drugs O
commonly O
used O
in O
the O
management O
of O
chronic O
renal O
disease O
. O
Several O
classes O
of O
cardiovascular O
drugs O
are O
also O
discussed O
in O
relationship O
to O
their O
differential O
effects O
on O
the O
management O
and O
progression O
of O
renal O
disease O
. O

Green B-DRUG
tea I-DRUG
polyphenols I-DRUG
as O
potent O
enhancers B-DRUG
of O
glucocorticoid O
- O
induced O
mouse O
mammary O
tumor O
virus O
gene O
expression O
. O
The O
effect O
of O
natural O
and O
synthetic O
galloyl O
esters O
on O
glucocorticoid O
- O
induced O
gene O
expression O
was O
evaluated O
by O
using O
rat O
fibroblast O
3Y1 O
cells O
stably O
transfected O
with O
a O
luciferase O
reporter O
gene O
under O
the O
transcriptional O
regulation O
of O
the O
mouse O
mammary O
tumor O
virus O
promoter B-DRUG
. O
The O
glucocorticoid O
- O
induced O
gene O
transcription O
was O
strongly O
suppressed O
by O
synthetic O
alkyl O
esters O
; O
n B-DRUG
- I-DRUG
dodecyl I-DRUG
gallate I-DRUG
showed O
the O
most O
potent O
inhibition O
( O
66 O
% O
inhibition O
at O
10 O
microM O
) O
, O
which O
was O
far O
more O
potent O
than O
that O
of O
crude O
tannic B-DRUG
acid I-DRUG
. O
n O
- O
Octyl O
and O
n O
- O
cetyl O
gallate O
also O
showed O
good O
inhibition O
, O
while O
gallic O
acid O
itself O
was O
not O
so O
active O
, O
suggesting O
that O
the O
presence O
of O
hydrophobic O
side O
chain O
is O
important O
for O
the O
suppressive O
effect O
. O
On O
the O
other O
hand O
, O
surprisingly O
, O
green B-DRUG
tea I-DRUG
gallocatechins I-DRUG
, O
( O
- O
) O
- O
epigallocatechin O
- O
3 O
- O
O O
- O
gallate O
and O
theasinensin O
A O
, O
potently O
enhanced O
the O
promoter O
activity O
( O
182 O
and O
247 O
% O
activity O
at O
1 O
microM O
, O
respectively O
) O
. O
The O
regulation O
of O
the O
level O
of O
the O
glucocorticoid O
- O
induced O
gene O
expression O
by O
the O
antioxidative O
gallates O
is O
of O
great O
interest O
from O
a O
therapeutic O
point O
of O
view O
. O

Pharmacokinetic O
interaction O
between O
single O
oral O
doses O
of O
diltiazem B-DRUG
and O
sirolimus B-DRUG
in O
healthy O
volunteers O
. O
AIM O
AND O
BACKGROUND O
: O
The O
pharmacokinetic O
interaction O
between O
sirolimus B-DRUG
, O
a O
macrolide B-GROUP
immunosuppressant I-GROUP
metabolized O
by O
CYP3A4 O
, O
and O
the O
calcium B-GROUP
channel I-GROUP
blocker I-GROUP
diltiazem B-DRUG
was O
studied O
in O
18 O
healthy O
subjects O
. O
Several O
clinically O
important O
interactions O
have O
previously O
been O
reported O
for O
other O
immunosuppressive B-GROUP
drugs I-GROUP
that O
are O
metabolized O
by O
the O
same O
enzyme O
and O
for O
calcium B-GROUP
antagonists I-GROUP
. O
METHODS O
: O
Healthy O
subjects O
who O
were O
20 O
to O
43 O
years O
old O
participated O
in O
an O
open O
, O
three O
- O
period O
, O
randomized O
, O
crossover O
study O
of O
the O
pharmacokinetics O
of O
a O
single O
10 O
- O
mg O
oral O
dose O
of O
sirolimus B-DRUG
, O
a O
single O
oral O
120 O
- O
mg O
dose O
of O
diltiazem B-DRUG
, O
and O
the O
two O
drugs O
given O
together O
. O
The O
three O
study O
periods O
were O
separated O
by O
a O
21 O
- O
day O
washout O
phase O
. O
RESULTS O
: O
The O
geometric O
mean O
( O
90 O
% O
confidence O
interval O
) O
whole O
blood O
sirolimus B-DRUG
area O
under O
the O
plasma O
concentration O
time O
- O
curve O
increased O
60 O
% O
( O
35 O
% O
- O
90 O
% O
) O
, O
from O
736 O
to O
1178 O
ng O
x O
h O
/ O
mL O
, O
and O
maximum O
concentration O
increased O
43 O
% O
( O
14 O
% O
- O
81 O
% O
) O
, O
from O
67 O
to O
96 O
ng O
/ O
mL O
, O
with O
diltiazem B-DRUG
coadministration O
, O
whereas O
the O
mean O
elimination O
half O
- O
life O
of O
sirolimus B-DRUG
decreased O
slightly O
, O
from O
79 O
to O
67 O
hours O
. O
Apparent O
oral O
clearance O
and O
volume O
of O
distribution O
of O
sirolimus B-DRUG
decreased O
with O
38 O
% O
and O
45 O
% O
, O
respectively O
, O
when O
sirolimus B-DRUG
was O
given O
with O
diltiazem B-DRUG
. O
The O
plasma O
maximum O
concentration O
and O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
of O
diltiazem B-DRUG
, O
desacetyldiltiazem B-DRUG_N
, O
and O
desmethyldiltiazem B-DRUG_N
were O
unchanged O
after O
coadministration O
of O
sirolimus B-DRUG
, O
and O
no O
potentiation O
of O
the O
effects O
of O
diltiazem B-DRUG
on O
diastolic O
or O
systolic O
blood O
pressure O
or O
on O
the O
electrocardiographic O
parameters O
was O
seen O
. O
CONCLUSIONS O
: O
Single O
- O
dose O
diltiazem B-DRUG
coadministration O
leads O
to O
higher O
sirolimus B-DRUG
exposure O
, O
presumably O
by O
inhibition O
of O
the O
first O
- O
pass O
metabolism O
of O
sirolimus B-DRUG
. O
Because O
of O
the O
pronounced O
intersubject O
variability O
in O
the O
extent O
of O
the O
sirolimus B-DRUG
- O
diltiazem B-DRUG
interaction O
, O
whole O
blood O
sirolimus B-DRUG
concentrations O
should O
be O
monitored O

closely O
in O
patients O
treated O
with O
the O
two O
drugs O
. O

Fluvoxamine B-DRUG
inhibits O
the O
CYP2C9 O
catalyzed O
biotransformation O
of O
tolbutamide B-DRUG
. O
OBJECTIVE O
: O
Our O
objective O
was O
to O
examine O
the O
interaction O
between O
fluvoxamine B-DRUG
and O
tolbutamide B-DRUG
to O
confirm O
that O
fluvoxamine B-DRUG
inhibits O
CYP2C9 O
. O
METHODS O
: O
The O
study O
was O
carried O
out O
as O
an O
open O
, O
randomized O
, O
crossover O
design O
with O
14 O
healthy O
participants O
. O
In O
period O
A O
, O
all O
volunteers O
took O
500 O
mg O
of O
tolbutamide B-DRUG
orally O
. O
In O
period O
B O
, O
the O
volunteers O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
Each O
group O
took O
either O
150 O
mg O
or O
75 O
mg O
of O
fluvoxamine B-DRUG
a O
day O
for O
5 O
days O
( O
day O
- O
3 O
to O
day O
2 O
) O
. O
The O
groups O
then O
took O
500 O
mg O
of O
tolbutamide B-DRUG
as O
a O
single O
dose O
( O
day O
0 O
) O
. O
In O
both O
periods O
, O
blood O
and O
urine O
were O
sampled O
at O
regular O
intervals O
. O
Plasma O
was O
analyzed O
for O
tolbutamide B-DRUG
, O
and O
urine O
was O
analyzed O
for O
tolbutamide B-DRUG
and O
its O
two O
metabolites O
, O
4 B-DRUG_N
- I-DRUG_N
hydroxytolbutamide I-DRUG_N
and O
carboxytolbutamide B-DRUG_N
by O
means O
of O
HPLC O
. O
RESULTS O
: O
During O
treatment O
with O
fluvoxamine B-DRUG
, O
there O
was O
a O
statistically O
significant O
decrease O
in O
the O
median O
of O
the O
total O
clearance O
of O
tolbutamide B-DRUG
, O
from O
845 O
mL O
/ O
h O
to O
688 O
mL O
/ O
h O
, O
among O
the O
volunteers O
who O
received O
75 O
mg O
/ O
d O
. O
There O
was O
a O
reduction O
that O
reached O
borderline O
statistical O
significance O
in O
the O
group O
that O
received O
150 O
mg O
/ O
d O
of O
tolbutamide B-DRUG
. O
The O
clearance O
by O
means O
of O
4 B-DRUG_N
- I-DRUG_N
hydroxytolbutamide I-DRUG_N
and O
carboxytolbutamide B-DRUG_N
was O
significantly O
reduced O
in O
both O
groups O
( O
ie O
, O
from O
901 O
mL O
/ O
h O
to O
318 O
mL O
/ O
h O
in O
the O
group O
that O
received O
150 O
mg O
of O
tolbutamide B-DRUG
per O
day O
and O
from O
723 O
mL O
/ O
h O
to O
457 O
mL O
/ O
h O
in O
the O
group O
that O
received O
75 O
mg O
of O
tolbutamide B-DRUG
per O
day O
) O
. O
Thus O
there O
was O
a O
tendency O
toward O
a O
more O
pronounced O
inhibition O
of O
the O
4 O
- O
hydroxylation O
during O
treatment O
with O
150 O
mg O
/ O
d O
of O
fluvoxamine B-DRUG
compared O
with O
75 O
mg O
/ O
d O
, O
but O
the O
difference O
was O
not O
statistically O
significant O
. O
CONCLUSION O
: O
Fluvoxamine B-DRUG
is O
a O
moderate O
inhibitor O
of O
CYP2C9 O
in O
vivo O
. O

Longitudinal O
assessment O
of O
everolimus B-DRUG
in O
de O
novo O
renal O
transplant O
recipients O
over O
the O
first O
post O
- O
transplant O
year O
: O
pharmacokinetics O
, O
exposure O
- O
response O
relationships O
, O
and O
influence O
on O
cyclosporine B-DRUG
. O
OBJECTIVE O
: O
Our O
objective O
was O
to O
characterize O
the O
steady O
- O
state O
pharmacokinetics O
of O
everolimus B-DRUG
and O
cyclosporine B-DRUG
( O
INN O
, O
ciclosporin B-DRUG
) O
when O
coadministered O
in O
de O
novo O
kidney O
allograft O
recipients O
during O
the O
first O
year O
after O
transplantation O
. O
METHOD O
: O
This O
study O
was O
a O
multicenter O
randomized O
double O
- O
blind O
study O
of O
101 O
patients O
who O
were O
randomly O
assigned O
1 O
: O
1 O
: O
1 O
to O
receive O
everolimus B-DRUG
tablets O
at O
doses O
of O
0 O
. O
5 O
mg O
, O
1 O
mg O
, O
or O
2 O
mg O
twice O
daily O
with O
cyclosporine B-DRUG
and O
prednisone B-DRUG
. O
Blood O
sampling O
for O
the O
pharmacokinetics O
of O
everolimus B-DRUG
and O
cyclosporine B-DRUG
was O
performed O
on O
day O
1 O
, O
on O
weeks O
1 O
, O
2 O
, O
3 O
, O
and O
4 O
, O
and O
on O
months O
2 O
, O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
. O
Everolimus B-DRUG
dose O
- O
proportionality O
and O
stability O
over O
time O
were O
assessed O
in O
the O
context O
of O
linear O
regression O
and O
ANOVA O
models O
. O
Everolimus B-DRUG
exposure O
- O
response O
relationships O
between O
area O
under O
the O
blood O
concentration O
- O
time O
curve O
( O
AUC O
) O
and O
changes O
in O
platelets O
, O
leukocytes O
, O
and O
lipids O
were O
explored O
with O
the O
median O
- O
effect O
model O
. O
Potential O
differences O
in O
cyclosporine B-DRUG
dosing O
and O
pharmacokinetics O
at O
different O
levels O
of O
everolimus B-DRUG
exposure O
were O
assessed O
in O
the O
context O
of O
ANOVA O
. O
RESULTS O
: O
Everolimus B-DRUG
steady O
state O
was O
reached O
on O
or O
before O
day O
7 O
, O
with O
a O
median O
3 O
- O
fold O
accumulation O
of O
drug O
exposure O
compared O
with O
that O
after O
the O
first O
postoperative O
dose O
. O
Both O
steady O
- O
state O
maximum O
concentration O
and O
AUC O
were O
dose O
proportional O
over O
the O
full O
dose O
range O
when O
assessed O
on O
day O
1 O
, O
as O
well O
as O
for O
the O
full O
duration O
of O
the O
study O
at O
steady O
state O
. O
There O
was O
evidence O
for O
longitudinal O
stability O
in O
AUC O
of O
everolimus B-DRUG
during O
the O
course O
of O
the O
study O
. O
The O
interindividual O
pharmacokinetic O
variability O
for O
AUC O
was O
85 O
. O
4 O
% O
and O
intraindividual O
, O
interoccasion O
variability O
was O
40 O
. O
8 O
% O
. O
Age O
( O
range O
, O
17 O
- O
69 O
years O
) O
, O
weight O
( O
range O
, O
49 O
- O
106 O
kg O
) O
, O
and O
sex O
( O
65 O
men O
and O
36 O
women O
) O
were O
not O
significant O
contributors O
to O
variability O

. O
There O
was O
an O
increasing O
incidence O
of O
transient O
thrombocytopenia O
( O
or O
= O
100 O
x O
10 O
( O
9 O
) O
/ O
L O
) O
with O
increasing O
everolimus B-DRUG
AUC O
( O
P O
= O
. O
03 O
) O
. O
Cyclosporine B-DRUG
doses O
, O
trough O
concentrations O
, O
and O
AUC O
exhibited O
similar O
temporal O
patterns O
during O
the O
course O
of O
the O
study O
regardless O
of O
the O
co O
- O
administered O
everolimus B-DRUG
dose O
level O
( O
P O
= O
. O
13 O
, O
. O
82 O
, O
and O
. O
76 O
, O
respectively O
) O
. O
CONCLUSIONS O
: O
Everolimus B-DRUG
exhibited O
dose O
- O
proportional O
, O
stable O
exposure O
during O
the O
first O
post O
- O
transplant O
year O
. O
For O
a O
4 O
- O
fold O
range O
of O
everolimus B-DRUG
doses O
there O
were O
no O
differential O
effects O
on O
cyclosporine B-DRUG
dosing O
or O
pharmacokinetics O
. O

ADL B-DRUG
8 I-DRUG
- I-DRUG
2698 I-DRUG
, O
a O
trans O
- O
3 O
, O
4 O
- O
dimethyl O
- O
4 O
- O
( O
3 O
- O
hydroxyphenyl O
) O
piperidine O
, O
prevents O
gastrointestinal O
effects O
of O
intravenous O
morphine B-DRUG
without O
affecting O
analgesia O
. O
ADL B-DRUG
- I-DRUG
8 I-DRUG
- I-DRUG
2698 I-DRUG
is O
a O
novel O
peripherally B-GROUP
restricted I-GROUP
opioid I-GROUP
antagonist I-GROUP
that O
may O
selectively O
prevent O
opioid B-GROUP
- O
induced O
gastrointestinal O
effects O
without O
reversing O
analgesia O
. O
Gastrointestinal O
transit O
time O
( O
lactulose O
hydrogen O
breath O
test O
) O
was O
measured O
in O
14 O
volunteers O
with O
oral O
and O
intravenous O
placebo O
, O
oral O
placebo O
and O
intravenous O
morphine B-DRUG
( O
0 O
. O
05 O
mg O
x O
kg O
( O
- O
1 O
) O
) O
, O
and O
oral O
ADL B-DRUG
8 I-DRUG
- I-DRUG
2698 I-DRUG
( O
4 O
mg O
) O
and O
intravenous O
morphine B-DRUG
( O
0 O
. O
05 O
mg O
x O
kg O
( O
- O
1 O
) O
) O
in O
a O
double O
blind O
, O
cross O
- O
over O
study O
. O
Morphine B-DRUG
prolonged O
gastrointestinal O
transit O
time O
from O
69 O
to O
103 O
minutes O
( O
P O
= O
. O
005 O
) O
; O
Morphine B-DRUG
prolonged O
gastrointestinal O
transit O
time O
from O
69 O
to O
103 O
minutes O
( O
P O
= O
. O
005 O
) O
; O
this O
was O
prevented O
by O
ADL B-DRUG
8 I-DRUG
- I-DRUG
2698 I-DRUG
( O
P O
= O
. O
004 O
) O
. O
Postoperatively O
, O
45 O
patients O
were O
randomly O
assigned O
in O
a O
double O
- O
blind O
fashion O
to O
receive O
ADL B-DRUG
8 I-DRUG
- I-DRUG
2698 I-DRUG
( O
4 O
mg O
) O
or O
placebo O
and O
intravenous O
morphine B-DRUG
( O
0 O
. O
15 O
mg O
/ O
kg O
) O
or O
to O
receive O
oral O
and O
intravenous O
placebo O
. O
Analgesia O
and O
pupil O
constriction O
were O
measured O
. O
Morphine B-DRUG
analgesia O
and O
pupil O
constriction O
were O
unaffected O
by O
ADL B-DRUG
8 I-DRUG
- I-DRUG
2698 I-DRUG
and O
differed O
from O
placebo O
( O
P O
< O
. O
002 O
) O
. O
We O
conclude O
that O
ADL B-DRUG
8 I-DRUG
- I-DRUG
2698 I-DRUG
prevents O
morphine B-DRUG
- O
induced O
increases O
in O
gastrointestinal O
transit O
time O
by O
means O
of O
selective O
peripheral O
opioid O
anitagonism O
without O
affecting O
central O
opioid O
analgesia O
. O

Restoration O
of O
vancomycin B-DRUG
susceptibility O
in O
Enterococcus O
faecalis O
by O
antiresistance O
determinant O
gene O
transfer O
. O
We O
assessed O
the O
ability O
of O
gene O
transfer O
to O
reverse O
vancomycin B-DRUG
resistance O
in O
class O
A O
( O
VanA O
) O
glycopeptide O
- O
resistant O
Enterococcus O
faecalis O
. O
Recombinant O
shuttle O
vectors O
containing O
a O
vanH O
promoter O
- O
vanA O
antisense O
gene O
cassette O
fully O
restored O
vancomycin B-DRUG
susceptibility O
through O
a O
combined O
transcriptional O
activator O
binding O
domain O
decoy O
and O
inducible O
vanA O
antisense O
RNA O
effect O
. O

Rhabdomyolysis O
secondary O
to O
a O
drug O
interaction O
between O
simvastatin B-DRUG
and O
clarithromycin B-DRUG
. O
OBJECTIVE O
: O
To O
report O
a O
case O
of O
rhabdomyolysis O
resulting O
from O
concomitant O
use O
of O
clarithromycin B-DRUG
and O
simvastatin B-DRUG
. O
CASE O
SUMMARY O
: O
A O
64 O
- O
year O
- O
old O
African O
- O
American O
man O
was O
admitted O
to O
the O
hospital O
for O
worsening O
renal O
failure O
, O
elevated O
creatine O
phosphokinase O
, O
diffuse O
muscle O
pain O
, O
and O
severe O
muscle O
weakness O
. O
About O
three O
weeks O
prior O
to O
admission O
, O
the O
patient O
was O
started O
on O
clarithromycin B-DRUG
for O
sinusitis O
. O
The O
patient O
had O
been O
receiving O
simvastatin B-DRUG
for O
approximately O
six O
months O
. O
He O
was O
treated O
aggressively O
with O
intravenous O
hydration O
, O
sodium B-DRUG
bicarbonate I-DRUG
, O
and O
hemodialysis O
. O
A O
muscle O
biopsy O
revealed O
necrotizing O
myopathy O
secondary O
to O
a O
toxin O
. O
The O
patient O
continued O
to O
receive O
intermittent O
hemodialysis O
until O
his O
death O
from O
infectious O
complications O
that O
occurred O
three O
months O
after O
admission O
. O
There O
were O
several O
factors O
that O
could O
have O
increased O
his O
risk O
for O
developing O
rhabdomyolysis O
, O
including O
chronic O
renal O
failure O
. O
DISCUSSION O
: O
Clarithromycin B-DRUG
is O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
the O
major O
enzyme O
responsible O
for O
simvastatin B-DRUG
metabolism O
. O
The O
concomitant O
administration O
of O
macrolide B-GROUP
antibiotics I-GROUP
and O
other O
hydroxymethylglutaryl B-GROUP
coenzyme I-GROUP
A I-GROUP
( I-GROUP
HMG I-GROUP
- I-GROUP
CoA I-GROUP
) I-GROUP
reductase I-GROUP
inhibitors I-GROUP
have O
resulted O
in O
previous O
reports O
of O
rhabdomyolysis O
. O
Other O
factors O
may O
increase O
the O
risk O
of O
this O
drug O
interaction O
, O
including O
the O
administration O
of O
other O
medications O
that O
are O
associated O
with O
myopathy O
, O
underlying O
renal O
insufficiency O
, O
and O
administration O
of O
high O
doses O
of O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
. O
CONCLUSIONS O
: O
Macrolide B-GROUP
antibiotics I-GROUP
inhibit O
the O
metabolism O
of O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
that O
are O
metabolized O
by O
CYP3A4 O
( O
i O
. O
e O
. O
, O
atorvastatin B-DRUG
, O
cerivastatin B-DRUG
, O
lovastatin B-DRUG
, O
simvastatin B-DRUG
) O
. O
This O
interaction O
may O
result O
in O
myopathy O
and O
rhabdomyolysis O
, O
particularly O
in O
patients O
with O
renal O
insufficiency O
or O
those O
who O
are O
concurrently O
taking O
medications O
associated O
with O
myopathy O
. O

Toxicity O
of O
cadmium O
and O
zinc B-DRUG
to O
encystment O
and O
in O
vitro O
excystment O
of O
Parorchis O
acanthus O
( O
Digenea O
: O
Philophthalmidae O
) O
. O
The O
toxicity O
of O
cadmium O
, O
zinc B-DRUG
and O
cadmium O
/ O
zinc O
mixtures O
at O
concentrations O
ranging O
from O
1000 O
to O
50000 O
microg O
/ O
l O
were O
investigated O
against O
cercariae O
and O
metacercariae O
of O
Parorchis O
acanthus O
obtained O
from O
the O
dog O
whelk O
Nucella O
lapillus O
. O
Cercarial O
encystment O
at O
concentrations O
of O
25000 O
microg O
/ O
l O
or O
higher O
was O
significantly O
impaired O
by O
all O
test O
metals O
; O
however O
, O
at O
lower O
concentrations O
only O
zinc B-DRUG
demonstrated O
toxicity O
. O
Mixtures O
of O
cadmium O
and O
zinc B-DRUG
had O
a O
synergistic O
effect O
compared O
with O
single O
metal O
toxicity O
but O
only O
at O
50000 O
microg O
/ O
l O
. O
Excystment O
in O
vitro O
was O
only O
significantly O
affected O
by O
cercariae O
exposed O
to O
cadmium O
/ O
zinc O
mixtures O
whilst O
encysting O
. O
Twenty O
- O
four O
h O
exposures O
of O
fully O
formed O
cysts O
had O
no O
effect O
on O
excystment O
in O
vitro O
. O
Effects O
on O
in O
vitro O
excystment O
rates O
over O
a O
2 O
h O
period O
demonstrated O
widespread O
effects O
for O
cercariae O
- O
exposed O
P O
. O
acanthus O
. O
No O
effects O
were O
evident O
on O
excystment O
rates O
of O
cyst O
- O
exposed O
parasites O
. O

Toxicity O
of O
cadmium O
and O
zinc B-DRUG
to O
miracidia O
of O
Schistosoma O
mansoni O
. O
The O
specific O
objectives O
of O
this O
study O
were O
to O
elucidate O
metal O
toxicity O
to O
hatching O
, O
survival O
and O
avoidance O
behaviour O
of O
Schistosoma O
mansoni O
miracidia O
. O
The O
toxicity O
of O
cadmium O
, O
zinc B-DRUG
, O
and O
cadmium O
/ O
zinc O
mixtures O
at O
concentrations O
ranging O
from O
10000 O
to O
10 O
microg O
/ O
l O
was O
investigated O
. O
Metal O
mixture O
toxicity O
investigation O
was O
undertaken O
with O
equal O
concentrations O
of O
the O
metals O
. O
The O
hatching O
of O
miracidia O
from O
eggs O
was O
inhibited O
by O
concentrations O
of O
1000 O
- O
10000 O
microg O
/ O
l O
of O
single O
metals O
. O
Metal O
mixtures O
had O
no O
effect O
on O
egg B-DRUG
hatching O
. O
Survival O
of O
miracidia O
was O
reduced O
by O
increasing O
metal O
concentration O
except O
at O
concentrations O
of O
10 O
microg O
/ O
l O
for O
single O
metal O
toxicity O
where O
survival O
was O
increased O
above O
the O
control O
. O
Miracidia O
demonstrated O
a O
rapid O
avoidance O
behaviour O
when O
briefly O
exposed O
to O
heavy O
metals O
. O
The O
mechanisms O
of O
metal O
toxicity O
to O
miracidia O
are O
briefly O
discussed O
. O

[ O
Importance O
of O
pharmacogenetics O
] O
; O
Pharmacogenetics O
deals O
with O
the O
differences O
in O
effect O
of O
drugs O
caused O
by O
genetic O
variation O
. O
Differences O
can O
occur O
in O
therapeutic O
effect O
and O
in O
adverse O
events O
. O
Genetic O
variation O
in O
metabolism O
may O
result O
in O
high O
concentrations O
of O
drugs O
and O
an O
increased O
risk O
of O
adverse O
effects O
in O
slow O
metabolizers O
, O
which O
is O
important O
when O
using O
for O
example O
antidepressants B-GROUP
or O
chemotherapy O
. O
Genetic O
variation O
also O
occurs O
in O
proteins O
interacting O
with O
drugs O
, O
which O
may O
change O
the O
effect O
of O
e O
. O
g O
. O
asthma O
drugs O
and O
antipsychotics B-GROUP
. O
The O
selection O
of O
drugs O
and O
their O
dosages O
may O
be O
improved O
, O
and O
the O
number O
of O
adverse O
effects O
reduced O
by O
pharmacogenetic O
investigations O
. O
However O
, O
it O
may O
be O
important O
also O
in O
case O
of O
medical O
examinations O
for O
insurances O
and O
job O
appointments O
, O
since O
some O
patients O
may O
turn O
out O
to O
need O
expensive O
drugs O
or O
to O
be O
susceptible O
to O
a O
certain O
disease O
. O
Therefore O
, O
the O
use O
of O
genetic O
data O
in O
these O
instances O
has O
to O
be O
regulated O
. O

The O
effects O
of O
concomitant O
phenytoin B-DRUG
administration O
on O
the O
steady O
- O
state O
pharmacokinetics O
of O
quetiapine B-DRUG
. O
Quetiapine B-DRUG
fumarate I-DRUG
( O
' O
Seroquel B-BRAND
' O
) O
is O
a O
newly O
introduced O
atypical B-GROUP
antipsychotic I-GROUP
with O
demonstrated O
efficacy O
in O
the O
treatment O
of O
positive O
and O
negative O
symptoms O
of O
schizophrenia O
. O
It O
is O
extensively O
metabolized O
, O
predominantly O
by O
cytochrome O
P450 O
3A4 O
. O
Therefore O
, O
concurrent O
administration O
of O
drugs O
that O
induce O
or O
inhibit O
this O
enzyme O
may O
affect O
quetiapine B-DRUG
pharmacokinetics O
. O
This O
study O
demonstrated O
that O
the O
potent O
cytochrome O
P450 O
enzyme O
- O
inducer O
phenytoin B-DRUG
did O
indeed O
have O
a O
marked O
effect O
on O
the O
metabolism O
of O
quetiapine B-DRUG
, O
resulting O
in O
a O
5 O
- O
fold O
increase O
in O
clearance O
when O
administered O
concomitantly O
to O
patients O
with O
DSM O
- O
IV O
- O
diagnosed O
schizophrenia O
, O
schizoaffective O
disorder O
, O
or O
bipolar O
disorder O
. O
These O
results O
indicate O
that O
dosage O
adjustment O
of O
quetiapine B-DRUG
may O
be O
necessary O
when O
the O
two O
drugs O
are O
given O
concurrently O
and O
that O
caution O
may O
be O
required O
when O
administering O
other O
drugs O
that O
inhibit O
or O
induce O
cytochromes O
, O
particularly O
P450 O
3A4 O
. O

Effect O
of O
coadministered O
drugs O
and O
ethanol B-DRUG
on O
the O
binding O
of O
therapeutic O
drugs O
to O
human O
serum O
in O
vitro O
. O
The O
effects O
of O
coadministered O
drugs O
and O
ethanol B-DRUG
on O
the O
binding O
of O
therapeutic O
drugs O
to O
human O
serum O
in O
vitro O
was O
investigated O
. O
Acetaminophen B-DRUG
, O
lidocaine B-DRUG
, O
phenobarbital B-DRUG
, O
quinidine B-DRUG
, O
theophylline B-DRUG
, O
and O
valproic B-DRUG
acid I-DRUG
were O
added O
to O
pooled O
human O
serum O
at O
therapeutic O
concentrations O
. O
To O
each O
preparation O
was O
added O
one O
additional O
drug O
at O
three O
concentrations O
ranging O
from O
therapeutic O
to O
toxic O
. O
The O
following O
eight O
target O
drug O
/ O
added O
drug O
combinations O
were O
studied O
: O
acetaminophen B-DRUG
/ O
phenobarbital B-DRUG
. O
acetaminophen B-DRUG
/ O
theophylline B-DRUG
, O
lidocaine B-DRUG
/ O
quinidine B-DRUG
, O
phenobarbital B-DRUG
/ O
acetaminophen B-DRUG
, O
phenobarbital B-DRUG
/ O
valproic B-DRUG
acid I-DRUG
, O
quinidine B-DRUG
/ O
lidocaine B-DRUG
, O
theophylline B-DRUG
/ O
acetaminophen B-DRUG
, O
and O
valproic B-DRUG
acid I-DRUG
/ O
phenobarbital B-DRUG
. O
Each O
serum O
without O
the O
other O
added O
drug O
as O
well O
as O
the O
serum O
supplemented O
with O
the O
other O
drug O
at O
the O
three O
concentrations O
was O
dialyzed O
against O
phosphate O
buffer O
. O
Similarly O
dialyzed O
were O
phenobarbital B-DRUG
, O
quinidine B-DRUG
, O
and O
theophylline B-DRUG
, O
both O
alone O
at O
therapeutic O
concentrations O
in O
serum O
and O
with O
ethanol B-DRUG
at O
three O
different O
concentrations O
in O
serum O
. O
The O
percentage O
of O
drug O
binding O
in O
each O
preparation O
was O
calculated O
. O
Acetaminophen B-DRUG
diminished O
the O
binding O
of O
theophylline B-DRUG
to O
human O
serum O
by O
a O
net O
change O
of O
5 O
. O
7 O
% O
( O
percentage O
increase O
in O
free O
drug O
fraction O
[ O
FDF O
] O
, O
11 O
. O
0 O
% O
) O
at O
662 O
micromol O
/ O
L O
and O
by O
a O
net O
change O
of O
7 O
. O
1 O
% O
( O
percentage O
increase O
in O
FDF O
, O
13 O
. O
7 O
% O
) O
at O
1324 O
micromol O
/ O
L O
. O
Theophylline B-DRUG
decreased O
the O
binding O
of O
acetaminophen B-DRUG
by O
a O
net O
change O
of O
6 O
. O
8 O
% O
( O
percentage O
increase O
in O
FDF O
, O
8 O
. O
8 O
% O
) O
at O
277 O
. O
5 O
micromol O
/ O
L O
; O
phenobarbital B-DRUG
reduced O
it O
by O
a O
net O
change O
of O
6 O
. O
6 O
% O
( O
percentage O
increase O
in O
FDF O
, O
8 O
. O
5 O
% O
) O
at O
431 O
micromol O
/ O
L O
. O
Valproic B-DRUG
acid I-DRUG
diminished O
binding O
of O
phenobarbital B-DRUG
by O
a O
net O
change O
of O
9 O
. O
9 O
% O
( O
percentage O
increase O
in O
FDF O
, O
21 O
. O
2 O
% O
) O
at O
1732 O
micromol O
/ O
L O
. O
No O
significant O
effects O
were O

noted O
with O
other O
drug O
combinations O
or O
with O
the O
addition O
of O
ethanol B-DRUG
. O
Coingestion O
of O
acetaminophen B-DRUG
with O
theophylline B-DRUG
, O
phenobarbital B-DRUG
with O
acetaminophen B-DRUG
, O
and O
valproic B-DRUG
acid I-DRUG
with O
phenobarbital B-DRUG
at O
high O
to O
toxic O
concentrations O
decreases O
the O
binding O
of O
the O
target O
drug O
. O
The O
resulting O
increase O
in O
free O
drug O
concentration O
may O
lead O
to O
enhanced O
drug O
effect O
in O
vivo O
. O

Phenytoin O
intoxication O
induced O
by O
fluvoxamine B-DRUG
. O
A O
patient O
had O
phenytoin O
intoxication O
after O
administration O
of O
fluvoxamine B-DRUG
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
. O
The O
serum O
concentration O
of O
phenytoin B-DRUG
increased O
dramatically O
from O
16 O
. O
6 O
to O
49 O
. O
1 O
microg O
/ O
mL O
when O
fluvoxamine B-DRUG
was O
coadministered O
, O
although O
the O
daily O
dosage O
of O
phenytoin B-DRUG
and O
other O
drugs B-DRUG
had O
not O
changed O
. O
During O
phenytoin B-DRUG
and O
fluvoxamine O
treatment O
, O
ataxia O
, O
a O
typical O
side O
effect O
of O
phenytoin B-DRUG
, O
was O
observed O
. O
The O
genotypes O
of O
CYP2C9 B-DRUG
and O
2C19 O
, O
the O
enzymes O
responsible O
for O
phenytoin O
metabolism O
, O
were O
homozygous O
for O
the O
wild O
- O
type O
alleles O
( O
CYP2C9 B-DRUG
* O
1 O
/ O
* O
1 O
and O
2C19 O
* O
1 O
/ O
* O
1 O
) O
. O
The O
interaction O
may O
be O
a O
result O
of O
inhibition O
of O
both O
CYP2C9 B-DRUG
and O
2C19 O
by O
fluvoxamine B-DRUG
. O

Vancomycin O
resistance O
reversal O
in O
enterococci O
by O
flavonoids O
. O
The O
development O
of O
clinical O
vancomycin O
- O
resistant O
strains O
of O
enterococci O
( O
VRE O
) O
is O
a O
major O
cause O
for O
concern O
. O
Here O
we O
show O
that O
a O
combination O
of O
galangin B-DRUG
or O
3 O
, O
7 O
- O
dihydroxyflavone O
with O
vancomycin B-DRUG
may O
be O
used O
to O
sensitize O
resistant O
strains O
of O
Enterococcus O
faecalis O
and O
Enterococcus O
faecium O
to O
the O
level O
of O
vancomycin O
- O
sensitive O
strains O
. O
Minimum O
inhibitory O
concentrations O
( O
MICs O
) O
and O
viable O
counts O
were O
determined O
in O
Iso O
- O
sensitest O
broth O
using O
a O
microtitre O
method O
. O
MICs O
of O
vancomycin B-DRUG
against O
67 O
% O
of O
resistant O
clinical O
isolates O
and O
a O
type O
strain O
of O
enterococci O
were O
lowered O
from O
> O
250 O
microg O
mL O
( O
- O
1 O
) O
to O
1 O
4 O
microg O
mL O
( O
- O
1 O
) O
in O
the O
presence O
of O
galangin B-DRUG
( O
12 O
. O
5 O
microg O
mL O
( O
- O
1 O
) O
) O
or O
3 O
, O
7 O
- O
dihydroxyflavone O
( O
6 O
. O
25 O
microg O
mL O
( O
- O
1 O
) O
) O
. O
Viable O
counts O
for O
type O
culture O
E O
. O
faecalis O
ATCC O
51299 O
showed O
the O
flavonoids O
alone O
significantly O
lowered O
numbers O
of O
colony O
forming O
units O
( O
CFUs O
) O
. O
CFUs O
were O
maintained O
at O
low O
levels O
( O
10 O
( O
3 O
) O
CFU O
mL O
( O
- O
1 O
) O
) O
for O
24 O
h O
by O
vancomycin B-DRUG
/ O
flavone O
combinations O
. O
This O
combinational O
action O
in O
reversing O
vancomycin O
resistance O
of O
enterococci O
highlights O
novel O
drug O
targets O
and O
has O
importance O
in O
the O
design O
of O
new O
therapeutic O
regimes O
against O
resistant O
pathogens O
. O

Glucose B-DRUG
and O
insulin B-DRUG
exert O
additive O
ocular O
and O
renal O
vasodilator O
effects O
on O
healthy O
humans O
. O
AIMS O
/ O
HYPOTHESIS O
: O
There O
is O
evidence O
that O
insulin B-DRUG
and O
glucose B-DRUG
cause O
renal O
and O
ocular O
vasodilation O
. O
There O
is O
, O
however O
, O
currently O
no O
data O
on O
the O
effect O
of O
combined O
hyperglycaemia O
and O
hyperinsulinaemia B-DRUG
on O
the O
renal O
and O
ocular O
blood O
flow O
seen O
in O
diabetic O
patients O
on O
insulin O
therapy O
. O
METHODS O
: O
We O
carried O
out O
two O
different O
3 O
- O
way O
crossover O
studies O
in O
healthy O
subjects O
( O
each O
, O
n O
= O
9 O
) O
. O
In O
study O
one O
, O
hyperglycaemic O
clamps O
( O
5 O
. O
6 O
mmol O
/ O
l O
, O
11 O
. O
1 O
mmol O
/ O
1 O
, O
16 O
. O
7 O
mmol O
/ O
l O
) O
were O
carried O
out O
during O
placebo O
or O
insulin B-DRUG
( O
dose O
1 O
: O
1 O
mU O
/ O
kg O
/ O
min O
; O
dose O
2 O
: O
2 O
mU O
/ O
kg O
/ O
min O
) O
infusion O
. O
The O
second O
study O
was O
identical O
but O
endogenous O
insulin O
secretion O
was O
blocked O
with O
somatostatin B-DRUG
. O
The O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
and O
pulsatile O
choroidal O
blood O
flow O
were O
measured O
using O
the O
paraaminohippurate O
method O
, O
the O
inulin O
method O
and O
a O
laser O
interferometric O
measurement O
of O
fundus O
pulsation O
amplitude O
, O
respectively O
. O
RESULTS O
: O
Insulin B-DRUG
increased O
renal O
plasma O
flow O
and O
fundus O
pulsation O
amplitude O
but O
not O
the O
glomerular O
filtration O
rate O
. O
Hyperglycaemia O
increased O
all O
the O
renal O
and O
ocular O
parameters O
studied O
. O
Haemodynamic O
effects O
of O
glucose B-DRUG
and O
insulin B-DRUG
were O
additive O
when O
somatostatin B-DRUG
was O
co O
- O
administered O
but O
not O
under O
basal O
conditions O
. O
CONCLUSIONS O
/ O
INTERPRETATION O
: O
Glucose B-DRUG
and O
insulin B-DRUG
can O
exert O
additive O
vasodilator O
properties O
on O
renal O
and O
ocular O
circulation O
. O
To O
find O
out O
whether O
this O
observation O
is O
related O
to O
the O
increased O
regional O
perfusion O
in O
diabetes O
longitudinal O
studies O
on O
patients O
with O
Type O
I O
( O
insulin O
- O
dependent O
) O
diabetes O
mellitus O
are O
needed O
. O

Lack O
of O
interaction O
between O
levofloxacin B-DRUG
and O
oxycodone B-DRUG
: O
pharmacokinetics O
and O
drug O
disposition O
. O
Previous O
studies O
have O
demonstrated O
a O
significant O
reduction O
in O
the O
oral O
bioavailability O
of O
trovafloxacin B-DRUG
and O
ciprofloxacin B-DRUG
when O
administered O
concomitantly O
with O
an O
intravenous O
opiate B-GROUP
such O
as O
morphine B-DRUG
. O
This O
decrease O
in O
absorption O
results O
in O
a O
36 O
% O
and O
50 O
% O
lower O
AUC O
for O
trovafloxacin B-DRUG
and O
ciprofloxacin B-DRUG
, O
respectively O
, O
which O
could O
cause O
clinical O
failures O
. O
The O
authors O
investigated O
the O
possibility O
of O
a O
similar O
interaction O
between O
oxycodone B-DRUG
and O
levofloxacin B-DRUG
. O
Eight O
healthy O
volunteers O
were O
randomized O
in O
an O
open O
- O
label O
, O
two O
- O
way O
crossover O
study O
to O
receive O
oxycodone B-DRUG
, O
5 O
mg O
p O
. O
o O
. O
Q4H O
, O
and O
levofloxacin B-DRUG
, O
500 O
mg O
p O
. O
o O
. O
1 O
hour O
after O
starting O
the O
oxycodone B-DRUG
or O
levofloxacin B-DRUG
500 O
mg O
p O
. O
o O
. O
alone O
. O
Blood O
samples O
were O
drawn O
at O
0 O
, O
0 O
. O
5 O
, O
1 O
, O
1 O
. O
5 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
12 O
, O
18 O
, O
and O
24 O
hours O
for O
Cmax O
, O
tmax O
, O
and O
AUC O
determinations O
. O
There O
was O
not O
a O
significant O
difference O
( O
p O
> O
0 O
. O
05 O
) O
in O
AUC O
( O
48 O
. O
59 O
+ O
/ O
- O
8 O
. O
52 O
vs O
. O
49 O
. O
9 O
+ O
/ O
- O
9 O
. O
93 O
) O
, O
Cmax O
( O
7 O
. O
73 O
+ O
/ O
- O
2 O
. O
6 O
vs O
. O
6 O
. O
6 O
+ O
/ O
- O
2 O
. O
0 O
) O
, O
and O
tmax O
( O
1 O
. O
1 O
+ O
/ O
- O
0 O
. O
6 O
vs O
. O
1 O
. O
6 O
+ O
/ O
- O
1 O
. O
1 O
) O
for O
levofloxacin B-DRUG
versus O
levofloxacin B-DRUG
/ O
oxycodone B-DRUG
regimens O
. O
It O
was O
concluded O
that O
oral O
oxycodone B-DRUG
and O
levofloxacin B-DRUG
can O
be O
administered O
concomitantly O
without O
a O
significant O
decrease O
in O
AUC O
, O
Cmax O
, O
or O
tmax O
. O

Lack O
of O
an O
effect O
of O
azithromycin B-DRUG
on O
the O
disposition O
of O
zidovudine B-DRUG
and O
dideoxyinosine B-DRUG
in O
HIV O
- O
infected O
patients O
. O
Two O
studies O
were O
conducted O
in O
HIV O
- O
infected O
subjects O
to O
assess O
the O
potential O
for O
azithromycin B-DRUG
to O
interact O
with O
zidovudine B-DRUG
and O
dideoxyinosine B-DRUG
. O
Both O
studies O
used O
12 O
subjects O
. O
The O
zidovudine B-DRUG
study O
dosed O
subjects O
with O
1200 O
mg O
/ O
day O
of O
azithromycin B-DRUG
( O
n O
= O
7 O
) O
( O
later O
changed O
to O
600 O
mg O
/ O
day O
[ O
n O
= O
5 O
] O
) O
for O
Days O
8 O
to O
21 O
of O
a O
21 O
- O
day O
course O
of O
100 O
mg O
, O
five O
times O
/ O
day O
of O
zidovudine B-DRUG
. O
Subjects O
treated O
with O
200 O
mg O
of O
dideoxyinosine B-DRUG
twice O
daily O
for O
21 O
days O
received O
1200 O
mg O
of O
azithromycin B-DRUG
or O
an O
equivalent O
amount O
of O
placebo O
/ O
day O
for O
Days O
8 O
to O
21 O
. O
Antiretroviral B-GROUP
plasma O
and O
urine O
sampling O
were O
conducted O
on O
Days O
1 O
, O
7 O
, O
and O
21 O
for O
zidovudine B-DRUG
and O
on O
Days O
7 O
and O
21 O
for O
dideoxyinosine B-DRUG
. O
Peripheral O
mononuclear O
cells O
were O
also O
collected O
for O
quantitation O
of O
phosphorylated O
zidovudine B-DRUG
. O
Azithromycin B-DRUG
had O
no O
significant O
impact O
on O
the O
Cmax O
and O
AUC O
of O
zidovudine B-DRUG
, O
although O
it O
significantly O
decreased O
the O
zidovudine B-DRUG
tmax O
by O
44 O
% O
and O
increased O
the O
intracellular O
exposure O
to O
phosphorylated O
zidovudine B-DRUG
by O
110 O
% O
. O
Azithromycin B-DRUG
had O
no O
significant O
effect O
on O
dideoxyinosine B-DRUG
pharmacokinetics O
. O
Based O
on O
the O
results O
of O
these O
studies O
, O
it O
is O
concluded O
that O
azithromycin B-DRUG
may O
be O
safely O
coadministered O
with O
both O
zidovudine B-DRUG
and O
dideoxyinosine B-DRUG
. O

Effect O
of O
diazepam B-DRUG
and O
midazolam B-DRUG
on O
the O
antinociceptive O
effect O
of O
morphine B-DRUG
, O
metamizol B-DRUG
and O
indomethacin B-DRUG
in O
mice O
. O
The O
influence O
of O
midazolam B-DRUG
and O
diazepam B-DRUG
on O
antinociceptive O
effect O
of O
morphine B-DRUG
( O
10 O
mg O
/ O
kg O
) O
, O
metamizol B-DRUG
( O
500 O
mg O
/ O
kg O
) O
and O
indomethacin B-DRUG
( O
10 O
mg O
/ O
kg O
) O
was O
investigated O
in O
a O
mouse O
model O
using O
the O
tail O
- O
flick O
and O
hot O
- O
plate O
tests O
. O
All O
drugs O
were O
injected O
intraperitoneally O
. O
Benzodiazepines B-GROUP
were O
administered O
to O
mice O
30 O
min O
before O
applying O
the O
analgesic B-GROUP
drugs I-GROUP
. O
Measurement O
of O
nociception O
was O
performed O
within O
2 O
h O
after O
benzodiazepine B-GROUP
administration O
. O
Diazepam B-DRUG
at O
doses O
of O
0 O
. O
25 O
mg O
/ O
kg O
and O
2 O
. O
5 O
mg O
/ O
kg O
injected O
with O
morphine B-DRUG
was O
found O
to O
decrease O
the O
antinociceptive O
effect O
of O
morphine B-DRUG
. O
Similarly O
, O
diazepam B-DRUG
decreased O
the O
antinociceptive O
effect O
of O
metamizol B-DRUG
( O
only O
in O
the O
tail O
- O
flick O
test O
) O
and O
indomethacin B-DRUG
. O
Midazolam B-DRUG
used O
at O
doses O
of O
1 O
. O
25 O
mg O
/ O
kg O
and O
2 O
. O
5 O
mg O
/ O
kg O
decreased O
the O
antinociceptive O
effect O
of O
morphine B-DRUG
, O
metamizol B-DRUG
( O
only O
in O
the O
tail O
- O
flick O
test O
) O
and O
indomethacin B-DRUG
. O

Pharmacological O
treatment O
of O
depression O
: O
the O
role O
of O
paroxetine B-DRUG
. O
Depression O
is O
reaching O
epidemic O
proportions O
in O
the O
western O
world O
. O
With O
each O
successive O
generation O
more O
people O
are O
becoming O
more O
severely O
depressed O
at O
a O
younger O
age O
. O

Influence O
of O
estradiol B-DRUG
and O
progesterone B-DRUG
on O
the O
sensitivity O
of O
rat O
thoracic O
aorta O
to O
noradrenaline B-DRUG
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
low O
and O
high O
doses O
of O
estradiol B-DRUG
, O
and O
of O
progesterone B-DRUG
on O
the O
response O
to O
noradrenaline B-DRUG
in O
rat O
thoracic O
aorta O
. O
Two O
weeks O
after O
bilateral O
ovariectomy O
, O
female O
rats O
received O
a O
s O
. O
c O
. O
injection O
of O
vehicle O
( O
corn O
oil O
, O
0 O
. O
1 O
mL O
/ O
day O
) O
, O
estradiol B-DRUG
( O
10 O
microg O
/ O
kg O
/ O
day O
or O
4 O
mg O
/ O
kg O
/ O
day O
) O
and O
/ O
or O
progesterone B-DRUG
( O
20 O
mg O
/ O
kg O
/ O
day O
) O
, O
for O
eight O
days O
. O
On O
the O
ninth O
day O
, O
the O
rats O
were O
sacrificed O
and O
aortic O
rings O
, O
with O
or O
without O
endothelium O
, O
were O
used O
to O
generate O
concentration O
- O
response O
curves O
to O
noradrenaline B-DRUG
. O
Aortic O
rings O
with O
intact O
endothelium O
from O
the O
high O
- O
dose O
( O
4 O
mg O
/ O
kg O
/ O
day O
) O
estradiol B-DRUG
group O
were O
supersensitive O
to O
noradrenaline B-DRUG
compared O
to O
the O
vehicle O
or O
low O
- O
dose O
( O
10 O
microg O
/ O
kg O
/ O
day O
) O
estradiol O
groups O
( O
pD2 O
values O
= O
7 O
. O
86 O
+ O
/ O
- O
0 O
. O
09 O
, O
7 O
. O
30 O
+ O
/ O
- O
0 O
. O
11 O
and O
7 O
. O
35 O
+ O
/ O
- O
0 O
. O
04 O
, O
respectively O
) O
. O
Endothelium O
- O
intact O
aortic O
rings O
from O
high O
- O
estradiol B-DRUG
rats O
were O
supersensitive O
to O
noradrenaline B-DRUG
when O
compared O
to O
vehicle O
- O
, O
progesterone B-DRUG
- O
and O
progesterone B-DRUG
+ O
high O
- O
estradiol B-DRUG
- O
treated O
rats O
( O
pD2 O
values O
= O
7 O
. O
77 O
+ O
/ O
- O
0 O
. O
12 O
, O
7 O
. O
21 O
+ O
/ O
- O
0 O
. O
13 O
, O
6 O
. O
93 O
+ O
/ O
- O
0 O
. O
04 O
and O
7 O
. O
22 O
+ O
/ O
- O
0 O
. O
18 O
, O
respectively O
) O
. O
There O
were O
no O
significant O
differences O
among O
the O
pD2 O
values O
for O
noradrenaline B-DRUG
in O
aortic O
rings O
without O
endothelium O
. O
Both O
of O
these O
effects O
were O
endothelium O
- O
dependent O
. O

[ O
Drug O
treatment O
of O
erection O
disorders O
in O
patients O
with O
cardiovascular O
disease O
] O

Erectile O
dysfunction O
is O
a O
frequent O
condition O
in O
cardiovascular O
patients O
. O
Since O
the O
arrival O
of O
oral O
erection B-GROUP
- I-GROUP
supporting I-GROUP
medication I-GROUP
, O
patients O
want O
to O
know O
how O
safe O
sexual O
activity O
is O
in O
cardiovascular O
disease O
in O
general O
and O
during O
use O
of O
erection B-GROUP
- I-GROUP
supporting I-GROUP
medication I-GROUP
in O
particular O
. O
Sexual O
intercourse O
with O
a O
steady O
partner O
causes O
no O
more O
cardiovascular O
risk O
than O
normal O
daily O
activities O
such O
as O
ironing O
, O
2 O
kilometers O
of O
walking O
without O
climbing O
, O
paperhanging O
, O
playing O
golf O
or O
gardening O
. O
The O
relative O
risk O
of O
myocardial O
infarction O
during O
sexual O
activity O
is O
not O
significantly O
higher O
than O
for O
healthy O
persons O
. O
The O
incidence O
of O
cardiovascular O
morbidity O
and O
mortality O
is O
not O
higher O
among O
users O
of O
sildenafil B-DRUG
. O
Sildenafil B-DRUG
is O
contraindicated O
in O
patients O
using O
long B-GROUP
- I-GROUP
acting I-GROUP
nitrates I-GROUP
or O
who O
may O
need O
to O
use O
short B-GROUP
- I-GROUP
acting I-GROUP
nitrates I-GROUP
, O
because O
the O
combination O
may O
cause O
a O
sharp O
fall O
of O
the O
blood O
pressure O
. O
No O
interactions O
have O
been O
observed O
with O
beta B-GROUP
- I-GROUP
receptor I-GROUP
blockers I-GROUP
, O
calcium B-GROUP
antagonists I-GROUP
, O
thiazide B-GROUP
and I-GROUP
loop I-GROUP
diuretics I-GROUP
and O
ACE B-GROUP
inhibitors I-GROUP
. O
Before O
prescribing O
a O
symptomatic O
( O
pharmaceutical O
) O
treatment O
for O
patients O
with O
an O
erection O
disorder O
, O
attention O
should O
be O
given O
tot O
the O
sexological O
, O
psychological O
and O
medical O
backgrounds O
of O
the O
disorder O
. O
Secondary O
prevention O
of O
atherosclerotic O
risk O
factors O
is O
also O
important O
: O
regulation O
of O
blood O
pressure O
and O
blood O
sugar O
level O
, O
hyperlipidaemia O
and O
obesity O
, O
as O
well O
as O
a O
change O
of O
lifestyle O
( O
giving O
up O
smoking O
, O
adapting O
of O
diet O
and O
more O
physical O
exertion O
) O
. O
Patients O
with O
a O
very O
low O
cardiac O
capacity O
should O
be O
advised O
to O
refrain O
from O
treatment O
of O
the O
erection O
disorder O
. O

Influence O
of O
coadministration O
of O
fluoxetine B-DRUG
on O
cisapride B-DRUG
pharmacokinetics O
and O
QTc O
intervals O
in O
healthy O
volunteers O
. O
STUDY O
OBJECTIVE O
: O
To O
evaluate O
the O
effect O
of O
fluoxetine B-DRUG
on O
the O
pharmacokinetics O
and O
cardiovascular O
safety O
of O
cisapride B-DRUG
at O
steady O
state O
in O
healthy O
men O
. O
DESIGN O
: O
Open O
- O
label O
, O
three O
- O
phase O
, O
sequential O
study O
. O
SETTING O
: O
Clinical O
research O
center O
. O
SUBJECTS O
: O
Twelve O
healthy O
male O
volunteers O
. O
INTERVENTIONS O
: O
Each O
subject O
was O
treated O
according O
to O
the O
following O
sequence O
: O
baseline O
; O
phase O
1 O
( O
days O
1 O
- O
6 O
) O
: O
cisapride B-DRUG
10 O
mg O
4 O
times O
/ O
day O
; O
washout O
( O
days O
7 O
- O
13 O
) O
; O
phase O
2 O
( O
days O
14 O
- O
44 O
) O
: O
fluoxetine B-DRUG
20 O
mg O
/ O
day O
; O
and O
phase O
3 O
( O
days O
45 O
- O
52 O
) O
: O
cisapride B-DRUG
10 O
mg O
4 O
times O
/ O
day O
( O
days O
45 O
- O
51 O
) O
plus O
fluoxetine B-DRUG
20 O
mg O
/ O
day O
( O
days O
45 O
- O
52 O
) O
. O
MEASUREMENTS O
and O
MAIN O
RESULTS O
: O
Blood O
samples O
were O
drawn O
and O
12 O
- O
lead O
electrocardiograms O
performed O
at O
specified O
time O
points O
after O
the O
last O
morning O
dose O
of O
cisapride B-DRUG
in O
phases O
1 O
and O
3 O
. O
Blood O
samples O
also O
were O
taken O
before O
morning O
doses O
on O
the O
3rd O
, O
4th O
, O
and O
5th O
days O
of O
phases O
1 O
and O
3 O
. O
Electrocardiograms O
were O
done O
at O
baseline O
and O
on O
the O
last O
day O
of O
the O
washout O
period O
and O
phase O
2 O
. O
Coadministration O
of O
fluoxetine B-DRUG
significantly O
decreased O
cisapride B-DRUG
plasma O
concentrations O
. O
There O
were O
no O
clinically O
significant O
changes O
in O
corrected O
QT O
intervals O
during O
administration O
of O
cisapride B-DRUG
alone O
or O
with O
fluoxetine B-DRUG
. O
Cisapride B-DRUG
was O
well O
tolerated O
when O
administered O
alone O
or O
with O
fluoxetine B-DRUG
. O
CONCLUSION O
: O
Cisapride B-DRUG
can O
be O
administered O
safely O
to O
patients O
receiving O
low O
therapeutic O
dosages O
of O
fluoxetine B-DRUG
. O

Olanzapine B-DRUG
: O
an O
updated O
review O
of O
its O
use O
in O
the O
management O
of O
schizophrenia O
. O
Olanzapine B-DRUG
, O
a O
thienobenzodiazepine B-GROUP
derivative I-GROUP
, O
is O
a O
second B-GROUP
generation I-GROUP
( I-GROUP
atypical I-GROUP
) I-GROUP
antipsychotic I-GROUP
agent I-GROUP
which O
has O
proven O
efficacy O
against O
the O
positive O
and O
negative O
symptoms O
of O
schizophrenia O
. O
Compared O
with O
conventional B-GROUP
antipsychotics I-GROUP
, O
it O
has O
greater O
affinity O
for O
serotonin O
5 O
- O
HT2A O
than O
for O
dopamine O
D2 O
receptors O
. O
In O
large O
, O
well O
controlled O
trials O
in O
patients O
with O
schizophrenia O
or O
related O
psychoses O
, O
olanzapine B-DRUG
5 O
to O
20 O
mg O
/ O
day O
was O
significantly O
superior O
to O
haloperidol B-DRUG
5 O
to O
20 O
mg O
/ O
day O
in O
overall O
improvements O
in O
psychopathology O
rating O
scales O
and O
in O
the O
treatment O
of O
depressive O
and O
negative O
symptoms O
, O
and O
was O
comparable O
in O
effects O
on O
positive O
psychotic O
symptoms O
. O
The O
1 O
- O
year O
risk O
of O
relapse O
( O
rehospitalisation O
) O
was O
significantly O
lower O
with O
olanzapine B-DRUG
than O
with O
haloperidol B-DRUG
treatment O
. O
In O
the O
first O
double O
- O
blind O
comparative O
study O
( O
28 O
- O
week O
) O
of O
olanzapine B-DRUG
and O
risperidone B-DRUG
, O
olanzapine B-DRUG
10 O
to O
20 O
mg O
/ O
day O
proved O
to O
be O
significantly O
more O
effective O
than O
risperidone B-DRUG
4 O
to O
12 O
mg O
/ O
day O
in O
the O
treatment O
of O
negative O
and O
depressive O
symptoms O
but O
not O
on O
overall O
psychopathology O
symptoms O
. O
In O
contrast O
, O
preliminary O
results O
from O
an O
8 O
- O
week O
controlled O
study O
suggested O
risperidone B-DRUG
2 O
to O
6 O
mg O
/ O
day O
was O
superior O
to O
olanzapine B-DRUG
5 O
to O
20 O
mg O
/ O
day O
against O
positive O
and O
anxiety O
/ O
depressive O
symptoms O
( O
p O
< O
0 O
. O
05 O
) O
, O
although O
consistent O
with O
the O
first O
study O
, O
both O
agents O
demonstrated O
similar O
efficacy O
on O
measures O
of O
overall O
psychopathology O
. O
Improvements O
in O
general O
cognitive O
function O
seen O
with O
olanzapine B-DRUG
treatment O
in O
a O
1 O
- O
year O
controlled O
study O
of O
patients O
with O
early O
- O
phase O
schizophrenia O
, O
were O
significantly O
greater O
than O
changes O
seen O
with O
either O
risperidone B-DRUG
or O
haloperidol B-DRUG
. O
However O
, O
preliminary O
results O
from O
an O
8 O
- O
week O
trial O
showed O
comparable O
cognitive O
enhancing O
effects O
of O
olanzapine B-DRUG
and O
risperidone B-DRUG
treatment O
in O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
. O
Several O
studies O
indicate O
that O
olanzapine B-DRUG
has O
benefits O
against O
symptoms O
of O
aggression O
and O
agitation O
, O
while O
other O
studies O
strongly O
support O
the O
effectiveness O
of O
olanzapine B-DRUG
in O
the O
treatment O
of O
depressive O
symptomatology O
. O
Olanzapine B-DRUG
is O
associated O
with O
significantly O
fewer O
extrapyramidal O
symptoms O
than O
haloperidol B-DRUG
and O

risperidone B-DRUG
. O
In O
addition O
, O
olanzapine B-DRUG
is O
not O
associated O
with O
a O
risk O
of O
agranulocytosis O
as O
seen O
with O
clozapine B-DRUG
or O
clinically O
significant O
hyperprolactinaemia O
as O
seen O
with O
risperidone B-DRUG
or O
prolongation O
of O
the O
QT O
interval O
. O
The O
most O
common O
adverse O
effects O
reported O
with O
olanzapine B-DRUG
are O
bodyweight O
gain O
, O
somnolence O
, O
dizziness O
, O
anticholinergic O
effects O
( O
constipation O
and O
dry O
mouth O
) O
and O
transient O
asymptomatic O
liver O
enzyme O
elevations O
. O
In O
comparison O
with O
haloperidol B-DRUG
, O
the O
adverse O
events O
reported O
significantly O
more O
frequently O
with O
olanzapine B-DRUG
in O
> O
or O
= O
3 O
. O
5 O
% O
of O
patients O
were O
dry O
mouth O
, O
bodyweight O
gain O
and O
increased O
appetite O
and O
compared O
with O
risperidone B-DRUG
, O
only O
bodyweight O
gain O
occurred O
significantly O
more O
frequently O
with O
olanzapine B-DRUG
. O
The O
high O
acquisition O
cost O
of O
olanzapine B-DRUG
is O
offset O
by O
reductions O
in O
other O
treatment O
costs O
( O
inpatient O
and O
/ O
or O
outpatient O
services O
) O
of O
schizophrenia O
. O
Pharmacoeconomic O
analyses O
indicate O
that O
olanzapine B-DRUG
does O
not O
significantly O
increase O
, O
and O
may O
even O
decrease O
, O
the O
overall O
direct O
treatment O
costs O
of O
schizophrenia O
, O
compared O
with O
haloperidol B-DRUG
. O
Compared O
with O
risperidone B-DRUG
, O
olanzapine B-DRUG
has O
also O
been O
reported O
to O
decrease O
overall O
treatment O
costs O
, O
despite O
the O
several O
- O
fold O
higher O
daily O
acquisition O
cost O
of O
the O
drug O
. O
Olanzapine B-DRUG
treatment O
improves O
quality O
of O
life O
in O
patients O
with O
schizophrenia O
and O
related O
psychoses O
to O
a O
greater O
extent O
than O
haloperidol B-DRUG
, O
and O
to O
broadly O
the O
same O
extent O
as O
risperidone B-DRUG
. O
CONCLUSIONS O
: O
Olanzapine B-DRUG
demonstrated O
superior O
antipsychotic O
efficacy O
compared O
with O
haloperidol B-DRUG
in O
the O
treatment O
of O
acute O
phase O
schizophrenia O
, O
and O
in O
the O
treatment O
of O
some O
patients O
with O
first O
- O
episode O
or O
treatment O
- O
resistant O
schizophrenia O
. O
The O
reduced O
risk O
of O
adverse O
events O
and O
therapeutic O
superiority O
compared O
with O
haloperidol B-DRUG
and O
risperidone B-DRUG
in O
the O
treatment O
of O
negative O
and O
depressive O
symptoms O
support O
the O
choice O
of O
olanzapine B-DRUG
as O
a O
first O
- O
line O
option O
in O
the O
management O
of O
schizophrenia O
in O
the O
acute O
phase O
and O
for O
the O
maintenance O
of O
treatment O
response O
. O

The O
emerging O
roles O
of O
non B-GROUP
- I-GROUP
nucleoside I-GROUP
reverse I-GROUP
transcriptase I-GROUP
inhibitors I-GROUP
in O
antiretroviral B-GROUP
therapy O
. O
The O
availability O
of O
potent O
non B-GROUP
- I-GROUP
nucleoside I-GROUP
reverse I-GROUP
transcriptase I-GROUP
inhibitor I-GROUP
( O
NNRTI B-GROUP
) O
- O
based O
regimens O
for O
antiretroviral B-GROUP
therapy O
and O
concerns O
regarding O
protease B-GROUP
inhibitor I-GROUP
( O
PI B-GROUP
) O
- O
related O
metabolic O
disturbances O
have O
led O
to O
significant O
shifts O
in O
treatment O
practices O
in O
HIV O
infection O
. O
NNRTI B-GROUP
- O
based O
regimens O
may O
have O
several O
advantages O
over O
PI B-GROUP
- O
based O
therapy O
for O
initial O
or O
prolonged O
therapy O
, O
including O
more O
convenient O
administration O
regimens O
, O
lower O
tablet O
volume O
, O
fewer O
drug O
interactions O
, O
and O
central O
nervous O
system O
penetration O
. O
No O
data O
from O
prospective O
clinical O
trials O
currently O
exist O
comparing O
the O
3 O
approved O
agents O
( O
efavirenz B-DRUG
, O
nevirapine B-DRUG
or O
delavirdine B-DRUG
) O
. O
Both O
efavirenz B-DRUG
and O
nevirapine B-DRUG
have O
been O
compared O
to O
triple O
therapy O
with O
the O
PI B-GROUP
indinavir B-DRUG
over O
48 O
weeks O
as O
initial O
therapy O
, O
with O
similar O
responses O
being O
observed O
with O
nevirapine B-DRUG
regimens O
and O
superiority O
observed O
with O
efavirenz B-DRUG
. O
A O
smaller O
24 O
- O
week O
study O
has O
suggested O
nevirapine B-DRUG
may O
be O
superior O
to O
the O
PI B-GROUP
nelfinavir B-DRUG
. O
Limited O
comparative O
data O
in O
patients O
with O
high O
viral O
loads O
treated O
with O
nevirapine B-DRUG
- O
or O
delavirdine B-DRUG
- O
based O
regimens O
currently O
exist O
. O
However O
, O
cohort O
data O
and O
selected O
patient O
data O
from O
clinical O
trials O
suggest O
comparable O
activity O
to O
PI B-GROUP
- O
based O
regimens O
in O
these O
patients O
. O
The O
superiority O
of O
efavirenz B-DRUG
over O
indinavir B-DRUG
- O
based O
regimens O
has O
been O
observed O
in O
comparative O
data O
in O
a O
subset O
of O
patients O
with O
high O
viral O
loads O
. O
In O
treatment O
- O
experienced O
patients O
, O
available O
uncontrolled O
data O
suggest O
these O
agents O
contribute O
to O
regimen O
efficacy O
in O
NNRTI B-GROUP
- O
na O
ve O
, O
treatment O
- O
experienced O
patients O
. O
Efavirenz B-DRUG
has O
demonstrated O
superiority O
over O
nelfinavir B-DRUG
in O
nucleoside O
- O
experienced O
patients O
, O
although O
combining O
these O
2 O
agents O
may O
represent O
the O
best O
approach O
in O
these O
circumstances O
. O
The O
tolerability O
of O
NNRTIs B-GROUP
appears O
generally O
good O
with O
few O
individuals O
discontinuing O
in O
clinical O
studies O
as O
a O
result O
of O
adverse O
drug O
events O
. O
The O
majority O
of O
adverse O
events O
with O
NNRTIs B-GROUP
occur O
within O
the O
first O
month O
, O
and O
are O
predictable O
and O
manageable O
without O
therapy O
interruption O
. O

[ O
Pharmacologic O
interactions O
in O
chronic O
treatments O
: O
corrective O
measures O
for O
its O
prevention O
in O
a O
basic O
area O
of O
rural O
health O
] O

OBJECTIVES O
: O
To O
identify O
the O
pharmacological O
interactions O
of O
clinical O
relevance O
( O
PICR O
) O
in O
the O
medication O
authorization O
cards O
( O
MAC O
) O
of O
the O
chronically O
ill O
and O
to O
establish O
strategies O
to O
minimise O
their O
appearance O
. O
DESIGN O
: O
Cross O
- O
sectional O
descriptive O
study O
. O
SETTING O
: O
Rural O
primary O
care O
centre O
. O
PATIENTS O
: O
Random O
sample O
of O
626 O
MAC O
out O
of O
a O
total O
of O
1306 O
. O
MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
In O
December O
1998 O
, O
the O
following O
was O
gathered O
for O
every O
MAC O
with O
more O
than O
one O
drug O
treatment O
: O
age O
, O
sex O
, O
number O
of O
drugs O
, O
intrinsic O
value O
, O
drugs O
prescribed O
, O
daily O
dose O
and O
pharmacological O
interactions O
( O
PI O
) O
, O
classified O
( O
using O
the O
scale O
of O
Hansten O
1996 O
) O
into O
light O
and O
clinically O
relevant O
. O
Statistical O
analysis O
: O
Mantel O
- O
Haenszel O
( O
alpha O
= O
0 O
. O
05 O
) O
. O
Patients O
' O
mean O
age O
was O
69 O
. O
1 O
( O
95 O
% O
CI O
, O
+ O
/ O
- O
1 O
. O
2 O
) O
. O
Mean O
number O
of O
drugs O
per O
MAC O
was O
4 O
( O
95 O
% O
CI O
, O
+ O
/ O
- O
0 O
. O
2 O
) O
. O
341 O
PI O
affecting O
197 O
patients O
( O
31 O
. O
5 O
% O
, O
95 O
% O
CI O
, O
+ O
/ O
- O
3 O
. O
6 O
) O
were O
identified O
. O
24 O
. O
9 O
% O
( O
95 O
% O
CI O
, O
+ O
/ O
- O
4 O
. O
5 O
) O
were O
PICR O
, O
detected O
in O
11 O
. O
7 O
% O
( O
95 O
% O
CI O
, O
+ O
/ O
- O
2 O
. O
5 O
) O
of O
the O
MAC O
. O
The O
existence O
of O
PI O
was O
related O
to O
the O
number O
of O
drugs O
prescribed O
to O
each O
patient O
( O
p O
< O
0 O
. O
01 O
) O
. O
There O
were O
26 O
PI O
with O
drugs O
of O
low O
intrinsic O
value O
( O
7 O
. O
6 O
% O
; O
95 O
% O
CI O
, O
+ O
/ O
- O
2 O
. O
8 O
) O
. O
74 O
. O
1 O
% O
( O
95 O
% O
CI O
, O
+ O
/ O
- O
9 O
. O
3 O
) O
of O
the O
total O
PICR O
could O
be O
avoided O
by O
simple O
recommendations O
; O
and O
the O
remaining O
25 O
. O
9 O
% O
( O
95 O
% O
CI O
, O
+ O
/ O
- O
9 O
. O
3 O
) O
by O
monitoring O
and O
follow O
- O
up O
of O
patients O
. O
CONCLUSIONS O
: O
It O
is O
important O
to O
identify O
the O
medications O
most O
commonly O
involved O
in O
the O
PICR O
so O
as O
to O
establish O
corrective O
measures O
to O
minimise O
the O
risks O
arising O
from O
multiple O
medication O
. O
Four O
educational O
messages O
advise O
on O
over O
60 O
% O
of O
the O
PICR O
detected O
. O

Prescribing O
. O
Keys O
to O
maximizing O
benefit O
while O
avoiding O
adverse O
drug O
effects O
. O
When O
prescribing O
for O
older O
patients O
, O
some O
physicians O
are O
overly O
cautious O
, O
and O
this O
strategy O
can O
result O
in O
a O
less O
than O
optimal O
treatment O
outcome O
. O
The O
reluctance O
to O
treat O
aggressively O
is O
understandable O
because O
the O
geriatric O
population O
is O
susceptible O
to O
adverse O
drug O
reactions O
. O
The O
key O
to O
maximizing O
therapy O
lies O
in O
individualizing O
it O
as O
much O
as O
possible O
. O
There O
are O
a O
number O
of O
steps O
physicians O
can O
take O
to O
ensure O
that O
their O
patients O
are O
not O
being O
undertreated O
. O
These O
steps O
include O
regular O
reevaluations O
of O
dosages O
and O
plasma O
drug O
concentrations O
, O
recognition O
and O
understanding O
of O
drug O
side O
effects O
, O
and O
avoidance O
of O
certain O
agents O
. O
Close O
monitoring O
allows O
physicians O
to O
minimize O
risks O
, O
maximize O
benefits O
, O
and O
get O
the O
most O
out O
of O
what O
modern O
medications O
can O
do O
to O
help O
older O
patients O
. O

Sildenafil B-DRUG
citrate I-DRUG
: O
a O
therapeutic O
update O
. O
BACKGROUND O
: O
Since O
its O
approval O
by O
the O
US O
Food O
and O
Drug O
Administration O
in O
March O
1998 O
, O
sildenafil B-DRUG
citrate I-DRUG
has O
been O
used O
by O
millions O
of O
men O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
Recent O
studies O
and O
consensus O
reports O
have O
expanded O
our O
understanding O
of O
its O
efficacy O
, O
safety O
, O
contraindications O
, O
and O
drug O
interactions O
. O
OBJECTIVE O
: O
This O
paper O
reviews O
recent O
studies O
of O
the O
efficacy O
of O
sildenafil B-DRUG
, O
its O
adverse O
effects O
and O
drug O
interactions O
, O
and O
socioeconomic O
factors O
involved O
in O
its O
use O
, O
with O
a O
focus O
on O
specific O
patient O
populations O
( O
prostate O
cancer O
, O
diabetes O
mellitus O
, O
ischemic O
heart O
disease O
, O
spinal O
cord O
injuries O
, O
neurologic O
disorders O
) O
. O
METHODS O
: O
Clinical O
studies O
, O
case O
reports O
, O
and O
commentaries O
and O
editorials O
concerning O
sildenafil B-DRUG
published O
in O
the O
international O
literature O
between O
January O
1999 O
and O
August O
2000 O
were O
identified O
through O
searches O
of O
MEDLINE O
, O
PREMEDLINE O
, O
and O
International O
Pharmaceutical O
Abstracts O
, O
using O
the O
terms O
sildenafil B-DRUG
, O
Viagra B-BRAND
, O
and O
erectile O
dysfunction O
. O
RESULTS O
: O
Sildenafil B-DRUG
has O
demonstrated O
effectiveness O
in O
men O
with O
erectile O
dysfunction O
associated O
with O
prostatectomy O
, O
radiation O
therapy O
, O
diabetes O
mellitus O
, O
certain O
neurologic O
disorders O
, O
and O
drug O
therapy O
( O
eg O
, O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
[ O
SSRIs B-GROUP
] O
) O
. O
It O
has O
not O
been O
as O
effective O
in O
women O
with O
sexual O
dysfunction O
, O
with O
the O
exception O
of O
SSRI B-GROUP
- O
associated O
sexual O
dysfunction O
. O
Some O
disorders O
unrelated O
to O
sexual O
dysfunction O
( O
eg O
, O
esophageal O
motility O
dysfunction O
) O
may O
also O
respond O
to O
sildenafil B-DRUG
. O
In O
the O
general O
population O
, O
sildenafil B-DRUG
is O
considered O
to O
have O
an O
acceptable O
tolerability O
profile O
; O
however O
, O
patients O
with O
moderate O
to O
severe O
cardiovascular O
disease O
or O
those O
taking O
nitrate B-GROUP
therapy O
are O
at O
increased O
risk O
for O
potentially O
serious O
cardiovascular O
adverse O
effects O
with O
sildenafil B-DRUG
therapy O
. O
In O
addition O
, O
patients O
taking O
drugs O
that O
inhibit O
the O
cytochrome O
P450 O
3A4 O
isozyme O
, O
which O
metabolizes O
sildenafil B-DRUG
, O
may O
experience O
increased O
drug O
concentrations O
and O
possible O
toxicity O
from O
normal O
doses O
of O
sildenafil B-DRUG
. O
CONCLUSIONS O
: O
Sildenafil B-DRUG
is O
an O
effective O
first O
- O
line O
therapy O
for O
erectile O
dysfunction O
in O
men O
. O
The O
decision O
to O
prescribe O
this O
agent O
should O

include O
such O
considerations O
as O
the O
cost O
- O
risk O
- O
benefit O
balance O
, O
patient O
access O
, O
drug O
distribution O
pathways O
, O
and O
prescription O
drug O
coverage O
. O

Acute O
hydrocortisone B-DRUG
administration O
does O
not O
affect O
subjective O
responses O
to O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
in O
humans O
. O
RATIONALE O
: O
Stress O
and O
glucocorticoids B-GROUP
facilitate O
and O
reinstate O
psychostimulant O
self O
- O
administration O
in O
rodents O
. O
However O
, O
the O
effects O
of O
stress O
and O
glucocorticoids B-GROUP
on O
the O
subjective O
and O
behavioral O
effects O
of O
psychostimulants B-GROUP
have O
not O
been O
well O
studied O
in O
humans O
. O
OBJECTIVES O
: O
To O
examine O
the O
effects O
of O
acute O
hydrocortisone B-DRUG
pretreatment O
on O
the O
subjective O
and O
behavioral O
effects O
of O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
. O
METHODS O
: O
Hydrocortisone B-DRUG
( O
100 O
mg O
) O
and O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
( O
20 O
mg O
) O
were O
administered O
orally O
to O
16 O
healthy O
male O
and O
female O
volunteers O
in O
a O
four O
- O
session O
, O
placebo O
- O
controlled O
, O
within O
- O
subject O
, O
crossover O
design O
. O
To O
prevent O
stomach O
irritation O
, O
subjects O
received O
rantidine B-DRUG
hydrochloride I-DRUG
before O
each O
experimental O
session O
. O
Dependent O
measures O
included O
self O
- O
reported O
mood O
and O
subjective O
effects O
( O
Addiction O
Research O
Center O
inventory O
, O
the O
profile O
of O
mood O
states O
, O
and O
a O
series O
of O
visual O
analogue O
scales O
) O
, O
vital O
signs O
, O
salivary O
cortisol O
, O
and O
psychomotor O
performance O
. O
RESULTS O
: O
Hydrocortisone B-DRUG
elevated O
salivary O
cortisol O
levels O
, O
produced O
modest O
dysphoria O
, O
and O
reduced O
subjects O
' O
reports O
of O
wanting O
more O
drug O
. O
However O
, O
hydrocortisone B-DRUG
pretreatment O
did O
not O
affect O
any O
of O
the O
physiological O
, O
behavioral O
, O
or O
subjective O
effects O
of O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
. O
CONCLUSIONS O
: O
In O
contrast O
to O
the O
effects O
of O
glucocorticoids B-GROUP
in O
rodent O
studies O
, O
these O
results O
indicate O
that O
an O
acute O
increase O
in O
cortisol O
does O
not O
enhance O
the O
psychostimulant O
effects O
of O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
in O
humans O
. O

The O
effects O
of O
ketamine B-DRUG
and O
of O
Innovar B-BRAND
anesthesia O
on O
digitalis B-GROUP
tolerance O
in O
dogs O
. O
In O
a O
comparison O
of O
digitalis B-GROUP
tolerance O
in O
dogs O
anesthetized O
with O
ketamine B-DRUG
, O
Innovar B-BRAND
Vet I-BRAND
, O
or O
pentobarbital B-DRUG
, O
the O
dosage O
of O
ouabain B-DRUG
needed O
to O
cause O
ventricular O
tachycardia O
was O
significantly O
higher O
, O
as O
was O
the O
LD50 O
of O
ouabain B-DRUG
, O
with O
ketamine B-DRUG
or O
Innovar B-BRAND
than O
with O
pentobarbital B-DRUG
. O
Ventricular O
tachycardia O
induced O
by O
ouabain B-DRUG
was O
generally O
converted O
to O
sinus O
rhythm O
following O
administration O
of O
Innovar B-BRAND
, O
ketamine B-DRUG
, O
or O
droperidol B-DRUG
but O
not O
after O
administration O
of O
fentayl B-DRUG
alone O
or O
after O
pentobarbital B-DRUG
. O

Interaction O
between O
oxytocin B-DRUG
and O
antidiuretic O
hormone O
and O
its O
effect O
on O
the O
milk O
secretion O
by O
alveoli O
of O
the O
mammary O
gland O
of O
lactating O
rats O
. O
Interaction O
between O
exogenous O
and O
endogenous O
oxytocin B-DRUG
and O
vasopressin O
was O
found O
to O
affect O
the O
mechanism O
of O
milk O
ejection O
by O
the O
alveoli O
of O
the O
mammary O
gland O
in O
lactating O
rats O
. O
Inhibition O
and O
stimulation O
of O
the O
effect O
of O
oxytocin B-DRUG
on O
milk O
ejection O
by O
vasopressin O
was O
demonstrated O
. O
On O
the O
basis O
of O
the O
principles O
observed O
the O
concentrations O
fo O
these O
hormones O
were O
investigated O
in O
the O
plasma O
of O
dogs O
deprived O
of O
water O
for O
3 O
days O
and O
then O
allowed O
to O
drink O
. O

Interaction O
of O
clindamycin B-DRUG
and O
gentamicin B-DRUG
in O
vitro O
. O
The O
minimal O
inhibitory O
concentrations O
of O
clindamycin B-DRUG
and O
gentamicin B-DRUG
alone O
and O
in O
combinations O
were O
determined O
by O
a O
microdilution O
method O
for O
163 O
aerobic O
, O
facultative O
, O
and O
anaerobic O
clinical O
isolates O
. O
All O
77 O
strains O
of O
Staphylococcus O
aureus O
, O
Diplococcus O
pneumoniae O
, O
Streptococcus O
pyogenes O
, O
and O
anaerobic O
bacteria O
( O
except O
for O
three O
strains O
of O
Clostridium O
) O
were O
inhibited O
by O
1 O
. O
6 O
mug O
or O
less O
of O
clindamycin B-DRUG
per O
ml O
. O
Gentamicin B-DRUG
did O
not O
interfere O
with O
the O
activity O
of O
clindamycin B-DRUG
within O
the O
range O
of O
concentrations O
tested O
( O
0 O
. O
1 O
to O
100 O
mug O
/ O
ml O
) O
; O
for O
some O
strains O
combinations O
were O
synergistic O
. O
Sixty O
- O
two O
( O
94 O
% O
) O
of O
66 O
strains O
of O
Enterobacteriaceae O
and O
Pseudomonas O
aeruginosa O
were O
inhibited O
by O
6 O
. O
2 O
mug O
or O
less O
of O
gentamicin B-DRUG
per O
ml O
. O
Combinations O
of O
clindamycin B-DRUG
and O
gentamicin B-DRUG
were O
indifferent O
for O
29 O
strains O
and O
synergistic O
for O
33 O
strains O
. O
All O
20 O
strains O
of O
enterococcus O
, O
three O
strains O
of O
Clostridium O
, O
three O
strains O
of O
Escherichia O
coli O
, O
and O
one O
strain O
of O
Proteus O
rettgeri O
were O
resistant O
to O
both O
clindamycin B-DRUG
( O
minimal O
inhibitory O
concentration O
greater O
than O
3 O
. O
1 O
mug O
/ O
ml O
) O
and O
gentamicin B-DRUG
( O
minimal O
inhibitory O
concentration O
greater O
than O
6 O
. O
2 O
mug O
/ O
ml O
) O
. O
Combinations O
of O
clindamycin B-DRUG
and O
gentamicin B-DRUG
were O
indifferent O
for O
16 O
and O
synergistic O
for O
11 O
of O
the O
resistant O
strains O
. O
Except O
for O
clindamycin B-DRUG
- O
sensitive O
isolates O
, O
synergy O
was O
usually O
observed O
only O
at O
concentrations O
of O
one O
or O
both O
drugs O
which O
are O
not O
readily O
obtainable O
in O
vivo O
. O
Antagonism O
was O
never O
observed O
. O

Molecular O
basis O
for O
the O
selective O
toxicity O
of O
amphotericin B-DRUG
B I-DRUG
for O
yeast O
and O
filipin B-DRUG_N
for O
animal O
cells O
. O
Among O
the O
polyene B-GROUP
antibiotics I-GROUP
, O
many O
, O
like O
filipin B-DRUG_N
, O
cannot O
be O
used O
clinically O
because O
they O
are O
toxic O
; O
amphotericin B-DRUG
B I-DRUG
, O
however O
, O
is O
useful O
in O
therapy O
of O
human O
fungal O
infections O
because O
it O
is O
less O
toxic O
. O
Both O
the O
toxicity O
of O
filipin B-DRUG_N
and O
the O
therapeutic O
value O
of O
amphotericin B-DRUG
B I-DRUG
can O
be O
rationalized O
at O
the O
cellular O
and O
molecular O
level O
by O
the O
following O
observations O
: O
( O
i O
) O
these O
polyene B-GROUP
antibiotics I-GROUP
showed O
differential O
effects O
on O
cells O
; O
filipin B-DRUG_N
was O
more O
potent O
in O
lysing O
human O
red O
blood O
cells O
, O
whereas O
amphotericin B-DRUG
B I-DRUG
was O
more O
potent O
in O
inhibiting O
yeast O
cell O
growth O
; O
and O
( O
ii O
) O
the O
effects O
of O
filipin B-DRUG_N
were O
more O
efficiently O
inhibited O
by O
added O
cholesterol O
, O
the O
major O
membrane O
sterol O
in O
human O
cells O
, O
whereas O
the O
effects O
of O
amphotericin B-DRUG
B I-DRUG
were O
more O
efficiently O
inhibited O
by O
ergosterol O
, O
the O
major O
membrane O
sterol O
in O
yeast O
. O
The O
simplest O
inference O
is O
that O
the O
toxicity O
and O
effectiveness O
of O
polyenes O
are O
determined O
by O
their O
relative O
avidities O
for O
the O
predominant O
sterol O
in O
cell O
membranes O
. O

Studies O
on O
the O
mechanism O
of O
action O
of O
miconazole B-DRUG
: O
effect O
of O
miconazole B-DRUG
on O
respiration O
and O
cell O
permeability O
of O
Candida O
albicans O
. O
The O
antifungal B-GROUP
drug I-GROUP
, O
miconazole B-DRUG
nitrate I-DRUG
, O
inhibits O
the O
growth O
of O
several O
species O
of O
Candida O
. O
Candida O
albicans O
, O
one O
of O
the O
pathogenic O
species O
, O
was O
totally O
inhibited O
at O
a O
concentration O
of O
approximately O
10 O
mug O
/ O
ml O
. O
Endogenous O
respiration O
was O
unaffected O
by O
the O
drug O
at O
a O
concentration O
as O
high O
as O
100 O
mug O
/ O
ml O
, O
whereas O
exogenous O
respiration O
was O
markedly O
sensitive O
and O
inhibited O
to O
an O
extent O
of O
85 O
% O
. O
The O
permeability O
of O
the O
cell O
membrane O
was O
changed O
as O
evidenced O
by O
the O
leakage O
of O
260 O
- O
nm O
absorbing O
materials O
, O
amino O
acids O
, O
proteins O
, O
and O
inorganic O
cations O
. O
The O
results O
we O
present O
clearly O
show O
that O
the O
drug O
alters O
the O
cellular O
permeability O
, O
and O
thus O
the O
exogenous O
respiration O
becomes O
sensitive O
to O
the O
drug O
. O

Effect O
of O
probenecid B-DRUG
on O
the O
apparent O
volume O
of O
distribution O
and O
elimination O
of O
cloxacillin B-DRUG
. O
According O
to O
Gibaldi O
et O
al O
. O
( O
1968 O
, O
1970 O
) O
, O
the O
higher O
serum O
concentrations O
of O
penicillins B-GROUP
and O
cephaloridine B-DRUG
reached O
after O
administration O
of O
probenecid B-DRUG
are O
due O
not O
only O
to O
slower O
renal O
elimination O
but O
also O
to O
an O
altered O
distribution O
in O
the O
body O
. O
To O
determine O
whether O
probenecid B-DRUG
has O
a O
direct O
effect O
on O
the O
distribution O
of O
cloxacillin B-DRUG
, O
the O
elimination O
and O
distribution O
of O
cloxacillin B-DRUG
was O
studied O
in O
six O
patients O
, O
five O
lacking O
kidney O
function O
and O
one O
with O
a O
partially O
impaired O
renal O
function O
, O
in O
the O
presence O
or O
absence O
of O
probenecid B-DRUG
. O
No O
significant O
difference O
was O
found O
between O
the O
mean O
values O
of O
the O
volume O
of O
distribution O
of O
cloxacillin B-DRUG
with O
and O
without O
probenecid B-DRUG
( O
13 O
. O
0 O
and O
12 O
. O
6 O
liters O
, O
respectively O
) O
. O
Thus O
, O
the O
hypothesis O
of O
Gibaldi O
et O
al O
. O
could O
not O
be O
confirmed O
for O
cloxacillin B-DRUG
in O
patients O
lacking O
kidney O
function O
. O
In O
spite O
of O
the O
absence O
of O
kidney O
function O
, O
the O
value O
of O
the O
elimination O
rate O
constant O
was O
significantly O
decreased O
in O
the O
presence O
of O
probenecid B-DRUG
( O
from O
0 O
. O
326 O
to O
0 O
. O
263 O
/ O
h O
) O
. O
This O
might O
be O
explained O
by O
a O
blockade O
by O
probenecid B-DRUG
of O
the O
elimination O
of O
cloxacillin B-DRUG
by O
the O
liver O
. O

Behavioral O
mechanisms O
underlying O
the O
link O
between O
smoking O
and O
drinking O
. O
Many O
people O
use O
both O
alcohol B-DRUG
and O
nicotine B-DRUG
( O
i O
. O
e O
. O
, O
cigarettes O
and O
other O
tobacco O
products O
) O
. O
The O
behavioral O
effects O
of O
these O
two O
drugs O
differ O
, O
and O
they O
do O
not O
act O
on O
the O
same O
target O
sites O
in O
the O
brain O
, O
although O
they O
may O
share O
, O
or O
partly O
share O
, O
certain O
properties O
. O
The O
initiation O
of O
alcohol B-DRUG
or O
nicotine B-DRUG
use O
may O
be O
precipitated O
by O
similar O
personality O
characteristics O
in O
the O
user O
, O
such O
as O
impulsivity O
and O
sensation O
seeking O
. O
Moreover O
, O
the O
mechanisms O
underlying O
the O
development O
of O
dependence O
may O
be O
similar O
for O
alcohol B-DRUG
and O
nicotine B-DRUG
. O
Thus O
, O
certain O
factors O
, O
such O
as O
reinforcing O
drug O
effects O
, O
conditioning O
processes O
, O
automatic O
behavior O
, O
and O
stress O
, O
may O
influence O
the O
development O
of O
dependence O
on O
both O
drugs O
. O
Other O
factors O
, O
such O
as O
tolerance O
and O
sensitization O
to O
the O
drugs O
' O
actions O
and O
the O
development O
of O
withdrawal O
symptoms O
, O
may O
also O
contribute O
to O
dependence O
. O
This O
review O
discusses O
the O
actions O
of O
the O
two O
drugs O
on O
certain O
brain O
chemical O
( O
i O
. O
e O
. O
, O
neurotransmitter O
) O
systems O
and O
the O
extent O
to O
which O
the O
effects O
of O
the O
two O
drugs O
may O
interact O
. O

[ O
Dose O
- O
time O
effects O
of O
competitive O
displacement O
of O
radiopertechnetate B-DRUG
by O
sodium B-DRUG_N
perchlorate I-DRUG_N
following O
oral O
and O
intravenous O
administration O
] O
The O
effect O
of O
various O
doses O
of O
sodium B-DRUG_N
perchlorate I-DRUG_N
in O
several O
dose O
fractions O
on O
the O
extent O
and O
the O
time O
scale O
of O
displacement O
of O
radiopertechnetate B-DRUG
, O
in O
dependence O
on O
application O
mode O
, O
was O
studied O
. O
An O
intravenous O
dose O
of O
50 O
mg O
perchlorate B-DRUG_N
was O
in O
respect O
of O
competitive O
suppression O
of O
organs O
actively O
concentrating O
pertechnetate B-DRUG
as O
effective O
as O
intravenous O
1000 O
mg O
ClO O
- O
4 O
- O
simultaneously O
or O
1000 O
mg O
orally O
30 O
min O
before O
the O
injection O
of O
radiopertechnetate B-DRUG
. O
An O
intravenous O
injection O
of O
perchlorate B-DRUG_N
given O
later O
also O
produces O
a O
complete O
and O
immediately O
beginning O
depletion O
of O
pertechnetate B-DRUG
already O
accumulated O
in O
the O
thyroid O
, O
within O
a O
period O
of O
195 O
min O
after O
99m O
- O
TcO O
- O
4 O
- O
injection O
with O
a O
corresponding O
increase O
in O
blood O
levels O
. O
20 O
mg O
result O
in O
incomplete O
depletion O
which O
becomes O
complete O
after O
a O
second O
additional O
dose O
. O
The O
intravenous O
application O
of O
perchlorate B-DRUG_N
offers O
advantages O
in O
clinical O
use O
. O

Herbal O
remedies O
, O
nephropathies O
, O
and O
renal O
disease O
. O
The O
use O
of O
herbal O
remedies O
is O
becoming O
increasingly O
popular O
in O
the O
United O
States O
. O
Research O
has O
shown O
that O
herbal O
remedy O
use O
may O
be O
associated O
with O
acute O
renal O
failure O
. O
In O
addition O
, O
the O
use O
of O
herbal O
remedies O
may O
be O
detrimental O
for O
the O
patient O
with O
compromised O
renal O
function O
. O
Patients O
with O
renal O
insufficiency O
or O
renal O
failure O
may O
be O
at O
risk O
for O
further O
kidney O
damage O
as O
well O
as O
complications O
related O
to O
interactions O
of O
herbal O
remedies O
with O
complex O
renal O
therapy O
regimens O
. O
This O
article O
will O
describe O
the O
escalating O
use O
of O
herbal O
therapy O
and O
the O
hazards O
of O
herbal O
remedy O
use O
among O
patients O
. O

Sirolimus B-DRUG
: O
mammalian O
target O
of O
rapamycin B-DRUG
inhibitor O
to O
prevent O
kidney O
rejection O
. O
Current O
immunosuppressive O
therapies O
are O
effective O
but O
can O
be O
associated O
with O
significant O
adverse O
reactions O
. O
Sirolimus B-DRUG
works O
differently O
from O
the O
immunosuppressants B-GROUP
currently O
available O
, O
and O
except O
for O
increased O
lipid O
levels O
, O
the O
adverse O
reaction O
profile O
of O
sirolimus B-DRUG
does O
not O
appear O
to O
overlap O
to O
any O
great O
extent O
with O
that O
associated O
with O
cyclosporine B-DRUG
or O
tacrolimus B-DRUG
. O
While O
additional O
research O
is O
needed O
, O
the O
initial O
clinical O
data O
in O
kidney O
recipients O
suggest O
that O
sirolimus B-DRUG
, O
in O
combination O
with O
cyclosporine B-DRUG
or O
tacrolimus B-DRUG
, O
might O
have O
the O
potential O
to O
reduce O
the O
frequency O
of O
rejection O
episodes O
, O
permit O
reductions O
in O
cyclosporine B-DRUG
or O
tacrolimus B-DRUG
dosage O
, O
and O
permit O
steroid O
withdrawal O
( O
Kelly O
, O
1999 O
) O
. O

The O
effects O
of O
chlordiazepoxide B-DRUG
, O
amphetamine B-DRUG
and O
cocaine B-DRUG
on O
bar O
- O
press O
behavior O
in O
normal O
and O
genetically O
nervous O
dogs O
. O
Studies O
on O
two O
strains O
of O
pointer O
dogs O
have O
demonstrated O
that O
administration O
of O
a O
benzodiazepine B-GROUP
( O
chlordiazepoxide B-DRUG
) O
facilitates O
acquisition O
of O
goal O
- O
directed O
behavior O
in O
" O
genetically O
nervous O
" O
subjects O
. O
Continued O
admistration O
of O
the O
drug O
is O
required O
to O
maintain O
barpress O
response O
in O
this O
strain O
of O
dogs O
. O
The O
concomitant O
administration O
of O
either O
cocaine B-DRUG
or O
amphetamine B-DRUG
, O
compounds O
which O
inhibit O
neuronal O
reuptake O
of O
norepinephrine O
, O
disrupts O
the O
behavioral O
response O
of O
the O
genetically O
nervous O
E O
- O
strain O
subjects O
to O
a O
far O
greater O
extent O
than O
the O
stable O
A O
- O
strain O
subjects O
. O
It O
is O
also O
shown O
that O
after O
14 O
days O
of O
daily O
administration O
of O
chlordiazepoxide B-DRUG
, O
withdrawal O
of O
the O
drug O
not O
only O
re O
- O
results O
in O
almost O
complete O
loss O
of O
bar O
- O
press O
response O
in O
the O
E O
- O
strain O
subjects O
but O
also O
results O
in O
a O
temporary O
decrease O
in O
the O
acquired O
behavioral O
response O
of O
the O
stable O
A O
- O
strain O
subjects O
. O

Development O
and O
pharmacology O
of O
fluvastatin B-DRUG
. O
Fluvastatin B-DRUG
is O
the O
first O
synthetic B-GROUP
3 I-GROUP
- I-GROUP
hydroxy I-GROUP
- I-GROUP
3 I-GROUP
- I-GROUP
methylglutaryl I-GROUP
coenzyme I-GROUP
A I-GROUP
( I-GROUP
HMGCoA I-GROUP
) I-GROUP
reductase I-GROUP
inhibitor I-GROUP
to O
be O
approved O
for O
clinical O
use O
, O
and O
has O
been O
studied O
extensively O
in O
humans O
since O
1986 O
. O
It O
is O
structurally O
distinct O
from O
the O
other O
currently O
available O
HMGCoA B-GROUP
reductase I-GROUP
inhibitors I-GROUP
( O
lovastatin B-DRUG
, O
simvastatin B-DRUG
, O
and O
pravastatin B-DRUG
) O
, O
leading O
to O
unique O
biopharmaceutical O
properties O
relative O
to O
the O
other O
agents O
of O
this O
class O
. O
Absorption O
of O
fluvastatin B-DRUG
is O
virtually O
complete O
across O
all O
species O
, O
including O
man O
, O
and O
is O
not O
affected O
by O
the O
presence O
of O
food O
. O
Systemic O
exposure O
is O
limited O
, O
as O
fluvastatin B-DRUG
is O
subject O
to O
first O
- O
pass O
metabolism O
, O
and O
the O
plasma O
half O
- O
life O
of O
the O
drug O
is O
approximately O
30 O
minutes O
. O
Some O
95 O
% O
of O
a O
single O
dosage O
of O
fluvastatin B-DRUG
is O
excreted O
via O
the O
biliary O
route O
, O
with O
less O
than O
2 O
% O
of O
this O
being O
the O
parent O
compound O
. O
Additionally O
, O
there O
is O
no O
evidence O
of O
circulating O
active O
metabolites O
or O
accumulation O
during O
chronic O
dosing O
. O
Studies O
of O
the O
effect O
of O
food O
on O
the O
pharmacokinetics O
of O
fluvastatin B-DRUG
have O
demonstrated O
marked O
reductions O
in O
the O
rate O
of O
bioavailability O
- O
- O
from O
40 O
% O
to O
60 O
% O
; O
however O
, O
a O
comparison O
of O
fluvastatin B-DRUG
administration O
with O
the O
evening O
meal O
or O
at O
bedtime O
has O
revealed O
no O
significant O
differences O
in O
the O
extent O
of O
bioavailability O
( O
area O
under O
the O
curve O
) O
of O
these O
two O
regimens O
. O
Furthermore O
, O
no O
significant O
difference O
in O
pharmacodynamic O
effect O
( O
reduction O
in O
low O
- O
density O
lipoprotein O
cholesterol O
levels O
) O
could O
be O
ascertained O
between O
mealtime O
dosing O
and O
bedtime O
dosing O
. O
The O
pharmacokinetics O
of O
fluvastatin B-DRUG
have O
also O
been O
assessed O
in O
various O
demographic O
groups O
. O
Relative O
to O
the O
general O
population O
, O
plasma O
concentrations O
of O
fluvastatin B-DRUG
do O
not O
vary O
as O
a O
function O
of O
either O
age O
or O
gender O
. O
In O
addition O
, O
administration O
to O
a O
patient O
population O
with O
hepatic O
insufficiency O
resulted O
in O
a O
2 O
. O
5 O
- O
fold O
increase O
in O
both O
the O
rate O
and O
extent O
of O
bioavailability O
relative O
to O
controls O
. O
Also O
, O
although O
minimal O
alterations O
of O
fluvastatin B-DRUG
clearance O
in O
patients O
with O
renal O
insufficiency O
are O
anticipated O
due O
to O
limited O
renal O
excretion O
( O
5 O
% O
) O
, O
a O
study O
in O
this O
patient O
group O
is O
currently O
underway O
to O
examine O
this O
further O
. O
Interaction O
studies O
have O
been O
performed O

with O
fluvastatin B-DRUG
and O
several O
drugs O
with O
which O
it O
might O
be O
coadministered O
. O
Cholestyramine B-DRUG
, O
an O
anionic O
- O
binding O
resin O
, O
has O
a O
considerable O
effect O
in O
lowering O
the O
rate O
and O
extent O
of O
fluvastatin B-DRUG
bioavailability O
. O
Although O
this O
effect O
was O
noted O
even O
when O
cholestyramine B-DRUG
was O
given O
4 O
hours O
prior O
to O
fluvastatin B-DRUG
, O
this O
regimen O
did O
not O
result O
in O
diminished O
efficacy O
. O
Further O
, O
no O
effects O
on O
either O
warfarin B-DRUG
levels O
or O
prothrombin O
times O
were O
observed O
in O
a O
study O
involving O
concomitant O
administration O
of O
warfarin B-DRUG
and O
fluvastatin B-DRUG
. O
Moreover O
, O
additional O
interaction O
studies O
with O
niacin B-DRUG
and O
propranolol B-DRUG
have O
not O
demonstrated O
any O
effect O
on O
fluvastatin B-DRUG
plasma O
levels O
, O
and O
administration O
to O
a O
patient O
population O
chronically O
receiving O
digoxin B-DRUG
resulted O
in O
no O
difference O
in O
the O
extent O
of O
bioavailability O
of O
digoxin B-DRUG
relative O
to O
control O
data O
. O
The O
results O
generated O
to O
date O
in O
clinical O
pharmacokinetic O
studies O
with O
fluvastatin B-DRUG
thus O
support O
its O
use O
in O
a O
broad O
population O
of O
hypercholesterolaemic O
patients O
. O

Tumor O
phenotype O
and O
susceptibility O
to O
progression O
as O
an O
expression O
of O
subpopulations O
of O
initiated O
murine O
cells O
. O
Currently O
, O
it O
is O
conceived O
that O
a O
number O
of O
events O
, O
or O
hits O
, O
are O
required O
for O
the O
induction O
of O
tumors O
by O
chemical O
agents O
. O
The O
first O
phase O
of O
this O
sequence O
, O
initiation O
, O
is O
considered O
to O
result O
from O
at O
least O
one O
event O
in O
the O
genetic O
apparatus O
. O
Analyses O
of O
this O
sequence O
, O
however O
, O
usually O
give O
little O
consideration O
to O
the O
nature O
of O
the O
target O
cell O
or O
to O
the O
characteristics O
of O
the O
resultant O
tumors O
. O
Vesselinovitch O
et O
al O
. O
( O
Cancer O
Res O
. O
, O
38 O
: O
2003 O
- O
2010 O
, O
1978 O
) O
have O
reported O
that O
a O
single O
, O
small O
pulse O
of O
carcinogen O
can O
induce O
early O
and O
numerous O
liver O
tumors O
when O
administered O
neonatally O
to O
mice O
with O
a O
genetic O
predisposition O
to O
hepatotumorigenesis O
. O
In O
the O
current O
study O
, O
the O
nonpredisposed O
strain O
C57BL O
/ O
6N O
was O
also O
shown O
to O
be O
highly O
susceptible O
to O
diethylnitrosamine O
during O
the O
neonatal O
period O
. O
C57BL O
/ O
6N O
demonstrated O
large O
numbers O
of O
two O
of O
the O
three O
types O
of O
liver O
tumors O
seen O
in O
livers O
of O
genetically O
predisposed O
mice O
, O
one O
of O
which O
required O
the O
additional O
stimulus O
of O
dietary O
phenobarbital B-DRUG
for O
growth O
. O
Tumors O
of O
more O
malignant O
phenotype O
were O
demonstrated O
only O
in O
genetically O
predisposed O
mice O
( O
C57BL O
/ O
6N O
X O
C3H O
/ O
HeN O
F1 O
) O
that O
received O
one O
dose O
of O
carcinogen O
. O
These O
findings O
suggest O
that O
the O
phenotype O
of O
a O
tumor O
that O
results O
from O
a O
pulse O
of O
a O
chemical O
carcinogen O
may O
depend O
upon O
the O
target O
cell O
. O
The O
initiated O
cells O
that O
result O
from O
this O
hit O
may O
vary O
from O
those O
that O
demonstrate O
very O
little O
progression O
in O
cell O
type O
and O
may O
or O
may O
not O
require O
exogenous O
enhancement O
of O
growth O
to O
those O
that O
can O
progress O
very O
rapidly O
to O
fully O
malignant O
behavior O
. O
The O
latter O
might O
arise O
from O
a O
hit O
in O
a O
genetically O
initiated O
cell O
, O
the O
result O
of O
which O
is O
a O
more O
rapid O
progression O
in O
tumor O
type O
. O

Analgesic O
effects O
of O
antihistaminics B-GROUP
. O
The O
literature O
provides O
considerable O
evidence O
indicating O
that O
several O
, O
but O
not O
all O
antihistaminics B-GROUP
, O
are O
indeed O
analgesic B-GROUP
agents I-GROUP
and O
some O
are O
analgesic B-GROUP
adjuvants I-GROUP
as O
well O
. O
Those O
for O
which O
effectiveness O
is O
reported O
includes O
diphenhydramine B-DRUG
, O
hydroxyzine B-DRUG
, O
orphenadrine B-DRUG
, O
pyrilamine B-DRUG
, O
phenyltoloxamine B-DRUG_N
, O
promethazine B-DRUG
, O
methdilazine B-DRUG
, O
and O
tripelennamine B-DRUG
. O
The O
proposed O
mechanisms O
of O
analgesic O
action O
of O
antihistaminics B-GROUP
are O
reviewed O
and O
discussed O
. O
The O
literature O
suggests O
that O
more O
than O
one O
mechanism O
of O
action O
exists O
for O
them O
. O
There O
is O
considerable O
evidence O
suggesting O
that O
histaminergic O
and O
serotoninergic O
central O
pathways O
are O
involved O
in O
nociception O
and O
that O
antihistaminic B-GROUP
drugs O
can O
modulate O
their O
responses O
( O
1 O
) O
. O
The O
evidence O
for O
a O
role O
for O
norepinephrine O
and O
dopamine O
and O
the O
effects O
of O
antihistaminics B-GROUP
on O
them O
are O
less O
well O
established O
. O
Still O
other O
pathways O
have O
been O
proposed O
. O
A O
greater O
understanding O
of O
pain O
mechanisms O
will O
aid O
in O
elucidating O
the O
role O
of O
antihistaminics B-GROUP
in O
analgesia O
. O

[ O
The O
GABA O
- O
ergic O
system O
and O
brain O
edema O
] O
It O
has O
been O
shown O
in O
rats O
with O
experimental O
toxic O
and O
traumatic O
edemas O
that O
picrotoxin B-DRUG_N
( O
1 O
mg O
/ O
kg O
) O
removes O
the O
antiedematous O
action O
of O
diazepam B-DRUG
, O
phenazepam B-DRUG_N
, O
phenibut B-DRUG_N
and O
amizyl B-DRUG_N
and O
reduces O
the O
action O
of O
phentolamine B-DRUG
. O
When O
the O
dose O
of O
picrotoxin B-DRUG_N
is O
minimized O
to O
0 O
. O
5 O
mg O
/ O
kg O
such O
an O
effect O
is O
not O
observed O
. O
Prolonged O
daily O
administration O
of O
picrotoxin B-DRUG_N
in O
a O
dose O
of O
1 O
mg O
/ O
kg O
results O
in O
the O
development O
of O
brain O
edema O
. O
It O
is O
recommended O
that O
GABA O
- O
positive O
drugs O
be O
included O
into O
a O
complex O
of O
treatment O
measures O
for O
edema O
. O

[ O
Stimulation O
by O
cerulein B-DRUG_N
- O
- O
an O
analog O
of O
the O
octapeptide O
cholecystokinin O
- O
- O
of O
3H B-DRUG_N
- I-DRUG_N
spiroperidol I-DRUG_N
binding O
after O
the O
long O
- O
term O
administration O
of O
neuroleptics B-GROUP
] O
It O
has O
been O
established O
in O
experiments O
on O
white O
male O
rats O
that O
prolonged O
administration O
( O
twice O
a O
day O
for O
14 O
days O
) O
of O
haloperidol B-DRUG
( O
0 O
. O
25 O
mg O
/ O
kg O
) O
and O
pyreneperone B-DRUG_N
( O
0 O
. O
25 O
mg O
/ O
kg O
) O
resulted O
in O
the O
reduced O
interaction O
between O
3H B-DRUG_N
- I-DRUG_N
spiroperidol I-DRUG_N
and O
low O
affinity O
binding O
sites O
for O
apomorphine B-DRUG
in O
subcortical O
structures O
, O
whereas O
3H B-DRUG_N
- I-DRUG_N
spiroperidol I-DRUG_N
binding O
with O
high O
affinity O
binding O
sites O
for O
apomorphine B-DRUG
increased O
both O
in O
the O
frontal O
cortex O
and O
subcortical O
structures O
of O
the O
forebrain O
. O
After O
prolonged O
administration O
of O
neuroleptics B-GROUP
the O
displacing O
effect O
of O
cerulein B-DRUG_N
, O
an O
analog O
of O
cholecystokinin O
octapeptide O
, O
was O
replaced O
by O
the O
stimulant O
action O
on O
3H B-DRUG_N
- I-DRUG_N
spiroperidol I-DRUG_N
binding O
. O
It O
is O
assumed O
that O
increased O
interaction O
between O
3H B-DRUG_N
- I-DRUG_N
spiroperidol I-DRUG_N
and O
high O
affinity O
binding O
sites O
for O
apomorphine B-DRUG
on O
dopamine2 O
- O
and O
serotonin2 O
- O
receptors O
underlies O
the O
antipsychotic O
action O
of O
neuroleptics B-GROUP
after O
their O
prolonged O
administration O
. O
Cholecystokinin O
octapeptide O
is O
a O
necessary O
factor O
for O
realization O
of O
this O
action O
of O
neuroleptics B-GROUP
. O

Dual O
effect O
of O
ouabain B-DRUG
on O
the O
palytoxin B-DRUG_N
- O
induced O
contraction O
and O
norepinephrine O
release O
in O
the O
guinea O
- O
pig O
vas O
deferens O
. O
Palytoxin B-DRUG_N
( O
PTX B-DRUG_N
) O
, O
C129H223N3O54 O
, O
isolated O
from O
marine O
coelenterates O
of O
Palythoa O
tuberculosa O
, O
caused O
a O
first O
rapid O
contraction O
followed O
by O
the O
slow O
phasic O
contraction O
of O
guinea O
- O
pig O
vas O
deferens O
. O
In O
the O
presence O
of O
ouabain B-DRUG
( O
10 O
( O
- O
5 O
) O
M O
) O
, O
PTX B-DRUG_N
( O
10 O
( O
- O
8 O
) O
M O
) O
failed O
to O
cause O
the O
first O
contraction O
; O
however O
, O
the O
second O
contraction O
was O
potentiated O
. O
In O
the O
presence O
of O
phentolamine B-DRUG
( O
10 O
( O
- O
6 O
) O
M O
) O
, O
the O
second O
contraction O
was O
inhibited O
selectively O
. O
When O
ouabain B-DRUG
was O
applied O
to O
the O
muscle O
in O
the O
presence O
of O
phentolamine B-DRUG
, O
both O
first O
and O
second O
contractile O
responses O
to O
PTX B-DRUG_N
were O
abolished O
. O
When O
the O
muscle O
was O
exposed O
to O
the O
potassium O
- O
depleted O
solution O
, O
the O
first O
contractile O
response O
to O
PTX B-DRUG_N
was O
rather O
potentiated O
. O
PTX B-DRUG_N
caused O
the O
release O
of O
norepinephrine O
from O
the O
muscle O
. O
Exposure O
of O
the O
muscle O
to O
ouabain B-DRUG
( O
10 O
( O
- O
5 O
) O
M O
) O
markedly O
increased O
the O
PTX B-DRUG_N
- O
induced O
release O
. O
It O
is O
indicated O
that O
the O
first O
and O
second O
contractile O
responses O
to O
PTX B-DRUG_N
have O
entirely O
different O
properties O
. O
The O
second O
response O
is O
due O
to O
a O
release O
of O
norepinephrine O
from O
nerves O
and O
was O
potentiated O
by O
ouabain B-DRUG
through O
the O
increase O
in O
the O
norepinephrine O
release O
, O
whereas O
the O
first O
response O
was O
not O
due O
to O
the O
norepinephrine O
release O
but O
presumably O
to O
a O
direct O
action O
on O
smooth O
muscle O
cell O
and O
was O
inhibited O
by O
ouabain B-DRUG
. O
The O
mechanism O
of O
the O
action O
of O
PTX B-DRUG_N
was O
discussed O
in O
the O
relation O
with O
Na O
, O
K O
- O
ATPase O
. O

[ O
Quantitative O
approach O
to O
treatment O
with O
incisive O
neuroleptics B-GROUP
by O
therapeutic O
monitoring O
] O
; O
The O
problems O
encountered O
during O
the O
longterm O
treatment O
of O
psychotic O
patients O
with O
neuroleptics B-GROUP
are O
illustrated O
by O
six O
typical O
case O
reports O
. O
A O
group O
of O
patients O
who O
had O
had O
a O
new O
acute O
episode O
despite O
seemingly O
adequate O
treatment O
were O
selected O
. O
In O
these O
six O
cases O
it O
was O
demonstrated O
that O
the O
neuroleptics B-GROUP
dosage O
was O
inappropriate O
, O
being O
either O
too O
high O
or O
too O
low O
as O
judged O
from O
the O
plasma O
concentrations O
. O
Ways O
of O
improving O
the O
adequacy O
of O
the O
treatment O
of O
psychotic O
patients O
with O
neuroleptics B-GROUP
are O
discussed O
. O

Intestinal O
absorption O
of O
arsenate B-DRUG_N
in O
the O
chick O
. O
The O
intestinal O
absorption O
of O
arsenate B-DRUG_N
( O
As B-DRUG_N
( I-DRUG_N
V I-DRUG_N
) I-DRUG_N
) O
has O
been O
investigated O
in O
the O
chick O
by O
means O
of O
the O
in O
situ O
ligated O
duodenal O
loop O
technique O
. O
By O
this O
procedure O
, O
it O
was O
observed O
that O
arsenate B-DRUG_N
is O
rapidly O
and O
essentially O
completely O
absorbed O
( O
80 O
- O
95 O
% O
) O
from O
the O
lumen O
at O
As B-DRUG_N
( I-DRUG_N
V I-DRUG_N
) I-DRUG_N
concentrations O
up O
to O
5 O
mM O
, O
declining O
to O
about O
50 O
% O
absorption O
at O
50 O
mM O
. O
Transfer O
from O
the O
intestinal O
lumen O
to O
the O
mucosal O
cells O
at O
low O
As B-DRUG_N
( I-DRUG_N
V I-DRUG_N
) I-DRUG_N
concentration O
( O
0 O
. O
1 O
mM O
) O
is O
rapid O
, O
while O
transfer O
from O
the O
mucosal O
cells O
to O
the O
body O
occurs O
more O
slowly O
. O
At O
stable O
As B-DRUG_N
( I-DRUG_N
V I-DRUG_N
) I-DRUG_N
concentrations O
greater O
than O
1 O
mM O
, O
fractional O
mucosal O
cell O
accumulation O
of O
As B-DRUG_N
( I-DRUG_N
V I-DRUG_N
) I-DRUG_N
remains O
constant O
, O
while O
fractional O
transfer O
to O
the O
body O
declines O
. O
However O
, O
total O
mucosal O
accumulation O
of O
As B-DRUG_N
( I-DRUG_N
V I-DRUG_N
) I-DRUG_N
and O
that O
transferred O
to O
the O
body O
increase O
in O
a O
linear O
logarithmic O
fashion O
from O
0 O
. O
05 O
to O
5 O
mm O
As B-DRUG_N
( I-DRUG_N
V I-DRUG_N
) I-DRUG_N
. O
The O
results O
indicate O
that O
As B-DRUG_N
( I-DRUG_N
V I-DRUG_N
) I-DRUG_N
readily O
penetrates O
both O
the O
mucosal O
and O
serosal O
surfaces O
of O
the O
epithelial O
membrane O
. O
Furthermore O
, O
arsenate B-DRUG_N
and O
phosphate B-DRUG
do O
not O
appear O
to O
share O
a O
common O
transport O
pathway O
in O
the O
duodenum O
and O
no O
evidence O
was O
obtained O
for O
any O
interaction O
between O
the O
two O
at O
this O
level O
. O
Vitamin B-DRUG
D3 I-DRUG
administration O
to O
rachitic O
chicks O
was O
effective O
in O
significantly O
elevating O
duodenal O
arsenate B-DRUG_N
absorption O
, O
acting O
primarily O
to O
enhance O
serosal O
transport O
. O

Spermine B-DRUG
promotes O
the O
translocation O
of O
phosphatidate O
phosphohydrolase O
from O
the O
cytosol O
to O
the O
microsomal O
fraction O
of O
rat O
liver O
and O
it O
enhances O
the O
effects O
of O
oleate O
in O
this O
respect O
. O
Spermine B-DRUG
( O
0 O
. O
5 O
- O
2 O
mM O
) O
promoted O
the O
translocation O
of O
phosphatidate O
phosphohydrolase O
from O
the O
soluble O
to O
the O
microsomal O
fraction O
in O
a O
cell O
- O
free O
system O
derived O
from O
rat O
liver O
. O
By O
contrast O
, O
spermidine B-DRUG_N
( O
1 O
mM O
) O
and O
putrescine B-DRUG_N
( O
1 O
mM O
) O
had O
no O
significant O
effect O
on O
the O
translocation O
when O
added O
alone O
. O
Spermine B-DRUG
, O
and O
to O
a O
lesser O
extent O
, O
spermidine B-DRUG_N
, O
enhanced O
the O
translocating O
action O
of O
oleate O
and O
increased O
its O
effectiveness O
in O
transferring O
the O
phosphohydrolase O
from O
the O
soluble O
to O
the O
microsomal O
fraction O
. O
It O
is O
proposed O
that O
the O
phosphohydrolase O
becomes O
metabolically O
active O
when O
it O
combines O
with O
membranes O
and O
that O
polyamines O
might O
help O
to O
regulate O
this O
interaction O
. O
This O
could O
facilitate O
the O
action O
of O
fatty O
acids O
and O
enable O
cells O
to O
increase O
their O
capacity O
for O
triacylglycerol O
synthesis O
to O
match O
an O
increased O
availability O
of O
fatty O
acids O
. O

Influence O
of O
calcium B-GROUP
- I-GROUP
channel I-GROUP
blockers I-GROUP
on O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
. O
Available O
data O
indicate O
that O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
are O
important O
factors O
in O
hemostasis O
and O
regulation O
of O
vascular O
tone O
. O
Plasma O
membrane O
and O
intracellular O
mobilization O
of O
calcium O
ions O
are O
intimately O
related O
to O
platelet O
activation O
and O
release O
of O
platelet O
contents O
. O
Release O
of O
arachidonic O
acid O
from O
membrane O
phospholipids O
as O
well O
as O
subsequent O
synthesis O
and O
release O
of O
vasoconstrictor O
thromboxane O
A2 O
are O
also O
regulated O
by O
movement O
of O
calcium O
ions O
. O
Adenosine O
3 O
' O
: O
5 O
' O
- O
cyclic O
phosphate O
in O
turn O
controls O
levels O
of O
free O
calcium O
ions O
in O
platelets O
and O
regulates O
calcium O
- O
dependent O
reactions O
. O
Slow B-GROUP
- I-GROUP
channel I-GROUP
calcium I-GROUP
blockers I-GROUP
, O
such O
as O
verapamil B-DRUG
, O
diltiazem B-DRUG
and O
nifedipine B-DRUG
, O
inhibit O
platelet O
activation O
in O
vitro O
, O
and O
decrease O
platelet O
adhesion O
intravascularly O
. O
These O
agents O
have O
also O
been O
shown O
to O
decrease O
platelet O
nucleotide O
release O
and O
thromboxane O
A2 O
generation O
. O
Some O
preliminary O
data O
suggest O
that O
calcium B-GROUP
blockers I-GROUP
also O
increase O
generation O
of O
vasodilator O
and O
platelet O
antiaggregant O
prostacyclin O
, O
which O
could O
contribute O
to O
decrease O
in O
platelet O
function O
. O
These O
effects O
of O
calcium B-GROUP
blockers I-GROUP
on O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
could O
contribute O
in O
part O
to O
their O
efficacy O
in O
patients O
with O
ischemic O
heart O
disease O
. O

Differential O
actions O
of O
intrathecal O
naloxone B-DRUG
on O
blocking O
the O
tail O
- O
flick O
inhibition O
induced O
by O
intraventricular O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
and O
morphine B-DRUG
in O
rats O
. O
In O
the O
present O
study O
, O
it O
is O
proposed O
that O
the O
opioids B-GROUP
applied O
to O
supraspinal O
brain O
sites O
produced O
their O
analgesic O
effects O
by O
the O
activation O
of O
different O
descending O
pain O
inhibitory O
systems O
. O
The O
blockade O
of O
the O
spinal O
endorphinergic O
system O
by O
intrathecal O
naloxone B-DRUG
on O
the O
production O
of O
tail O
- O
flick O
inhibition O
induced O
by O
intraventricular O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
and O
morphine B-DRUG
was O
then O
studied O
. O
Intraventricular O
injection O
of O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
and O
morphine B-DRUG
produced O
an O
inhibition O
of O
the O
tail O
- O
flick O
response O
to O
the O
heat O
stimulus O
in O
rats O
. O
Intrathecal O
injection O
of O
naloxone B-DRUG
at O
doses O
of O
0 O
. O
4 O
to O
40 O
micrograms O
caused O
a O
dose O
- O
related O
blockade O
of O
the O
inhibition O
of O
the O
tail O
- O
flick O
response O
induced O
by O
intraventricular O
injection O
of O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
, O
and O
a O
high O
dose O
of O
naloxone B-DRUG
( O
40 O
micrograms O
) O
completely O
blocked O
the O
tail O
- O
flick O
inhibition O
induced O
by O
intraventricular O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
( O
16 O
micrograms O
) O
. O
On O
the O
other O
hand O
, O
intrathecal O
naloxone B-DRUG
( O
12 O
- O
120 O
micrograms O
) O
had O
only O
a O
very O
weak O
effect O
on O
the O
tail O
- O
flick O
inhibition O
induced O
by O
intraventricular O
morphine B-DRUG
( O
40 O
micrograms O
) O
. O
Intraventricular O
injection O
of O
naloxone B-DRUG
at O
doses O
of O
1 O
. O
2 O
to O
12 O
micrograms O
equally O
antagonized O
in O
a O
dose O
- O
dependent O
manner O
the O
tail O
- O
flick O
inhibition O
induced O
by O
intraventricular O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
and O
morphine B-DRUG
. O
The O
results O
indicate O
that O
a O
spinal O
naloxone B-DRUG
- O
sensitive O
endorphinergic O
system O
is O
involved O
in O
the O
production O
of O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
but O
not O
morphine B-DRUG
- O
induced O
tail O
- O
flick O
inhibition O
, O
and O
suggest O
that O
intraventricular O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
and O
morphine B-DRUG
elicit O
their O
pharmacological O
actions O
via O
the O
activation O
of O
different O
descending O
pain O
inhibitory O
systems O
; O
descending O
epsilon O
and O
mu O
systems O
for O
beta B-DRUG_N
- I-DRUG_N
endorphin I-DRUG_N
and O
morphine B-DRUG
, O
respectively O
, O
are O
proposed O
. O

Neurochemical O
and O
functional O
consequences O
following O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
5 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
( O
MPTP B-DRUG_N
) O
and O
methamphetamine B-DRUG
. O
The O
neurochemical O
and O
functional O
consequences O
following O
MPTP B-DRUG_N
administration O
to O
the O
rat O
were O
evaluated O
and O
compared O
to O
similar O
effects O
following O
methamphetamine B-DRUG
administration O
. O
It O
was O
observed O
that O
MPTP B-DRUG_N
induced O
long O
lasting O
depletions O
of O
striatal O
dopamine O
concentrations O
and O
this O
neurotoxic O
effect O
could O
be O
prevented O
by O
pargyline B-DRUG
pretreatment O
. O
The O
MPTP B-DRUG
- O
induced O
neuronal O
damage O
produced O
a O
tolerance O
to O
the O
disruptive O
effects O
of O
amphetamine B-DRUG
and O
a O
supersensitivity O
to O
the O
disruptive O
effects O
of O
apomorphine B-DRUG
in O
rats O
responding O
in O
a O
schedule O
controlled O
paradigm O
. O
Methamphetamine B-DRUG
, O
like O
MPTP B-DRUG_N
, O
produced O
depletions O
of O
striatal O
dopamine O
but O
these O
actions O
were O
potentiated O
by O
pargyline B-DRUG
pretreatment O
. O
These O
observations O
are O
discussed O
in O
reference O
to O
possible O
deleterious O
effects O
following O
the O
administration O
of O
pargyline B-DRUG
to O
patients O
with O
Parkinson O
' O
s O
Disease O
. O

Jacalin B-DRUG_N
: O
an O
IgA O
- O
binding O
lectin O
. O
We O
previously O
reported O
that O
seeds O
of O
Artocarpus O
integrifolia O
( O
jackfruit O
) O
contain O
a O
lectin O
, O
which O
we O
call O
jacalin B-DRUG_N
, O
that O
is O
both O
a O
potent O
T O
cell O
mitogen O
and O
an O
apparently O
T O
cell O
- O
independent O
activator O
of O
human O
B O
cells O
for O
the O
secretion O
of O
immunoglobulins O
. O
During O
the O
above O
experiments O
we O
noted O
a O
massive O
precipitation O
in O
cell O
cultures O
stimulated O
with O
greater O
than O
or O
equal O
to O
100 O
micrograms O
of O
lectin O
. O
In O
this O
paper O
, O
we O
show O
that O
the O
precipitate O
is O
formed O
after O
the O
interaction O
of O
jacalin B-DRUG_N
and O
the O
serum O
protein O
added O
to O
the O
culture O
medium O
. O
More O
importantly O
, O
we O
demonstrate O
that O
IgA O
is O
probably O
the O
major O
serum O
constituent O
precipitated O
by O
the O
lectin O
and O
that O
no O
IgG O
or O
IgM O
can O
be O
detected O
in O
the O
precipitates O
. O
In O
secretions O
such O
as O
colostrum O
, O
IgA O
is O
the O
only O
protein O
precipitated O
by O
jacalin B-DRUG_N
. O
On O
the O
basis O
of O
this O
specificity O
we O
describe O
a O
simple O
and O
reliable O
affinity O
chromatography O
procedure O
for O
the O
purification O
of O
both O
human O
serum O
and O
colostrum O
IgA O
. O
Jacalin B-DRUG_N
is O
a O
D O
- O
Gal O
binding O
lectin O
and O
should O
be O
a O
useful O
tool O
for O
studying O
of O
serum O
and O
secretory O
IgA O
. O

Cancer O
in O
the O
elderly O
: O
basic O
science O
and O
clinical O
aspects O
. O
The O
incidence O
of O
cancer O
increases O
progressively O
with O
age O
. O
Rearrangements O
of O
genomes O
have O
been O
found O
to O
accompany O
cellular O
aging O
. O
These O
factors O
, O
in O
concert O
with O
age O
- O
dependent O
alterations O
in O
immune O
function O
and O
host O
defense O
, O
may O
help O
to O
explain O
the O
increased O
risk O
of O
malignant O
disease O
in O
aged O
persons O
. O
The O
clinical O
presentation O
and O
natural O
history O
of O
neoplasia O
are O
also O
affected O
by O
aging O
. O
This O
conference O
reviews O
recent O
developments O
in O
these O
areas O
, O
examines O
the O
effects O
of O
drug O
use O
in O
the O
elderly O
and O
implications O
for O
management O
, O
and O
discusses O
current O
information O
on O
how O
age O
may O
influence O
the O
response O
of O
cancer O
to O
therapy O
. O

Dexamethasone B-DRUG
and O
retinyl B-DRUG
acetate I-DRUG
similarly O
inhibit O
and O
stimulate O
EGF B-DRUG_N
- O
or O
insulin B-DRUG
- O
induced O
proliferation O
of O
prostatic O
epithelium O
. O
Prostatic O
epithelium O
proliferates O
in O
a O
defined O
medium O
consisting O
of O
basal O
medium O
RPMI1640 O
containing O
transferrin B-DRUG_N
( O
1 O
microgram O
/ O
ml O
) O
, O
EGF B-DRUG_N
( O
10 O
ng O
/ O
ml O
) O
, O
and O
insulin B-DRUG
( O
3 O
. O
7 O
micrograms O
/ O
ml O
or O
0 O
. O
1 O
IU O
/ O
ml O
) O
. O
Although O
neither O
dexamethasone B-DRUG
nor O
retinyl B-DRUG
acetate I-DRUG
affected O
the O
proliferation O
of O
prostatic O
epithelium O
in O
RPMI1640 O
containing O
transferrin B-DRUG_N
alone O
, O
they O
modify O
the O
mitogenic O
effect O
of O
EGF B-DRUG_N
and O
insulin B-DRUG
. O
Dexamethasone B-DRUG
at O
10 O
( O
- O
10 O
) O
M O
or O
retinyl B-DRUG
acetate I-DRUG
at O
about O
3 O
X O
10 O
( O
- O
9 O
) O
M O
inhibits O
proliferation O
stimulated O
by O
EGF B-DRUG_N
. O
Higher O
concentrations O
of O
dexamethasone B-DRUG
( O
10 O
( O
- O
8 O
) O
- O
10 O
( O
- O
6 O
) O
M O
) O
or O
retinyl B-DRUG
acetate I-DRUG
( O
3 O
X O
10 O
( O
- O
8 O
) O
- O
10 O
( O
- O
7 O
) O
M O
) O
enhance O
the O
mitogenic O
activity O
of O
EGF B-DRUG_N
. O
Dexamethasone B-DRUG
had O
a O
similar O
effect O
in O
the O
presence O
of O
insulin B-DRUG
. O
However O
, O
retinyl B-DRUG
acetate I-DRUG
stimulated O
, O
but O
did O
not O
significantly O
inhibit O
, O
proliferation O
in O
the O
presence O
of O
insulin B-DRUG
. O
These O
results O
suggest O
that O
both O
dexamethasone B-DRUG
and O
retinyl B-DRUG
acetate I-DRUG
, O
and O
possibly O
other O
glucocorticoids B-GROUP
and O
retinoids B-GROUP
, O
may O
regulate O
the O
proliferation O
of O
prostate O
epithelium O
by O
a O
dose O
- O
dependent O
modification O
of O
the O
activity O
of O
insulin B-DRUG
and O
EGF B-DRUG_N
. O

Pharmacokinetics O
of O
calcium B-GROUP
- I-GROUP
entry I-GROUP
blockers I-GROUP
. O
Effective O
use O
of O
drugs O
in O
therapy O
depends O
not O
only O
on O
clinical O
acumen O
but O
also O
on O
the O
availability O
of O
relevant O
pharmacokinetic O
and O
pharmacodynamic O
data O
. O
Such O
information O
assists O
in O
development O
of O
safe O
dosing O
regimens O
, O
prediction O
of O
abnormal O
handling O
of O
drugs O
in O
states O
of O
disease O
and O
disorder O
and O
anticipation O
of O
drug O
interactions O
. O
For O
the O
calcium B-GROUP
- I-GROUP
entry I-GROUP
blocking I-GROUP
agents I-GROUP
now O
available O
in O
the O
United O
States O
( O
verapamil B-DRUG
, O
nifedipine B-DRUG
and O
diltiazem B-DRUG
) O
, O
these O
data O
appeared O
well O
after O
clinical O
patterns O
of O
use O
evolved O
. O
Nonetheless O
, O
their O
relevance O
continues O
to O
be O
demonstrated O
by O
the O
dependence O
of O
each O
agent O
on O
intact O
liver O
blood O
flow O
and O
function O
for O
normal O
rates O
of O
elimination O
; O
by O
the O
nonlinear O
kinetic O
characteristics O
for O
verapamil B-DRUG
and O
diltiazem B-DRUG
( O
and O
probably O
for O
nifedipine B-DRUG
, O
as O
well O
) O
and O
the O
derivative O
implications O
for O
decreased O
dosing O
frequency O
requirements O
; O
and O
by O
observations O
now O
appearing O
on O
the O
relation O
between O
plasma O
drug O
levels O
and O
drug O
effects O
, O
both O
therapeutic O
and O
toxic O
. O
Such O
data O
are O
discussed O
herein O
, O
with O
emphasis O
on O
those O
aspects O
that O
impact O
on O
the O
clinical O
use O
of O
the O
calcium B-GROUP
- I-GROUP
entry I-GROUP
antagonists I-GROUP
. O

Selective O
survival O
in O
pentazocine B-DRUG
and O
tripelennamine B-DRUG
of O
Pseudomonas O
aeruginosa O
serotype O
O11 O
from O
drug O
addicts O
. O
The O
growth O
of O
Pseudomonas O
aeruginosa O
, O
particularly O
serotype O
O11 O
, O
in O
pentazocine B-DRUG
and O
tripelennamine B-DRUG
was O
evaluated O
as O
a O
possible O
explanation O
for O
the O
association O
of O
deep O
- O
seated O
infection O
with O
this O
organism O
and O
abuse O
of O
these O
drugs O
. O
The O
mean O
reduction O
of O
growth O
caused O
by O
the O
drugs O
was O
1 O
, O
000 O
- O
fold O
greater O
for O
49 O
Pseudomonas O
strains O
from O
normal O
subjects O
than O
for O
32 O
strains O
from O
drug O
addicts O
( O
4 O
. O
2 O
vs O
. O
1 O
. O
3 O
logs O
of O
reduction O
at O
2 O
hr O
, O
P O
less O
than O
. O
0005 O
) O
. O
A O
common O
phenotypic O
subset O
of O
the O
serotype O
O11 O
strains O
from O
drug O
addicts O
was O
especially O
resistant O
to O
the O
inhibitory O
effects O
. O
Twelve O
strains O
of O
Staphylococcus O
aureus O
( O
a O
frequent O
cause O
of O
infection O
in O
heroin B-DRUG_N
, O
but O
not O
in O
pentazocine B-DRUG
and O
tripelennamine B-DRUG
, O
addicts O
) O
were O
completely O
inhibited O
by O
the O
drug O
combination O
. O
Dose O
- O
response O
curves O
( O
derived O
from O
the O
results O
of O
using O
the O
tablets O
as O
well O
as O
pure O
powders O
) O
showed O
that O
tripelennamine B-DRUG
was O
responsible O
for O
the O
inhibitory O
activity O
, O
which O
was O
partially O
antagonized O
by O
pentazocine B-DRUG
. O
We O
conclude O
that O
an O
ability O
of O
some O
P O
. O
aeruginosa O
serotype O
O11 O
strains O
, O
but O
not O
S O
. O
aureus O
, O
to O
survive O
in O
pentazocine B-DRUG
and O
tripelennamine B-DRUG
may O
explain O
in O
part O
a O
shift O
from O
S O
. O
aureus O
to O
P O
. O
aeruginosa O
as O
common O
pathogens O
of O
drug O
addicts O
in O
areas O
where O
abuse O
of O
this O
combination O
of O
drugs O
has O
increased O
. O

Pharmacokinetic O
evaluation O
of O
the O
digoxin B-DRUG
- O
amiodarone B-DRUG
interaction O
. O
Amiodarone B-DRUG
is O
known O
to O
raise O
serum O
digoxin B-DRUG
levels O
. O
This O
study O
was O
designed O
to O
evaluate O
the O
pharmacokinetic O
basis O
of O
this O
interaction O
in O
10 O
normal O
subjects O
. O
The O
pharmacokinetic O
variables O
for O
digoxin B-DRUG
were O
determined O
after O
a O
1 O
. O
0 O
mg O
intravenous O
dose O
of O
digoxin B-DRUG
in O
each O
subject O
, O
before O
and O
after O
oral O
amiodarone B-DRUG
, O
400 O
mg O
daily O
for O
3 O
weeks O
. O
During O
amiodarone B-DRUG
administration O
, O
systemic O
clearance O
of O
digoxin B-DRUG
was O
reduced O
from O
234 O
+ O
/ O
- O
72 O
ml O
/ O
min O
( O
mean O
+ O
/ O
- O
standard O
deviation O
) O
to O
172 O
+ O
/ O
- O
33 O
ml O
/ O
min O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O
This O
was O
due O
to O
reductions O
in O
both O
renal O
clearance O
( O
from O
105 O
+ O
/ O
- O
39 O
to O
84 O
+ O
/ O
- O
15 O
ml O
/ O
min O
) O
( O
p O
less O
than O
0 O
. O
05 O
) O
and O
nonrenal O
clearance O
( O
from O
130 O
+ O
/ O
- O
38 O
to O
88 O
+ O
/ O
- O
20 O
ml O
/ O
min O
) O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O
Digoxin B-DRUG
half O
- O
life O
of O
elimination O
was O
prolonged O
from O
34 O
+ O
/ O
- O
13 O
to O
40 O
+ O
/ O
- O
16 O
hours O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O
Digoxin B-DRUG
volume O
of O
distribution O
was O
not O
significantly O
changed O
. O
Amiodarone B-DRUG
caused O
a O
three O
- O
to O
fivefold O
increase O
in O
serum O
reverse O
triiodothyronine O
levels O
, O
but O
changes O
in O
thyroid O
function O
were O
not O
quantitatively O
related O
to O
the O
changes O
in O
digoxin B-DRUG
pharmacokinetics O
. O
These O
alterations O
in O
digoxin B-DRUG
pharmacokinetics O
produced O
by O
amiodarone B-DRUG
explain O
the O
increase O
in O
serum O
digoxin B-DRUG
level O
that O
has O
been O
observed O
when O
this O
drug O
combination O
has O
been O
used O
clinically O
. O

Misonidazole B-DRUG_N
protects O
mouse O
tumour O
and O
normal O
tissues O
from O
the O
toxicity O
of O
oral O
CCNU B-DRUG
. O
Because O
the O
nitrosourea B-GROUP
CCNU B-DRUG
is O
given O
exclusively O
by O
the O
oral O
route O
in O
man O
, O
we O
have O
carried O
out O
studies O
in O
mice O
on O
the O
antitumour O
activity O
, O
acute O
toxicity O
and O
pharmacokinetics O
of O
oral O
CCNU B-DRUG
, O
either O
alone O
or O
in O
combination O
with O
the O
chemosensitizer O
misonidazole B-DRUG_N
. O
In O
both O
plasma O
and O
KHT O
tumour O
the O
peak O
concentration O
and O
" O
early O
" O
AUC O
for O
total O
nitrosoureas B-GROUP
were O
about O
1 O
. O
4 O
- O
1 O
. O
5 O
fold O
greater O
for O
the O
oral O
compared O
to O
the O
i O
. O
p O
. O
route O
. O
These O
differences O
were O
reflected O
in O
the O
roughly O
twofold O
greater O
antitumour O
activity O
for O
the O
oral O
route O
. O
In O
contrast O
, O
acute O
toxicity O
tests O
showed O
that O
oral O
CCNU B-DRUG
was O
1 O
. O
45 O
times O
less O
toxic O
to O
normal O
tissue O
, O
although O
the O
dose O
- O
limiting O
organ O
may O
be O
different O
for O
the O
two O
routes O
. O
Misonidazole B-DRUG_N
reduced O
the O
antitumour O
activity O
of O
oral O
CCNU B-DRUG
by O
dose O
modifying O
factors O
( O
DMF O
) O
of O
0 O
. O
58 O
- O
0 O
. O
71 O
. O
Similarly O
, O
the O
acute O
toxicity O
was O
also O
diminished O
by O
a O
DMF O
of O
0 O
. O
74 O
. O
Misonidazole B-DRUG_N
has O
a O
complex O
effect O
on O
oral O
CCNU B-DRUG
pharmacokinetics O
. O
The O
plasma O
and O
tumour O
total O
nitrosourea B-GROUP
peak O
concentrations O
were O
reduced O
by O
1 O
. O
5 O
and O
1 O
. O
7 O
fold O
respectively O
. O
Misonidazole B-DRUG_N
also O
reduced O
the O
" O
early O
" O
nitrosourea B-GROUP
AUC O
, O
with O
the O
extent O
of O
the O
reduction O
depending O
on O
the O
minimum O
effective O
concentration O
( O
MEC O
) O
chosen O
. O
For O
example O
, O
the O
plasma O
nitrosourea B-GROUP
AUC O
was O
reduced O
by O
factors O
of O
1 O
. O
05 O
and O
9 O
. O
6 O
for O
MEC O
values O
of O
1 O
and O
2 O
micrograms O
ml O
- O
1 O
respectively O
. O
We O
propose O
these O
pharmacokinetic O
changes O
to O
be O
the O
underlying O
mechanism O
for O
the O
reduction O
of O
oral O
CCNU B-DRUG
cytotoxicity O
by O
misonidazole B-DRUG_N
. O
Clinical O
trials O
of O
such O
combinations O
should O
be O
accompanied O
by O
detailed O
pharmacokinetic O
evaluation O
. O

Enhanced O
theophylline B-DRUG
clearance O
secondary O
to O
phenytoin B-DRUG
therapy O
. O
This O
report O
describes O
two O
cases O
in O
which O
theophylline B-DRUG
clearance O
accelerated O
markedly O
with O
concomitant O
phenytoin B-DRUG
administration O
. O
Maximum O
calculated O
theophylline B-DRUG
clearance O
ranged O
from O
2 O
1 O
/ O
2 O
to O
3 O
1 O
/ O
2 O
times O
baseline O
. O
Onset O
of O
the O
interaction O
began O
within O
five O
days O
of O
beginning O
concurrent O
therapy O
. O
With O
combined O
use O
, O
clinicians O
should O
be O
aware O
, O
when O
phenytoin B-DRUG
is O
added O
, O
of O
the O
potential O
for O
reexacerbation O
of O
pulmonary O
symptomatology O
due O
to O
lowered O
serum O
theophylline B-DRUG
concentrations O
. O

Stereoselective O
behavioral O
effects O
of O
N B-DRUG_N
- I-DRUG_N
allylnormetazocine I-DRUG_N
in O
pigeons O
and O
squirrel O
monkeys O
. O
The O
behavioral O
effects O
of O
the O
stereoisomers O
of O
N B-DRUG_N
- I-DRUG_N
allylnormetazocine I-DRUG_N
( O
NANM B-DRUG_N
) O
were O
compared O
with O
those O
of O
phencyclidine B-DRUG_N
( O
PCP B-DRUG_N
) O
in O
pigeons O
and O
squirrel O
monkeys O
responding O
under O
a O
multiple O
fixed O
- O
interval O
fixed O
- O
ratio O
( O
FI O
FR O
) O
schedule O
of O
food O
presentation O
. O
Intermediate O
doses O
of O
( B-DRUG_N
+ I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
or O
PCP B-DRUG_N
produced O
transient O
increases O
in O
FI O
responding O
in O
monkeys O
and O
sustained O
increases O
in O
FI O
responding O
in O
pigeons O
; O
higher O
doses O
decreased O
FI O
and O
FR O
responding O
in O
both O
species O
. O
In O
contrast O
to O
its O
enantiomer O
, O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
failed O
to O
increase O
FI O
responding O
significantly O
in O
either O
species O
; O
at O
high O
doses O
, O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
decreased O
FI O
and O
FR O
responding O
. O
In O
monkeys O
, O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
was O
about O
10 O
times O
more O
potent O
than O
( B-DRUG_N
+ I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
in O
decreasing O
responding O
, O
whereas O
in O
pigeons O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
was O
about O
equipotent O
with O
( B-DRUG_N
+ I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
. O
In O
both O
species O
, O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
, O
but O
not O
( B-DRUG_N
+ I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
, O
antagonized O
the O
rate O
- O
decreasing O
effects O
of O
morphine B-DRUG
on O
FI O
and O
FR O
responding O
. O
In O
monkeys O
, O
the O
effects O
of O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
, O
but O
not O
( B-DRUG_N
+ I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
or O
PCP B-DRUG_N
, O
were O
antagonized O
by O
naloxone B-DRUG
; O
the O
doses O
of O
naloxone B-DRUG
required O
to O
antagonize O
the O
effects O
of O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
were O
more O
than O
100 O
times O
higher O
than O
those O
required O
to O
antagonize O
the O
effects O
of O
morphine B-DRUG
. O
In O
pigeons O
, O
naloxone B-DRUG
did O
not O
systematically O
alter O
the O
effects O
of O
( B-DRUG_N
- I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
, O
( B-DRUG_N
+ I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
or O
PCP B-DRUG_N
. O
Haloperidol B-DRUG
reduced O
or O
eliminated O
the O
increases O
in O
FI O
responding O
produced O
by O
intermediate O
doses O
of O
either O
( B-DRUG_N
+ I-DRUG_N
) I-DRUG_N
- I-DRUG_N
NANM I-DRUG_N
or O
PCP B-DRUG_N
in O
pigeons O
, O
but O
did O
not O
antagonize O
the O
decreases O
in O
FI O
or O
FR O
responding O
produced O
by O
high O
doses O
of O
PCP O
or O
either O
stereoisomer O
of O
NANM B-DRUG_N
. O
The O
results O
demonstrate O
a O
high O
degree O
of O
stereoselectivity O
in O
the O
behavioral O
effects O
of O
NANM B-DRUG_N
. O
The O
levorotatory O
isomer O
had O
opioid O
- O
antagonist O
and O
non O
- O
opioid O
agonist O
effects O
in O
pigeons O
and O
mixed O
opioid O
agonist O
- O
antagonist O
effects O

in O
monkeys O
. O
The O
dextrorotatory O
isomer O
, O
on O
the O
other O
hand O
, O
had O
effects O
similar O
to O
those O
of O
PCP B-DRUG_N
in O
both O
species O
. O

Increased O
hepatotoxicity O
of O
acetaminophen B-DRUG
by O
concomitant O
administration O
of O
caffeine B-DRUG
in O
the O
rat O
. O
Since O
caffeine B-DRUG
is O
frequently O
co O
- O
administered O
with O
acetaminophen B-DRUG
, O
it O
is O
of O
clinical O
interest O
to O
study O
the O
effect O
of O
caffeine B-DRUG
on O
the O
hepatotoxicity O
of O
acetaminophen B-DRUG
. O
In O
male O
Sprague O
- O
Dawley O
rats O
fasted O
for O
18 O
h O
, O
concomitant O
administration O
of O
caffeine B-DRUG
( O
0 O
. O
1 O
g O
/ O
kg O
, O
i O
. O
p O
. O
) O
as O
judged O
by O
increased O
serum O
enzyme O
activities O
and O
increased O
incidence O
of O
hepatic O
necrosis O
. O
Careful O
observations O
on O
hepatotoxicity O
are O
suggested O
when O
acetaminophen B-DRUG
is O
prescribed O
with O
caffeine B-DRUG
. O

High O
- O
dose O
cisplatin B-DRUG
with O
sodium B-DRUG
thiosulfate I-DRUG
protection O
. O
Nephrotoxicity O
frequently O
limits O
the O
dose O
of O
cisplatin B-DRUG
to O
less O
than O
120 O
mg O
/ O
m2 O
per O
injection O
. O
Sodium B-DRUG
thiosulfate I-DRUG
is O
a O
neutralizing O
agent O
for O
cisplatin B-DRUG
that O
protects O
against O
renal O
damage O
. O
To O
determine O
whether O
injection O
of O
thiosulfate B-DRUG
would O
permit O
larger O
doses O
of O
cisplatin B-DRUG
to O
be O
administered O
, O
a O
fixed O
9 O
. O
9 O
- O
g O
/ O
m2 O
dose O
of O
thiosulfate B-DRUG
was O
given O
intravenously O
over O
three O
hours O
concurrently O
with O
escalating O
doses O
of O
cisplatin B-DRUG
. O
Cisplatin B-DRUG
was O
administered O
over O
the O
last O
two O
hours O
of O
the O
thiosulfate B-DRUG
infusion O
. O
Using O
this O
technique O
, O
it O
was O
possible O
to O
escalate O
the O
cisplatin B-DRUG
dose O
to O
225 O
mg O
/ O
m2 O
before O
dose O
- O
limiting O
toxicities O
were O
encountered O
. O
Comparison O
of O
cisplatin B-DRUG
pharmacokinetics O
in O
patients O
treated O
with O
202 O
. O
5 O
mg O
/ O
m2 O
plus O
thiosulfate B-DRUG
to O
those O
in O
patients O
treated O
with O
100 O
mg O
/ O
m2 O
without O
thiosulfate B-DRUG
indicated O
that O
there O
were O
no O
changes O
in O
the O
elimination O
rate O
constant O
, O
volume O
of O
distribution O
, O
or O
total O
body O
clearance O
of O
cisplatin B-DRUG
. O
The O
total O
drug O
exposure O
for O
the O
plasma O
was O
approximately O
twofold O
at O
the O
higher O
cisplatin B-DRUG
dose O
. O
This O
study O
demonstrates O
that O
concurrent O
administration O
of O
thiosulfate B-DRUG
permits O
at O
least O
a O
twofold O
increase O
in O
dose O
and O
total O
exposure O
to O
cisplatin B-DRUG
. O

Interferon O
induction O
: O
tool O
for O
establishing O
interactions O
among O
homopolyribonucleotides O
. O
Hitherto O
unrecognized O
interactions O
between O
homopolyribonucleotides O
and O
complexes O
thereof O
are O
suggested O
by O
interferon O
induction O
data O
obtained O
in O
a O
highly O
sensitive O
assay O
system O
of O
primary O
rabbit O
kidney O
cell O
cultures O
superinduced O
by O
metabolic O
inhibitors O
. O

Repeated O
oral O
administration O
of O
coumaphos B-DRUG_N
in O
sheep O
: O
interactions O
of O
coumaphos B-DRUG_N
with O
bishydroxycoumarin B-DRUG
, O
trichlorfon B-DRUG_N
, O
and O
phenobarbital B-DRUG
sodium I-DRUG
. O
Interactions O
between O
treatments O
with O
coumaphos B-DRUG_N
, O
bishydroxycoumarin B-DRUG
( O
an O
anticoagulant B-GROUP
) O
, O
trichlorfon B-DRUG_N
( O
an O
organophosphorous B-GROUP
compound I-GROUP
) O
, O
and O
phenobarbital B-DRUG
sodium I-DRUG
( O
an O
inducer O
of O
microsomal O
enzymes O
) O
were O
investigated O
in O
sheep O
. O
A O
daily O
dose O
of O
2 O
mg O
of O
coumaphos B-DRUG_N
/ O
kg O
of O
body O
weight O
for O
6 O
days O
did O
not O
affect O
the O
plasma O
enzymes O
or O
the O
antiprothrombinemic O
effect O
of O
bishydroxy B-DRUG
- I-DRUG
coumarin I-DRUG
in O
wethers O
. O
The O
treatment O
of O
ewes O
with O
an O
intravenous O
( O
IV O
) O
injection O
of O
trichlorfon B-DRUG_N
, O
insufficient O
to O
produce O
significant O
inhibition O
of O
erythrocyte O
acetylcholinesterase O
( O
AChE O
) O
activity O
, O
appeared O
to O
produce O
additive O
effects O
with O
those O
produced O
by O
subsequent O
treatment O
with O
4 O
mg O
of O
coumaphos B-DRUG_N
/ O
kg O
/ O
day O
. O
In O
ewes O
given O
40 O
mg O
of O
phenobarbital B-DRUG
sodium I-DRUG
/ O
kg O
for O
5 O
days O
intraperitoneally O
( O
IP O
) O
, O
the O
anticholinesterase O
effect O
of O
4 O
mg O
of O
coumaphos B-DRUG_N
/ O
kg O
was O
significantly O
reduced O
and O
signs O
of O
toxicity O
were O
not O
present O
. O
Treatment O
with O
daily O
doses O
of O
2 O
mg O
of O
coumaphos B-DRUG_N
/ O
kg O
for O
6 O
days O
did O
not O
modify O
the O
anticholinesterase O
effect O
of O
a O
2nd O
series O
of O
treatments O
given O
6 O
weeks O
later O
. O

Diagnostic O
, O
treatment O
and O
aftercare O
approaches O
to O
cocaine B-DRUG
abuse O
. O
The O
general O
public O
feels O
that O
cocaine B-DRUG
is O
not O
particularly O
dangerous O
because O
it O
does O
not O
produce O
a O
well O
defined O
physical O
dependency O
and O
abstinence O
syndrome O
. O
However O
, O
when O
addiction O
is O
defined O
as O
compulsion O
, O
loss O
of O
control O
and O
continued O
use O
in O
spite O
of O
adverse O
consequences O
, O
cocaine B-DRUG
drug O
hunger O
can O
be O
seen O
as O
an O
agent O
of O
addictive O
disease O
. O
Withdrawal O
from O
cocaine B-DRUG
dependence O
usually O
involves O
depression O
, O
anxiety O
and O
lethargy O
. O
These O
usually O
clear O
within O
a O
week O
, O
leaving O
only O
the O
" O
drug O
hunger O
" O
to O
contend O
with O
. O
Medication O
is O
rarely O
needed O
. O
When O
cocaine B-DRUG
is O
the O
primary O
addiction O
, O
after O
withdrawal O
the O
most O
effective O
treatment O
is O
group O
therapy O
with O
other O
recovering O
cocaine O
abusers O
. O
We O
incorporate O
the O
principles O
of O
recovery O
and O
define O
positive O
and O
constructive O
alternatives O
in O
dealing O
with O
cocaine O
hunger O
. O
Recovery O
programs O
should O
be O
flexible O
and O
involve O
individual O
and O
family O
education O
on O
recovery O
and O
the O
nature O
of O
addictive O
disease O
. O
Exercise O
that O
produces O
cardiopulmonary O
stimulation O
is O
a O
helpful O
means O
of O
reducing O
drug O
hunger O
and O
anxiety O
during O
recovery O
therapy O
. O

Failure O
of O
neomycin B-DRUG
to O
modify O
ACTH B-GROUP
induced O
hypertension O
in O
sheep O
. O
Studies O
in O
rats O
have O
shown O
that O
neomycin B-DRUG
administration O
attenuates O
certain O
types O
of O
adrenocortical B-GROUP
steroid I-GROUP
dependent O
hypertension O
, O
including O
ACTH B-DRUG
hypertension O
. O
The O
effects O
of O
oral O
neomycin B-DRUG
on O
ACTH B-GROUP
induced O
hypertension O
were O
examined O
in O
conscious O
sheep O
. O
Neomycin B-DRUG
has O
no O
effect O
on O
the O
blood O
pressure O
or O
metabolic O
responses O
to O
ACTH B-GROUP
in O
sheep O
. O

Changes O
in O
urinary O
homocysteine O
following O
synthetic B-GROUP
steroidal I-GROUP
estrogen I-GROUP
and I-GROUP
progestogen I-GROUP
administration O
to O
rats O
. O
The O
present O
work O
involved O
the O
administration O
of O
both O
ethynyl B-DRUG
estradiol I-DRUG
and O
levonorgestrel B-DRUG
to O
groups O
of O
rats O
, O
followed O
by O
determination O
of O
the O
homocysteine O
excretion O
rate O
in O
urine O
. O
The O
results O
indicate O
that O
a O
statistically O
significant O
difference O
exists O
between O
the O
excreted O
levels O
of O
homocysteine O
in O
the O
urine O
of O
both O
control O
and O
levonorgestrel B-DRUG
- O
treated O
rats O
and O
the O
levels O
shown O
by O
rats O
treated O
with O
ethynyl B-DRUG
estradiol I-DRUG
. O
The O
implications O
of O
these O
results O
are O
discussed O
, O
especially O
with O
respect O
to O
observations O
which O
indicate O
that O
homocysteine O
may O
be O
a O
precipitating O
factor O
in O
the O
development O
of O
thrombosis O
. O
Also O
included O
in O
this O
paper O
is O
a O
study O
which O
confirms O
the O
identity O
of O
the O
HPLC O
peak O
as O
being O
homocysteine O
by O
forming O
a O
radioactive O
derivative O
of O
this O
particular O
sulphydryl O
- O
containing O
amino O
acid O
, O
and O
then O
analysing O
the O
resulting O
mixture O
by O
TLC O
. O

Altered O
responsiveness O
to O
alcohol B-DRUG
after O
exposure O
to O
organic O
lead O
. O
Ethyl B-DRUG
alcohol I-DRUG
is O
known O
to O
effect O
the O
functional O
integrity O
of O
the O
limbic O
system O
, O
particularly O
the O
hippocampus O
, O
and O
to O
alter O
behaviors O
which O
are O
thought O
to O
be O
mediated O
through O
limbic O
function O
. O
Organometals O
also O
compromise O
the O
limbic O
system O
and O
result O
in O
deficits O
in O
learning O
and O
memory O
. O
Since O
both O
alcohol B-DRUG
and O
organoleads O
are O
present O
in O
the O
environment O
and O
seem O
to O
influence O
limbic O
integration O
, O
the O
interaction O
of O
these O
two O
compounds O
was O
assessed O
in O
the O
present O
experiment O
. O
Thirty O
male O
rats O
of O
the O
Fischer O
- O
344 O
strain O
were O
divided O
into O
three O
equal O
groups O
and O
were O
given O
injections O
of O
trimethyl B-DRUG_N
lead I-DRUG_N
( O
TML B-DRUG_N
) O
( O
8 O
. O
0 O
or O
17 O
. O
0 O
mg O
/ O
kg O
/ O
ml O
SC O
) O
or O
the O
saline O
vehicle O
. O
Fourteen O
days O
later O
, O
all O
animals O
were O
challenged O
with O
a O
single O
hypnotic O
dose O
of O
ethanol B-DRUG
( O
3 O
. O
5 O
g O
/ O
kg O
IP O
) O
. O
The O
20 O
% O
v O
/ O
v O
solution O
of O
alcohol B-DRUG
was O
prepared O
in O
water O
from O
a O
stock O
solution O
of O
95 O
% O
ethanol B-DRUG
. O
The O
latency O
to O
loss O
of O
the O
righting O
reflex O
and O
duration O
of O
sleep O
time O
were O
recorded O
while O
the O
rats O
were O
kept O
in O
sound O
- O
attenuating O
chambers O
. O
The O
rats O
treated O
with O
the O
highest O
dose O
of O
TML B-DRUG_N
manifested O
significantly O
longer O
latencies O
to O
lose O
the O
righting O
reflex O
and O
shorter O
durations O
of O
sleep O
than O
did O
controls O
. O
These O
results O
suggest O
that O
exposure O
to O
environmental O
lead B-DRUG_N
may O
alter O
the O
biological O
and O
behavioral O
responsiveness O
of O
an O
animal O
to O
alcohol B-DRUG
. O

Cholinergic O
role O
in O
alcohol B-DRUG
' O
s O
effects O
on O
evoked O
potentials O
in O
visual O
cortex O
of O
the O
albino O
rat O
. O
Photic O
evoked O
potentials O
were O
recorded O
from O
the O
visual O
cortex O
of O
chronically O
implanted O
albino O
rats O
. O
Since O
photic O
evoked O
potential O
components O
are O
representations O
of O
neural O
pathways O
which O
are O
activated O
during O
photic O
stimulation O
, O
study O
of O
the O
effects O
of O
alcohol B-DRUG
on O
these O
components O
may O
help O
to O
trace O
pathways O
which O
are O
affected O
by O
alcohol B-DRUG
. O
In O
the O
present O
study O
, O
evoked O
potentials O
were O
recorded O
at O
5 O
, O
20 O
, O
and O
40 O
min O
following O
IP O
injections O
of O
saline O
, O
ethanol B-DRUG
( O
2 O
. O
0 O
g O
/ O
kg O
) O
, O
physostigmine B-DRUG
( O
0 O
. O
6 O
mg O
/ O
kg O
) O
or O
atropine B-DRUG
( O
15 O
. O
0 O
mg O
/ O
kg O
) O
on O
separate O
days O
. O
Ethanol B-DRUG
depressed O
the O
amplitudes O
of O
most O
evoked O
potential O
components O
in O
comparison O
to O
saline O
administration O
. O
Component O
P2 O
, O
however O
, O
was O
increased O
in O
amplitude O
. O
Physostigmine B-DRUG
briefly O
reduced O
the O
amplitude O
of O
most O
components O
, O
including O
P2 O
. O
In O
contrast O
, O
atropine B-DRUG
increased O
the O
amplitudes O
of O
components O
P1 O
and O
P2 O
, O
while O
decreasing O
components O
N1 O
, O
N2 O
and O
N3 O
for O
varying O
durations O
of O
time O
. O
Physostigmine B-DRUG
pretreatment O
augmented O
the O
depressant O
effect O
of O
alcohol B-DRUG
on O
the O
early O
components O
P1 O
and O
N1 O
, O
while O
attenuating O
alcohol B-DRUG
' O
s O
influence O
on O
components O
P2 O
and O
P3 O
. O
Pretreatment O
with O
atropine B-DRUG
likewise O
further O
reduced O
the O
amplitudes O
of O
components O
P1 O
and O
N1 O
, O
and O
produced O
a O
similar O
effect O
on O
component O
N3 O
. O
Atropine B-DRUG
, O
either O
alone O
or O
in O
combination O
with O
alcohol B-DRUG
, O
produced O
approximately O
the O
same O
degree O
of O
enhancement O
of O
component O
P2 O
. O
In O
comparison O
to O
saline O
values O
, O
all O
three O
agents O
produced O
reliable O
increases O
in O
peak O
latency O
for O
most O
of O
the O
components O
, O
with O
only O
N3 O
showing O
no O
effects O
. O
The O
amplitude O
data O
from O
this O
study O
suggest O
that O
ethanol B-DRUG
' O
s O
augmentation O
of O
component O
P2 O
may O
result O
, O
at O
least O
in O
part O
, O
from O
alterations O
in O
cholinergic O
functions O
. O

Hypothermia O
as O
an O
index O
of O
the O
disulfiram B-DRUG
- O
ethanol B-DRUG
reaction O
in O
the O
rat O
. O
Decreased O
core O
temperature O
in O
female O
rats O
was O
investigated O
as O
one O
possible O
index O
of O
the O
disulfiram B-DRUG
- O
ethanol B-DRUG
reaction O
( O
DER O
) O
. O
Core O
temperature O
was O
decreased O
in O
rats O
in O
a O
dose O
- O
dependent O
manner O
when O
ethanol B-DRUG
was O
administered O
to O
rats O
treated O
with O
disulfiram B-DRUG
8 O
hours O
before O
the O
ethanol B-DRUG
challenge O
. O
The O
decrease O
in O
temperature O
began O
within O
20 O
minutes O
after O
ethanol B-DRUG
administration O
, O
reaching O
a O
maximal O
decrease O
between O
60 O
and O
120 O
minutes O
post O
ethanol B-DRUG
. O
The O
core O
temperature O
returned O
to O
normal O
300 O
minutes O
after O
ethanol B-DRUG
. O
The O
blood O
pressure O
( O
carotid O
cannulation O
) O
decreased O
along O
with O
the O
core O
temperature O
. O
Maximal O
hypotension O
was O
found O
120 O
minutes O
post O
ethanol B-DRUG
, O
and O
returned O
to O
normal O
300 O
minutes O
after O
ethanol B-DRUG
. O
Heart O
rate O
increased O
initially O
and O
returned O
to O
normal O
40 O
minutes O
after O
ethanol B-DRUG
challenge O
. O

Excretion O
of O
thioethers O
in O
urine O
after O
exposure O
to O
electrophilic O
chemicals O
. O
Electrophilic O
agents O
- O
- O
a O
class O
of O
chemicals O
that O
includes O
most O
genotoxic O
compounds O
- O
- O
can O
be O
inactivated O
by O
reaction O
with O
glutathione O
or O
other O
SH O
- O
bearing O
molecules O
. O
The O
conjugates O
so O
formed O
often O
appear O
in O
the O
urine O
as O
mercapturic O
acids O
or O
other O
thioether O
products O
. O
This O
paper O
critically O
reviews O
the O
suitability O
of O
the O
urinary O
thioether O
assay O
as O
a O
method O
for O
the O
detection O
of O
exposure O
to O
electrophilic O
agents O
or O
their O
precursors O
. O
In O
practice O
, O
the O
greatest O
value O
of O
the O
thioether O
assay O
appears O
to O
lie O
in O
its O
signal O
function O
. O
This O
is O
demonstrated O
for O
cigarette O
smokers O
and O
industrial O
workers O
involved O
in O
chemical O
waste O
incineration O
. O
Whenever O
increased O
thioether O
excretion O
is O
observed O
, O
it O
is O
likely O
to O
be O
due O
to O
exposure O
to O
one O
or O
more O
suspect O
compounds O
. O
However O
, O
when O
the O
thioether O
concentration O
ranges O
within O
the O
limits O
of O
the O
normal O
value O
, O
one O
must O
not O
conclude O
that O
there O
is O
no O
, O
or O
negligible O
, O
exposure O
. O
More O
specific O
applications O
of O
the O
assay O
of O
thio O
compounds O
in O
urine O
allow O
development O
of O
selective O
methods O
that O
may O
be O
useful O
for O
biological O
monitoring O
. O

Interaction O
on O
the O
antinociceptive O
effect O
between O
neurotensin B-DRUG_N
and O
enkephalins B-DRUG_N
or O
tuftsin B-DRUG_N
. O
The O
aim O
of O
this O
paper O
was O
to O
study O
the O
interaction O
between O
neurotensin B-DRUG_N
and O
both O
enkephalins B-DRUG_N
or O
its O
synthetic O
analogue O
D B-DRUG_N
- I-DRUG_N
Ala2 I-DRUG_N
- I-DRUG_N
metenkephalinamide I-DRUG_N
, O
or O
tuftsin B-DRUG_N
, O
on O
the O
antinonciceptive O
effect O
of O
these O
peptides O
in O
mice O
after O
intracisternal O
injection O
. O
Antinociception O
was O
measured O
by O
the O
hot O
- O
plate O
method O
. O
It O
was O
shown O
that O
neurotensin B-DRUG_N
antagonized O
evidently O
the O
antinociceptive O
effect O
of O
enkephalins B-DRUG_N
and O
their O
analogue O
. O
On O
the O
contrary O
, O
neurotensin B-DRUG_N
and O
tuftsin B-DRUG_N
were O
agonists O
in O
induction O
of O
analgesia O
. O
It O
is O
concluded O
that O
neurotensin B-DRUG_N
modulates O
in O
an O
opposite O
way O
the O
function O
of O
the O
enkephalinergic O
neurons O
and O
the O
central O
action O
of O
tuftsin B-DRUG_N
. O

Drug O
- O
lab O
interactions O
: O
implications O
for O
nutrition O
support O
. O
Acetylcysteine B-DRUG
interference O
with O
urine O
ketone O
test O
. O
It O
is O
important O
that O
health O
care O
professionals O
be O
aware O
of O
the O
potential O
for O
medications O
to O
interfere O
with O
clinical O
laboratory O
tests O
. O
Medications O
can O
cause O
in O
vivo O
effects O
when O
the O
concentration O
or O
activity O
of O
the O
analyte O
is O
altered O
before O
the O
analysis O
and O
therefore O
the O
assay O
result O
is O
true O
and O
accurate O
. O
An O
in O
vitro O
effect O
occurs O
when O
the O
medication O
interferes O
with O
the O
assay O
, O
and O
the O
result O
is O
erroneous O
and O
cannot O
be O
interpreted O
. O
This O
report O
describes O
a O
recently O
identified O
case O
of O
interference O
of O
acetylcysteine B-DRUG
with O
the O
urine O
test O
for O
ketones O
and O
demonstrates O
the O
importance O
of O
a O
thorough O
medication O
review O
in O
evaluating O
abnormal O
laboratory O
tests O
. O

[ O
2 O
epidemics O
of O
arsenical O
encephalopathy O
in O
the O
treatment O
of O
trypanosomiasis O
, O
Uganda O
, O
1992 O
- O
1993 O
] O
Since O
1988 O
, O
the O
french O
non O
- O
governmental O
organisation O
M O
decins O
Sans O
Fronti O
res O
is O
running O
a O
control O
program O
of O
human O
african O
trypanosomiasis O
in O
the O
district O
of O
Moyo O
, O
North O
- O
Uganda O
. O
Between O
1988 O
and O
1993 O
, O
more O
than O
7 O
, O
000 O
patients O
were O
diagnosed O
and O
treated O
. O
Since O
1988 O
, O
it O
has O
been O
noted O
that O
incidence O
of O
melarsoprol B-DRUG
reaction O
had O
increased O
systematically O
between O
June O
and O
October O
of O
each O
year O
, O
indicating O
strong O
seasonal O
variation O
. O
In O
1992 O
and O
1993 O
, O
two O
outbreaks O
of O
arsenical O
reactive O
encephalopathy O
( O
ARE O
) O
occurred O
in O
the O
sleeping O
sickness O
center O
of O
Adjumani O
. O
The O
incidence O
of O
ARE O
suddenly O
exceeded O
10 O
% O
of O
the O
patients O
treated O
by O
melarsoprol B-DRUG
during O
August O
1992 O
and O
September O
1993 O
. O
The O
onset O
of O
80 O
% O
of O
those O
" O
epidemic O
" O
cases O
, O
occurred O
between O
the O
5th O
and O
the O
11th O
day O
of O
treatment O
. O
Two O
retrospective O
studies O
were O
conducted O
in O
1992 O
( O
75 O
cases O
) O
and O
in O
1993 O
( O
51 O
cases O
) O
. O
Among O
the O
risk O
factors O
studied O
, O
two O
appear O
to O
increase O
the O
risk O
of O
ARE O
: O
the O
prescription O
of O
thiabendazole B-DRUG
to O
treat O
strongyloidiasis O
during O
the O
melarsoprol B-DRUG
cure O
and O
the O
bad O
general O
clinical O
conditions O
of O
patients O
. O
These O
observations O
suggest O
that O
exogenous O
co O
- O
factors O
could O
be O
involved O
in O
the O
occurrence O
of O
ARE O
. O
Recommendations O
were O
to O
avoid O
administration O
of O
diffusible O
anti B-GROUP
- I-GROUP
helminthic I-GROUP
treatment O
during O
the O
cure O
, O
and O
to O
improve O
the O
general O
conditions O
of O
patients O
before O
the O
cure O
of O
melarsoprol B-DRUG
. O

Interactions O
of O
cobalt B-DRUG
and O
iron B-DRUG
in O
absorption O
and O
retention O
. O
The O
effects O
of O
supplementary O
oral O
cobalt B-DRUG
and O
iron B-DRUG
, O
as O
well O
as O
the O
interaction O
between O
both O
at O
the O
absorption O
site O
, O
fecal O
and O
urinary O
excretion O
as O
well O
as O
the O
retention O
of O
these O
trace O
elements O
were O
determined O
by O
using O
four O
diets O
containing O
either O
9 O
or O
63 O
micrograms O
/ O
kg O
of O
Co B-DRUG
and O
48 O
or O
446 O
mg O
/ O
kg O
of O
Fe B-DRUG
over O
a O
period O
of O
19 O
days O
in O
a O
total O
of O
24 O
rats O
. O
Retention O
was O
calculated O
by O
the O
balance O
technique O
and O
by O
the O
comparative O
slaughter O
technique O
. O
After O
one O
day O
, O
fecal O
as O
well O
as O
urinary O
excretion O
of O
both O
elements O
had O
already O
responded O
to O
the O
dietary O
treatments O
, O
with O
constant O
values O
being O
reached O
after O
approximately O
three O
days O
. O
Cobalt B-DRUG
excretion O
was O
enhanced O
by O
supplementary O
cobalt B-DRUG
; O
fecal O
excretion O
, O
too O
, O
was O
increased O
by O
supplementary O
iron B-DRUG
; O
whereas O
urinary O
excretion O
was O
decreased O
in O
both O
cases O
. O
Additional O
iron B-DRUG
significantly O
inhibited O
the O
absorption O
of O
cobalt B-DRUG
in O
both O
dietary O
cobalt B-DRUG
treatments O
. O
The O
lower O
rate O
of O
absorption O
in O
the O
groups O
receiving O
446 O
mg O
Fe B-DRUG
instead O
of O
48 O
mg O
of O
Fe B-DRUG
per O
kg O
diet O
resulted O
in O
a O
decreased O
renal O
excretion O
of O
cobalt B-DRUG
. O
Consequently O
, O
the O
effect O
of O
iron B-DRUG
on O
the O
retention O
of O
cobalt B-DRUG
was O
lower O
than O
on O
absorption O
. O
This O
suggests O
that O
interactions O
between O
the O
two O
elements O
only O
take O
place O
at O
the O
site O
of O
absorption O
. O
Because O
of O
the O
low O
dietary O
cobalt B-DRUG
concentration O
as O
compared O
to O
the O
iron B-DRUG
contents O
of O
the O
diets O
, O
no O
effect O
of O
cobalt B-DRUG
on O
iron B-DRUG
absorption O
and O
excretion O
occurred O
. O
Differences O
in O
iron B-DRUG
balance O
were O
only O
observed O
between O
both O
dietary O
concentrations O
, O
showing O
a O
higher O
absolute O
but O
a O
lower O
relative O
absorption O
as O
well O
as O
retention O
in O
the O
groups O
fed O
further O
Fe B-DRUG
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Effect O
of O
estradiol B-DRUG
on O
endotoxin B-DRUG_N
- O
induced O
changes O
in O
steroid O
hormone O
levels O
and O
lethality O
in O
male O
rats O
. O
We O
examined O
the O
effect O
of O
exogenous O
estradiol B-DRUG
on O
the O
changes O
in O
serum O
steroid O
hormone O
levels O
induced O
by O
a O
nonlethal O
dose O
of O
Escherichia O
coli O
endotoxin B-DRUG_N
in O
male O
rats O
and O
the O
deaths O
due O
to O
nonlethal O
and O
lethal O
doses O
of O
endotoxin B-DRUG_N
. O
Injection O
of O
estradiol B-DRUG
5 O
min O
before O
a O
nonlethal O
dose O
of O
endotoxin B-DRUG_N
changed O
the O
serum O
sex O
steroid O
hormone O
response O
of O
male O
rats O
to O
endotoxin B-DRUG_N
. O
The O
serum O
estrogen O
concentrations O
of O
estradiol B-DRUG
+ O
endotoxin B-DRUG_N
- O
treated O
rats O
decreased O
by O
50 O
% O
, O
while O
those O
of O
the O
endotoxin B-DRUG_N
- O
treated O
rats O
increased O
( O
2 O
- O
to O
5 O
- O
fold O
) O
. O
The O
serum O
androgen O
concentrations O
of O
estradiol B-DRUG
+ O
endotoxin B-DRUG_N
- O
treated O
rats O
did O
not O
change O
significantly O
, O
while O
those O
of O
endotoxin B-DRUG_N
- O
treated O
rats O
dropped O
to O
30 O
- O
40 O
% O
0 O
. O
001 O
. O
Exogenous O
estradiol B-DRUG
also O
appeared O
to O
influence O
the O
percentage O
of O
endotoxin B-DRUG_N
- O
induced O
deaths O
in O
a O
dose O
- O
dependent O
manner O
. O
It O
reduced O
the O
number O
of O
deaths O
induced O
by O
nonlethal O
( O
2 O
mg O
/ O
kg O
) O
dose O
of O
endotoxin B-DRUG_N
but O
increased O
the O
number O
of O
deaths O
induced O
by O
a O
highly O
lethal O
dose O
( O
8 O
mg O
/ O
kg O
) O
. O
These O
results O
, O
together O
with O
the O
known O
relationships O
between O
estrogen B-GROUP
and O
the O
immune O
response O
, O
suggest O
that O
estrogens B-GROUP
affect O
the O
course O
of O
septic O
shock O
in O
a O
complex O
fashion O
and O
may O
have O
either O
protective O
or O
deleterious O
effect O
. O

Analysis O
of O
16 B-DRUG_N
, I-DRUG_N
16 I-DRUG_N
- I-DRUG_N
dimethylprostaglandin I-DRUG_N
E2 I-DRUG_N
- O
induced O
diarrhea O
in O
cecectomized O
rats O
. O
The O
16 B-DRUG_N
, I-DRUG_N
16 I-DRUG_N
- I-DRUG_N
dimethylprostaglandin I-DRUG_N
E2 I-DRUG_N
( O
dmPGE2 B-DRUG_N
) O
- O
induced O
diarrhea O
was O
analyzed O
in O
cecectomized O
rats O
prepared O
by O
resecting O
the O
cecum O
and O
its O
vasculature O
without O
disturbing O
the O
ileocecal O
junction O
. O
dmPGE2 B-DRUG_N
( O
0 O
. O
1 O
- O
1 O
. O
0 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
dose O
- O
dependently O
increased O
the O
number O
of O
defecation O
episodes O
and O
induced O
a O
soft O
and O
watery O
stool O
in O
cecectomized O
rats O
. O
At O
0 O
. O
3 O
mg O
/ O
kg O
, O
the O
diarrhea O
- O
inducing O
effects O
of O
dmPGE2 B-DRUG_N
were O
more O
pronounced O
in O
cecectomized O
than O
in O
control O
rats O
. O
When O
given O
i O
. O
p O
. O
, O
dmPGE2 B-DRUG_N
( O
0 O
. O
3 O
mg O
/ O
kg O
) O
induced O
a O
watery O
stool O
in O
cecectomized O
and O
control O
rats O
with O
the O
same O
efficacy O
, O
although O
these O
effects O
were O
short O
- O
lasting O
as O
compared O
to O
oral O
administration O
. O
Castor B-DRUG
oil I-DRUG
( O
4 O
ml O
/ O
kg O
, O
p O
. O
o O
. O
) O
also O
induced O
diarrhea O
, O
but O
did O
not O
produce O
a O
watery O
stool O
in O
cecectomized O
rats O
. O
There O
were O
no O
differences O
between O
cecectomized O
and O
control O
rats O
in O
basal O
small O
intestinal O
transits O
or O
in O
dmPGE2 B-DRUG_N
( O
0 O
. O
3 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
- O
induced O
enhancements O
. O
Moreover O
, O
the O
basal O
and O
dmPGE2 B-DRUG_N
- O
induced O
jejunal O
net O
fluid O
transfers O
were O
the O
same O
in O
cecectomized O
and O
in O
control O
rats O
. O
On O
the O
other O
hand O
, O
the O
enhanced O
secretion O
of O
colonic O
fluid O
by O
dmPGE2 B-DRUG_N
, O
given O
intraluminally O
, O
was O
only O
half O
of O
that O
in O
control O
rats O
, O
whereas O
the O
colonic O
transit O
- O
enhancing O
effect O
of O
dmPGE2 B-DRUG_N
in O
cecectomized O
rats O
was O
more O
pronounced O
than O
in O
control O
rats O
at O
15 O
but O
not O
at O
30 O
min O
after O
its O
administration O
. O
The O
basal O
colonic O
fluid O
contents O
and O
transits O
were O
the O
same O
in O
cecectomized O
and O
in O
control O
rats O
. O
Loperamide B-DRUG
and O
morphine B-DRUG
( O
0 O
. O
1 O
and O
1 O
. O
0 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
Loperamide B-DRUG
and O
morphine B-DRUG
( O
0 O
. O
1 O
and O
1 O
. O
0 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
inhibited O
the O
dmPGE2 B-DRUG_N
( O
0 O
. O

3 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
- O
induced O
diarrhea O
in O
cecectomized O
rats O
. O
N B-DRUG_N
- I-DRUG_N
methyllevallorphan I-DRUG_N
( O
5 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
N B-DRUG_N
- I-DRUG_N
methyllevallorphan I-DRUG_N
( O
5 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
completely O
antagonized O
the O
inhibitory O
effect O
of O
loperamide B-DRUG
and O
partly O
antagonized O
the O
effect O
of O
morphine B-DRUG
. O
These O
results O
suggest O
that O
oral O
administration O
of O
dmPGE2 B-DRUG_N
induces O
a O
more O
pronounced O
secretory O
diarrhea O
in O
cecectomized O
than O
in O
control O
rats O
, O
probably O
due O
to O
the O
lack O
of O
the O
reservoir O
function O
of O
the O
cecum O
in O
the O
operated O
animals O
. O
This O
secretory O
diarrhea O
model O
is O
suitable O
for O
evaluating O
the O
antidiarrheal O
activity O
of O
drugs O
. O

Therapeutic O
drug O
monitoring O
can O
avoid O
iatrogenic O
alterations O
caused O
by O
99mTc B-DRUG
- I-DRUG
methylene I-DRUG
diphosphonate I-DRUG
( O
MDP O
) O
- O
gentamicin B-DRUG
interaction O
. O
Gentamicin B-DRUG
is O
an O
aminoglycoside B-GROUP
antibiotic I-GROUP
used O
to O
treat O
a O
wide O
variety O
of O
infections O
caused O
by O
gram O
- O
negative O
organisms O
, O
but O
it O
is O
potentially O
toxic O
to O
the O
kidneys O
. O
Due O
to O
its O
nephrotoxicity O
, O
gentamicin B-DRUG
may O
cause O
abnormal O
renal O
uptake O
to O
be O
seen O
on O
99mTc B-DRUG
- I-DRUG
MDP I-DRUG
bone O
scintigraphy O
. O
The O
presence O
of O
the O
radiopharmaceutical B-GROUP
in O
the O
kidneys O
, O
along O
with O
an O
increase O
in O
renal O
retention O
, O
tend O
to O
produce O
scintigraphic O
results O
that O
falsely O
identify O
characteristics O
related O
to O
diseases O
such O
as O
renal O
vascular O
, O
or O
urinary O
tract O
obstruction O
, O
and O
even O
renal O
cancer O
. O
An O
altered O
biodistribution O
may O
provide O
misleading O
information O
that O
can O
either O
mask O
or O
mimic O
certain O
disease O
symptoms O
. O
A O
method O
to O
maximize O
the O
therapeutic O
benefit O
of O
gentamicin B-DRUG
while O
minimizing O
the O
risk O
of O
nephrotoxicity O
and O
the O
appearance O
of O
a O
hot O
kidney O
on O
scintigraphy O
is O
desirable O
. O
Serial O
pharmacokinetic O
dosing O
has O
been O
proposed O
as O
a O
method O
to O
accomplish O
this O
goal O
. O
Therapeutic O
drug O
monitoring O
( O
TDM O
) O
of O
gentamicin B-DRUG
therapy O
, O
and O
bone O
scintigraphy O
employing O
99mTc B-DRUG
- I-DRUG
MDP I-DRUG
as O
the O
radiopharmaceutical B-GROUP
was O
carried O
out O
in O
22 O
patients O
. O
The O
data O
presented O
here O
demonstrate O
that O
with O
serial O
pharmacokinetic O
dosing O
of O
gentamicin B-DRUG
, O
the O
iatrogenic O
alteration O
caused O
by O
gentamicin B-DRUG
therapy O
can O
be O
avoided O
. O

Immunosuppressive B-GROUP
drugs I-GROUP
and O
their O
complications O
. O
Drugs O
that O
suppress O
the O
immune O
system O
are O
widely O
used O
. O
They O
are O
part O
of O
the O
treatment O
of O
patients O
with O
organ O
transplants O
, O
malignancy O
, O
and O
increasingly O
those O
with O
conditions O
such O
as O
psoriasis O
, O
rheumatoid O
arthritis O
, O
and O
liver O
and O
bowel O
disease O
in O
which O
inflammation O
is O
an O
aetiological O
factor O
. O
Because O
of O
the O
broadening O
indications O
for O
immunosuppressive B-GROUP
drugs I-GROUP
, O
and O
the O
prolonged O
survival O
in O
conditions O
for O
which O
they O
are O
being O
used O
, O
many O
patients O
on O
immunosuppression O
are O
now O
cared O
for O
in O
the O
community O
or O
seen O
in O
non O
- O
specialist O
hospitals O
, O
usually O
in O
close O
collaboration O
with O
a O
specialist O
. O
This O
article O
looks O
at O
five O
commonly O
used O
immunosuppressive B-GROUP
drugs I-GROUP
in O
turn O
( O
corticosteroids B-GROUP
, O
cyclosporin B-DRUG
, O
azathioprine B-DRUG
, O
methotrexate B-DRUG
, O
cyclophosphamide B-DRUG
) O
, O
discussing O
the O
main O
, O
non O
- O
infection O
, O
unwanted O
effects O
, O
ways O
to O
avoid O
them O
and O
what O
to O
do O
if O
problems O
arise O
. O
The O
management O
of O
infection O
is O
dealt O
with O
as O
a O
separate O
section O
. O

Interaction O
of O
the O
constituents O
of O
alcoholic O
beverages O
in O
the O
promotion O
of O
liver O
damage O
. O
Little O
has O
been O
studied O
of O
the O
adverse O
effects O
of O
the O
exposure O
of O
the O
liver O
to O
the O
interaction O
of O
ethanol B-DRUG
with O
its O
congeners O
and O
acetaldehyde B-DRUG_N
, O
coexisting O
in O
the O
contents O
of O
alcoholic O
beverages O
. O
Twenty O
four O
male O
Wistar O
rats O
were O
divided O
into O
four O
groups O
. O
Two O
groups O
( O
SH O
/ O
DA O
; O
SH O
/ O
FA O
) O
were O
submitted O
to O
daily O
treatment O
with O
synthetic O
hydroalcoholic O
solutions O
containing O
ethanol B-DRUG
, O
methanol B-DRUG_N
, O
higher O
alcohols B-DRUG_N
and O
acetaldehyde B-DRUG_N
in O
the O
same O
proportions O
as O
those O
found O
in O
most O
common O
distilled O
and O
fermented O
alcoholic O
beverages O
; O
the O
third O
group O
( O
SH O
/ O
EA O
) O
was O
treated O
with O
a O
hydroalcoholic O
solution O
of O
ethanol B-DRUG
; O
the O
fourth O
group O
served O
as O
control O
and O
received O
an O
equivalent O
volume O
of O
an O
isocaloric O
solution O
of O
dextrose B-DRUG
. O
All O
the O
animals O
were O
killed O
at O
the O
end O
of O
the O
9th O
week O
of O
the O
experiment O
. O
The O
ratio O
between O
the O
liver O
weight O
and O
body O
weight O
was O
found O
to O
be O
lower O
in O
the O
treated O
animals O
than O
in O
the O
control O
group O
. O
The O
histology O
of O
the O
liver O
was O
altered O
in O
the O
three O
groups O
which O
were O
submitted O
to O
treatment O
with O
the O
hydroalcoholic O
solutions O
, O
with O
quantitative O
and O
qualitative O
differences O
between O
the O
groups O
. O
These O
results O
suggest O
that O
the O
hepatoxicity O
of O
ethanol B-DRUG
in O
alcoholic O
beverages O
is O
enhanced O
by O
interaction O
with O
its O
congeners O
and O
acetaldehyde B-DRUG_N
; O
they O
also O
suggest O
that O
alcoholic O
beverages O
are O
not O
equivalent O
in O
their O
potential O
to O
cause O
liver O
damage O
. O

Induction O
of O
apoptosis O
in O
breast O
cancer O
cells O
in O
response O
to O
vitamin B-GROUP
D I-GROUP
and O
antiestrogens B-GROUP
. O
1 O
, O
25 B-DRUG
- I-DRUG
Dihydroxycholecalciferol I-DRUG
D3 I-DRUG
( O
1 B-DRUG
, I-DRUG
25 I-DRUG
( I-DRUG
OH I-DRUG
) I-DRUG
2D3 I-DRUG
) O
, O
the O
active O
metabolite O
of O
vitamin B-GROUP
D I-GROUP
, O
is O
a O
potent O
inhibitor O
of O
breast O
cancer O
cell O
growth O
both O
in O
vivo O
and O
in O
vitro O
. O
We O
have O
shown O
that O
MCF O
- O
7 O
cells O
treated O
with O
100 O
nM O
1 B-DRUG
, I-DRUG
25 I-DRUG
( I-DRUG
OH I-DRUG
) I-DRUG
2D3 I-DRUG
exhibit O
characteristic O
apoptotic O
morphology O
( O
pyknotic O
nuclei O
, O
chromatin O
and O
cytoplasmic O
condensation O
, O
nuclear O
matrix O
protein O
reorganization O
) O
within O
48 O
h O
. O
In O
the O
experiments O
reported O
here O
, O
we O
examined O
the O
interactions O
between O
1 B-DRUG
, I-DRUG
25 I-DRUG
( I-DRUG
OH I-DRUG
) I-DRUG
2D3 I-DRUG
and O
the O
antiestrogen B-GROUP
4 B-DRUG_N
- I-DRUG_N
hydroxytamoxifen I-DRUG_N
( O
TAM B-DRUG_N
) O
, O
which O
also O
induces O
apoptosis O
in O
MCF O
- O
7 O
cells O
. O
Our O
data O
suggest O
that O
TAM B-DRUG_N
significantly O
potentiates O
the O
reduction O
in O
cell O
number O
induced O
by O
1 B-DRUG
, I-DRUG
25 I-DRUG
( I-DRUG
OH I-DRUG
) I-DRUG
2D3 I-DRUG
alone O
. O
Combined O
treatment O
with O
1 B-DRUG
, I-DRUG
25 I-DRUG
( I-DRUG
OH I-DRUG
) I-DRUG
2D3 I-DRUG
and O
TAM B-DRUG_N
enhances O
the O
degree O
of O
apoptosis O
assessed O
using O
morphological O
markers O
that O
identify O
chromatin O
and O
nuclear O
matrix O
protein O
condensation O
. O
We O
have O
selected O
a O
subclone O
of O
MCF O
- O
7 O
cells O
resistant O
to O
1 B-DRUG
, I-DRUG
25 I-DRUG
( I-DRUG
OH I-DRUG
) I-DRUG
2D3 I-DRUG
( O
MCF O
- O
7D3Res O
) O
. O
These O
cells O
express O
the O
vitamin O
D O
receptor O
and O
exhibit O
doubling O
times O
comparable O
to O
the O
parental O
MCF O
- O
7 O
cells O
, O
even O
when O
grown O
in O
100 O
mM O
1 B-DRUG
, I-DRUG
25 I-DRUG
( I-DRUG
OH I-DRUG
) I-DRUG
2D3 I-DRUG
. O
Treatment O
of O
both O
parental O
and O
resistant O
MCF O
- O
7 O
cells O
with O
TAM B-DRUG_N
induces O
apoptosis O
and O
clusterin O
. O
These O
data O
emphasize O
that O
apoptosis O
can O
be O
induced O
in O
MCF O
- O
7 O
cells O
either O
by O
activation O
of O
vitamin B-GROUP
- I-GROUP
D I-GROUP
- O
mediated O
signalling O
or O
disruption O
of O
estrogen B-GROUP
- O
dependent O
signalling O
. O

Pharmacokinetic O
profile O
of O
etodolac B-DRUG
in O
special O
populations O
. O
The O
pharmacokinetics O
of O
etodolac B-DRUG
in O
healthy O
normal O
volunteers O
has O
been O
extensively O
studied O
and O
is O
well O
described O
. O
Etodolac B-DRUG
is O
characterised O
by O
a O
high O
oral O
bioavailability O
, O
low O
clearance O
, O
a O
small O
volume O
of O
distribution O
, O
and O
a O
7 O
- O
hour O
half O
- O
life O
. O
It O
is O
essentially O
completely O
metabolised O
, O
therefore O
little O
is O
excreted O
unchanged O
. O
Etodolac B-DRUG
is O
highly O
protein O
bound O
. O
To O
investigate O
the O
effect O
of O
disease O
states O
or O
concomitant O
drug O
administration O
on O
a O
patient O
' O
s O
response O
to O
etodolac B-DRUG
, O
additional O
pharmacokinetic O
studies O
were O
carried O
out O
in O
special O
populations O
. O
Since O
etodolac B-DRUG
has O
a O
well O
- O
defined O
pharmacokinetic O
- O
pharmacodynamic O
relationship O
, O
measurement O
of O
pharmacokinetic O
parameters O
is O
clinically O
relevant O
. O
Data O
from O
studies O
to O
date O
show O
that O
disease O
states O
, O
underlying O
conditions O
, O
and O
concomitantly O
administered O
highly O
protein O
- O
bound O
drugs O
have O
essentially O
no O
effect O
on O
etodolac B-DRUG
pharmacokinetics O
. O
Therefore O
, O
etodolac B-DRUG
can O
generally O
be O
given O
without O
the O
need O
for O
dosage O
modifications O
in O
special O
populations O
such O
as O
uncompromised O
elderly O
patients O
, O
those O
with O
moderate O
renal O
impairment O
, O
and O
patients O
with O
stable O
hepatic O
disease O
. O

Effects O
of O
xanthine B-GROUP
derivatives I-GROUP
in O
a O
light O
/ O
dark O
test O
in O
mice O
and O
the O
contribution O
of O
adenosine O
receptors O
. O
We O
investigated O
the O
effects O
of O
adenosine O
receptor O
antagonists O
, O
caffeine B-DRUG
, O
theophylline B-DRUG
, O
8 B-DRUG_N
- I-DRUG_N
phenyltheophylline I-DRUG_N
, O
and O
8 B-DRUG_N
- I-DRUG_N
cyclopentyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
dipropylxanthine I-DRUG_N
( O
DPCPX B-DRUG_N
) O
, O
in O
a O
light O
/ O
dark O
test O
in O
mice O
. O
All O
antagonists O
decreased O
the O
time O
spent O
in O
the O
light O
zone O
in O
this O
test O
, O
which O
suggested O
that O
these O
compounds O
have O
anxiogenic O
effects O
. O
The O
anxiogenic O
effects O
of O
theophylline B-DRUG
were O
reduced O
by O
pretreatment O
with O
CGS B-DRUG_N
21680 I-DRUG_N
, O
an O
A2 O
- O
selective O
agonist O
, O
but O
not O
by O
N6 B-DRUG_N
- I-DRUG_N
cyclopentyladenosine I-DRUG_N
( O
CPA B-DRUG_N
) O
, O
an O
A1 O
- O
selective O
agonist O
. O
However O
, O
the O
antagonism O
of O
the O
theophylline B-DRUG
- O
induced O
anxiogenic O
effects O
by O
CGS21680 B-DRUG_N
was O
only O
observed O
in O
the O
time O
spent O
in O
the O
light O
zone O
, O
and O
DPCPX B-DRUG_N
- O
induced O
anxiogenic O
effects O
were O
neither O
reversed O
by O
CGS B-DRUG
21680 I-DRUG
nor O
by O
CPA B-DRUG_N
. O
Finally O
, O
it O
is O
notable O
that O
xanthine O
- O
derived O
adenosine O
antagonists O
tested O
here O
commonly O
showed O
anxiogenic O
effects O
in O
the O
light O
/ O
dark O
test O
in O
mice O
. O
It O
is O
suggested O
that O
there O
is O
a O
minor O
contribution O
of O
adenosine O
receptors O
to O
these O
effects O
, O
although O
theophylline B-DRUG
- O
induced O
anxiogenic O
effects O
were O
antagonized O
by O
an O
A2 O
receptor O
agonist O
. O

[ O
The O
effect O
of O
sandimmune B-BRAND
on O
the O
activity O
of O
mixed O
- O
function O
mono O
- O
oxidases O
in O
the O
liver O
microsomes O
] O
The O
effects O
of O
the O
immunodepressant B-GROUP
- O
- O
the O
drug O
sandimmune B-BRAND
- O
- O
on O
hepatic O
microsomal O
monooxygenase O
activities O
were O
studied O
. O
The O
agent O
was O
found O
to O
produce O
some O
inhibiting O
activity O
against O
hepatic O
microsomal O
7 O
- O
ethoxycoumarine O
deethylase O
in O
male O
Wistar O
rats O
in O
vitro O
and O
in O
vivo O
experiments O
. O
When O
given O
in O
a O
dose O
of O
50 O
mg O
/ O
kg O
, O
sandimmune B-BRAND
produced O
no O
statistically O
significant O
effect O
on O
the O
duration O
of O
hexanal O
- O
induced O
sleep O
in O
mice O
. O
The O
findings O
suggest O
that O
the O
agent O
has O
slight O
effects O
on O
the O
tested O
activities O
. O

[ O
The O
effect O
of O
cimetidine B-DRUG
on O
the O
renal O
excretion O
of O
verografin B-DRUG
and O
iodamide B-DRUG
in O
dogs O
] O
The O
intravenous O
injection O
of O
cimetidine B-DRUG
in O
a O
dose O
of O
20 O
mg O
/ O
kg O
enhanced O
verografine B-DRUG
and O
iodamide B-DRUG
excretion O
in O
chronic O
canine O
experiments O
. O
The O
higher O
verografine B-DRUG
and O
iodamide B-DRUG
excretion O
was O
due O
to O
their O
increased O
renal O
tubular O
secretion O
. O
In O
dogs O
, O
cimetidine B-DRUG
unchanged O
the O
secretion O
of O
cardiotrast B-DRUG
, O
a O
test O
agent O
for O
anionic O
transport O
. O
Possible O
extrarenal O
mechanisms O
of O
action O
of O
cimetidine B-DRUG
on O
verografine B-DRUG
and O
iodamide B-DRUG
transport O
were O
also O
examined O
. O

[ O
Hippocampus O
as O
interaction O
sites O
between O
cerebral O
memory O
systems O
] O

Most O
of O
the O
current O
theories O
assume O
that O
there O
are O
multiple O
forms O
of O
memory O
that O
are O
supported O
by O
separate O
brain O
systems O
and O
have O
different O
characteristics O
. O
Animals O
studies O
on O
the O
various O
dual O
- O
memory O
theories O
have O
been O
carried O
out O
mainly O
on O
the O
basis O
of O
hippocampal O
system O
function O
. O
Specifically O
, O
they O
have O
focused O
on O
aspects O
of O
learning O
and O
memory O
that O
are O
impaired O
( O
vs O
. O
spared O
) O
by O
lesions O
of O
the O
hippocampal O
formation O
. O
However O
, O
there O
are O
several O
instances O
in O
the O
animal O
literature O
showing O
that O
hippocampal O
lesions O
actually O
produced O
enhanced O
learning O
and O
memory O
function O
. O
Moreover O
, O
the O
acquisition O
of O
tasks O
that O
are O
facilitated O
by O
hippocampal O
lesions O
( O
or O
dysfunction O
) O
is O
nevertheless O
associated O
, O
in O
intact O
subjects O
, O
with O
specific O
neurobiological O
alterations O
in O
the O
hippocampus O
. O
This O
problem O
has O
been O
analysed O
using O
two O
different O
tasks O
in O
mice O
: O
a O
bar O
- O
press O
conditioning O
and O
a O
spatial O
discrimination O
task O
. O
Results O
showed O
that O
, O
depending O
on O
the O
task O
considered O
, O
the O
same O
pharmacological O
treatment O
produced O
either O
a O
facilitation O
or O
an O
impairment O
of O
acquisition O
. O
Moreover O
, O
each O
task O
induced O
significant O
alterations O
in O
hippocampal O
adenylate O
cyclase O
activity O
but O
in O
opposite O
directions O
. O
Together O
with O
previous O
findings O
, O
these O
results O
suggest O
that O
the O
hippocampus O
is O
involved O
in O
both O
the O
so O
- O
called O
" O
hippocampal O
- O
dependent O
" O
" O
hippocampal O
- O
independent O
" O
forms O
of O
memory O
. O
It O
is O
postulated O
that O
some O
of O
the O
observed O
training O
- O
induced O
neurobiological O
alterations O
might O
reflect O
the O
interaction O
between O
two O
( O
or O
more O
) O
competing O
memory O
systems O
at O
the O
hippocampal O
level O
. O
Thus O
, O
in O
addition O
to O
its O
proposed O
specific O
information O
processing O
functions O
( O
i O
. O
e O
. O
, O
relational O
) O
, O
the O
hippocampus O
would O
play O
a O
role O
in O
addressing O
information O
to O
the O
brain O
memory O
system O
that O
, O
in O
a O
given O
situation O
, O
has O
the O
best O
adaptive O
value O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Magnesium B-DRUG
and O
therapeutics O
. O
Two O
different O
types O
of O
therapy O
with O
magnesium B-DRUG
are O
used O
: O
physiological O
oral O
magnesium B-DRUG
supplementation O
which O
is O
totally O
atoxic O
since O
it O
palliates O
magnesium B-DRUG
deficiencies O
by O
simply O
normalizing O
the O
magnesium B-DRUG
intake O
and O
pharmacological O
magnesium B-DRUG
therapy O
which O
may O
induce O
toxicity O
since O
it O
creates O
iatrogenic O
magnesium B-DRUG
overload O
. O
Primary O
and O
secondary O
magnesium B-DRUG
deficiencies O
constitute O
the O
sole O
indication O
of O
physiological O
oral O
magnesium B-DRUG
therapy O
. O
It O
is O
therefore O
necessary O
to O
be O
well O
acquainted O
with O
the O
clinical O
and O
paraclinical O
pattern O
of O
magnesium B-DRUG
deficit O
and O
to O
discriminate O
between O
magnesium B-DRUG
deficiency O
due O
to O
an O
insufficient O
magnesium B-DRUG
intake O
which O
only O
requires O
oral O
physiological O
supplementation O
and O
magnesium B-DRUG
depletion O
related O
to O
a O
dysregulation O
of O
the O
control O
mechanisms O
of O
magnesium B-DRUG
status O
which O
requires O
more O
or O
less O
specific O
regulation O
of O
its O
causal O
dysregulation O
. O
Physiological O
oral O
magnesium B-DRUG
load O
constitutes O
the O
best O
tool O
for O
diagnosis O
of O
magnesium B-DRUG
deficiency O
and O
the O
first O
step O
of O
its O
treatment O
. O
Physiological O
oral O
magnesium B-DRUG
supplementation O
( O
5 O
mg O
/ O
kg O
/ O
day O
) O
is O
easy O
and O
can O
be O
carried O
out O
in O
the O
diet O
or O
with O
magnesium B-DRUG
salts I-DRUG
, O
with O
practically O
only O
one O
contra O
- O
indication O
: O
overt O
renal O
failure O
. O
Specific O
and O
aspecific O
treatments O
of O
magnesium B-DRUG
depletion O
are O
tricky O
using O
for O
example O
magnesium B-GROUP
sparing I-GROUP
diuretics I-GROUP
, O
pharmacological O
doses O
of O
vitamin B-DRUG
B6 I-DRUG
, O
physiological O
doses O
of O
vitamin B-GROUP
D I-GROUP
and O
of O
selenium B-DRUG
. O
In O
order O
to O
use O
the O
pharmacological O
properties O
of O
induced O
therapeutic O
hypermagnesaemia O
, O
high O
oral O
doses O
of O
magnesium B-DRUG
( O
> O
10 O
mg O
/ O
kg O
/ O
day O
) O
are O
advisable O
for O
chronic O
indications O
and O
the O
parenteral O
route O
is O
suitable O
for O
acute O
indications O
. O
There O
are O
3 O
types O
of O
indications O
: O
specific O
( O
for O
the O
treatment O
of O
some O
forms O
of O
magnesium B-DRUG
deficit O
i O
. O
e O
. O
acute O
) O
, O
pharmacological O
( O
i O
. O
e O
. O
without O
alterations O
of O
magnesium B-DRUG
status O
) O
and O
mixed O
- O
- O
pharmacological O
and O
aetiopathogenic O
- O
- O
( O
for O
example O
complications O
of O
chronic O
alcoholism O
) O
. O
Today O
pharmacological O
magnesium B-DRUG
therapy O
mainly O
concerns O
the O
obstetrical O
, O
cardiological O
and O
anaesthesiological O
fields O
. O
The O
main O
indications O
are O
eclampsia O
, O
some O
dysrhythmias O
( O
torsades O
de O
pointe O
particularly O
) O
and O
myocardial O
ischaemias O
. O
But O
it O
is O
now O
difficult O
to O
situate O
the O
exact O
place O
of O
the O
pharmacological O
indications O
of O
magnesium B-DRUG
. O
Magnesium B-DRUG

infusions O
can O
only O
be O
envisaged O
in O
intensive O
care O
units O
with O
careful O
monitoring O
of O
pulse O
, O
arterial O
pressure O
, O
deep O
tendon O
reflexes O
, O
hourly O
diuresis O
, O
electrocardiogram O
and O
respiratory O
recordings O
. O
High O
oral O
magnesium B-DRUG
doses O
besides O
their O
laxative O
action O
may O
bring O
latent O
complications O
which O
may O
reduce O
lifespan O
. O
There O
may O
remain O
some O
indications O
of O
the O
laxative O
and O
antacid O
properties O
of O
non O
soluble O
magnesium B-DRUG
, O
particularly O
during O
intermittent O
haemodialysis O
. O
Lastly O
local O
use O
of O
the O
mucocutaneous O
and O
cytoprotective O
properties O
of O
magnesium B-DRUG
is O
still O
valid O
, O
in O
cardioplegic B-DRUG
solutions I-DRUG
and O
for O
preservation O
of O
transplants O
particularly O
. O

Interaction O
between O
glycine B-DRUG
and O
glutamate B-DRUG
in O
the O
development O
of O
spontaneous O
motility O
in O
chick O
embryos O
. O
In O
this O
study O
we O
investigated O
whether O
also O
glycine B-DRUG
fulfils O
the O
function O
as O
co O
- O
activator O
in O
glutamatergic O
activation O
of O
NMDA O
receptors O
in O
the O
neuronal O
apparatus O
of O
spontaneous O
motility O
in O
chick O
embryos O
. O
The O
successive O
application O
of O
glycine B-DRUG
( O
5 O
or O
10 O
mg O
/ O
kg O
egg O
weight O
( O
e O
. O
w O
. O
) O
and O
glutamate B-DRUG
( O
15 O
mg O
/ O
kg O
e O
. O
w O
. O
) O
The O
successive O
application O
of O
glycine B-DRUG
( O
5 O
or O
10 O
mg O
/ O
kg O
egg O
weight O
( O
e O
. O
w O
. O
) O
and O
glutamate B-DRUG
( O
15 O
mg O
/ O
kg O
e O
. O
w O
. O
) O
in O
a O
10 O
min O
interval O
significantly O
increased O
the O
activation O
of O
spontaneous O
motility O
of O
17 O
- O
day O
- O
old O
chick O
embryos O
in O
comparison O
with O
the O
effect O
of O
glutamate B-DRUG
alone O
. O
This O
effect O
did O
not O
depend O
on O
the O
order O
of O
application O
of O
the O
drugs O
. O
In O
13 O
- O
day O
- O
old O
embryos O
, O
glycine B-DRUG
was O
ineffective O
in O
both O
doses O
. O
It O
is O
concluded O
from O
these O
results O
that O
the O
modulatory O
effect O
of O
glycine B-DRUG
is O
evidently O
a O
later O
developmental O
acquisition O
( O
after O
day O
15 O
of O
incubation O
) O
in O
the O
embryogenesis O
of O
NMDA O
- O
ergic O
activation O
of O
spontaneous O
motility O
in O
chick O
embryos O
similarly O
as O
glycinergic O
inhibition O
. O

Evidence O
for O
reduction O
of O
norepinephrine B-DRUG
uptake O
sites O
in O
the O
failing O
human O
heart O
. O
OBJECTIVES O
. O
This O
study O
investigated O
the O
role O
of O
neuronal O
uptake O
of O
norepinephrine B-DRUG
( O
uptake O
- O
1 O
) O
in O
human O
heart O
failure O
as O
a O
local O
factor O
for O
altering O
concentrations O
of O
norepinephrine O
at O
the O
cardiac O
myocyte O
membranes O
. O
BACKGROUND O
. O
Several O
beta O
- O
adrenergic O
neuroeffector O
defects O
occur O
in O
heart O
failure O
. O
Whether O
an O
alteration O
in O
norepinephrine B-DRUG
uptake O
- O
1 O
occurs O
is O
still O
unresolved O
. O
METHODS O
. O
The O
role O
of O
norepinephrine B-DRUG
uptake O
- O
1 O
was O
studied O
in O
electrically O
stimulated O
( O
1 O
Hz O
, O
37 O
degrees O
C O
) O
human O
ventricular O
cardiac O
preparations O
and O
isolated O
myocardial O
membranes O
. O
RESULTS O
. O
The O
effectiveness O
of O
norepinephrine B-DRUG
in O
increasing O
the O
force O
of O
contraction O
was O
decreased O
in O
relation O
to O
the O
degree O
of O
heart O
failure O
. O
In O
contrast O
, O
the O
potency O
of O
norepinephrine B-DRUG
was O
increased O
in O
failing O
hearts O
( O
New O
York O
Heart O
Association O
functional O
class O
IV O
) O
in O
relation O
to O
the O
concentrations O
producing O
50 O
% O
of O
the O
maximal O
effect O
( O
EC50 O
) O
. O
The O
EC50 O
values O
for O
isoproterenol B-DRUG
, O
which O
is O
not O
a O
substrate O
for O
norepinephrine B-DRUG
uptake O
- O
1 O
, O
were O
reduced O
in O
myocardium O
in O
functional O
classes O
II O
to O
III O
and O
IV O
compared O
with O
those O
in O
nonfailing O
myocardium O
. O
The O
uptake O
inhibitors O
cocaine B-DRUG
and O
desipramine B-DRUG
( O
3 O
mumol O
/ O
liter O
) O
potentiated O
the O
positive O
inotropic O
effects O
of O
norepinephrine B-DRUG
in O
nonfailing O
myocardium O
( O
p O
< O
0 O
. O
05 O
) O
but O
not O
in O
functional O
class O
IV O
myocardium O
. O
Radioligand O
binding O
experiments O
using O
the O
uptake O
inhibitor O
hydrogen O
- O
3 O
mazindol B-DRUG
revealed O
a O
significant O
decrease O
by O
approximately O
30 O
% O
in O
norepinephrine B-DRUG
uptake O
- O
1 O
carrier O
density O
in O
functional O
classes O
II O
to O
III O
and O
IV O
myocardium O
versus O
nonfailing O
myocardium O
( O
p O
< O
0 O
. O
05 O
) O
. O
CONCLUSIONS O
. O
In O
human O
heart O
failure O
, O
there O
is O
a O
presynaptic O
defect O
in O
the O
sympathetic O
nervous O
system O
, O
leading O
to O
reduced O
uptake O
- O
1 O
activity O
. O
This O
defect O
in O
the O
failing O
heart O
can O
be O
mimicked O
by O
the O
effects O
of O
uptake O
blocking O
agents O
, O
such O
as O
cocaine B-DRUG
and O
desipramine B-DRUG
, O
in O
the O
nonfailing O
heart O
only O
. O
Compromised O
norepinephrine B-DRUG
uptake O
- O
1 O
in O
functional O
class O
IV O

cannot O
be O
further O
increased O
by O
cocaine B-DRUG
and O
desipramine B-DRUG
. O
The O
pathophysiologic O
consequences O
could O
be O
an O
increased O
synaptic O
concentration O
of O
norepinephrine B-DRUG
predisposing O
to O
adenylyl O
cyclase O
desensitization O
. O

[ O
A O
pharmacological O
analysis O
of O
the O
effect O
of O
angiotensin B-DRUG_N
on O
stimulated O
gastric O
secretion O
] O
Chronic O
experiments O
on O
dogs O
with O
gastric O
fistulas O
were O
carried O
out O
to O
study O
the O
influence O
of O
angiotensin B-DRUG_N
1 I-DRUG_N
and O
angiotensin B-DRUG_N
2 I-DRUG_N
on O
pentagastrin B-DRUG
- O
and O
histamine B-DRUG
- O
induced O
gastric O
acid O
secretion O
. O
It O
was O
established O
that O
both O
angiotensins O
inhibited O
gastric O
acid O
secretion O
stimulated O
by O
pentagastrin B-DRUG
but O
not O
by O
histamine B-DRUG
. O
Comparative O
analysis O
of O
the O
effects O
of O
stimulation O
and O
inhibition O
of O
cholino O
- O
and O
adrenoreceptors O
on O
this O
inhibitory O
action O
of O
angiotensins B-DRUG_N
suggested O
the O
mediation O
of O
angiotensin B-DRUG_N
influence O
through O
the O
modulation O
of O
cholinergic O
reactions O
of O
parietal O
cells O
in O
the O
stomach O
. O

Interaction O
of O
gentamycin B-DRUG
and O
atracurium B-DRUG
in O
anaesthetised O
horses O
. O
Evoked O
hind O
limb O
digital O
extensor O
tension O
( O
hoof O
twitch O
) O
was O
maintained O
at O
40 O
% O
of O
baseline O
for O
1 O
h O
by O
atracurium B-DRUG
infusion O
in O
7 O
horses O
anaesthetised O
with O
halothane B-DRUG
. O
After O
1 O
h O
, O
atracurium B-DRUG
was O
discontinued O
and O
hoof O
twitch O
allowed O
to O
recover O
to O
75 O
% O
. O
Atracurium B-DRUG
was O
again O
given O
by O
infusion O
to O
maintain O
40 O
% O
twitch O
for O
a O
second O
hour O
, O
then O
2 O
mg O
gentamycin B-DRUG
/ O
kg O
bwt O
were O
given O
i O
. O
v O
. O
Atracurium B-DRUG
infusion O
was O
continued O
for O
a O
third O
hour O
, O
and O
then O
hoof O
twitch O
was O
again O
allowed O
to O
recover O
spontaneously O
to O
75 O
% O
. O
Gentamycin B-DRUG
reduced O
twitch O
strength O
from O
40 O
+ O
/ O
- O
1 O
% O
( O
mean O
+ O
/ O
- O
sem O
) O
to O
29 O
+ O
/ O
- O
4 O
% O
within O
7 O
. O
0 O
+ O
/ O
- O
1 O
. O
5 O
min O
( O
P O
= O
0 O
. O
02 O
) O
. O
Twitch O
gradually O
returned O
to O
pre O
- O
gentamycin B-DRUG
strength O
over O
the O
course O
of O
the O
next O
hour O
. O
Recovery O
of O
hoof O
twitch O
from O
50 O
% O
to O
75 O
% O
took O
7 O
. O
7 O
+ O
/ O
- O
0 O
. O
7 O
min O
for O
atracurium B-DRUG
alone O
and O
11 O
. O
5 O
+ O
/ O
- O
2 O
. O
7 O
min O
for O
atracurium B-DRUG
plus O
gentamycin B-DRUG
( O
P O
= O
0 O
. O
03 O
) O
. O
Recovery O
from O
50 O
% O
twitch O
to O
75 O
% O
fade O
recovery O
took O
13 O
. O
8 O
+ O
/ O
- O
0 O
. O
8 O
min O
for O
atracurium B-DRUG
alone O
and O
13 O
. O
7 O
+ O
/ O
- O
1 O
. O
2 O
min O
for O
atracurium B-DRUG
plus O
gentamycin B-DRUG
. O
At O
75 O
% O
recovery O
of O
fade O
, O
hoof O
twitch O
was O
87 O
+ O
/ O
- O
3 O
% O
for O
atracurium B-DRUG
alone O
and O
82 O
+ O
/ O
- O
4 O
% O
for O
atracurium B-DRUG
plus O
gentamycin B-DRUG
. O
Reversal O
of O
the O
block O
with O
edrophonium B-DRUG
and O
subsequent O
recovery O
of O
the O
horses O
from O
anaesthesia O
were O
uneventful O
. O
It O
was O
concluded O
that O
, O
although O
gentamycin B-DRUG
did O
augment O
the O
neuromuscular O
blockade O
of O
atracurium B-DRUG
, O
the O
effect O
was O
minimal O
. O

Anticoagulants B-GROUP
. O
Treatment O
plans O
for O
patients O
taking O
anticoagulants B-GROUP
can O
become O
complicated O
. O
Anticoagulants B-GROUP
predispose O
a O
patient O
to O
bleeding O
problems O
. O
Many O
drugs O
used O
in O
dentistry O
cannot O
be O
taken O
concomitantly O
with O
these O
medications O
. O

Administration O
of O
lithium B-DRUG
prophylaxis O
. O
Successful O
prophylaxis O
of O
manic O
- O
depressive O
disorder O
requires O
more O
than O
the O
prescription O
of O
lithium B-DRUG
carbonate I-DRUG
. O
The O
administrative O
arrangements O
in O
an O
area O
of O
Scotland O
were O
accompanied O
by O
a O
300 O
% O
increase O
in O
the O
frequency O
of O
admissions O
for O
mania O
, O
whereas O
in O
an O
area O
of O
the O
West O
Midlands O
, O
a O
large O
decrease O
was O
achieved O
. O

[ O
Multiple O
occupational O
exposure O
to O
solvents O
] O

This O
article O
review O
papers O
published O
over O
the O
last O
20 O
years O
on O
multiple O
occupational O
exposure O
to O
solvents O
. O
At O
low O
- O
levels O
of O
exposure O
the O
toxicokinetic O
interferences O
between O
solvents O
have O
generally O
not O
been O
observed O
in O
man O
and O
presumably O
a O
threshold O
limit O
exists O
. O
Conversely O
, O
at O
exposure O
levels O
close O
to O
the O
" O
limit O
values O
" O
metabolic O
interference O
has O
sometimes O
been O
observed O
and O
the O
behaviour O
of O
the O
biological O
indicators O
differs O
from O
what O
would O
be O
expected O
. O
Toxicodynamic O
interference O
between O
solvents O
can O
give O
rise O
to O
additive O
, O
potentiation O
, O
synergistic O
, O
antagonistic O
effects O
. O
For O
the O
identification O
of O
" O
limit O
values O
" O
, O
it O
has O
generally O
been O
suggested O
in O
the O
literature O
that O
the O
possible O
effects O
deriving O
from O
multiple O
exposure O
be O
considered O
as O
additive O
. O
However O
, O
numerous O
potentiation O
effects O
have O
frequently O
been O
reported O
for O
combined O
exposure O
to O
substances O
of O
widespread O
use O
. O
In O
this O
paper O
lists O
of O
multiple O
exposure O
in O
which O
the O
doses O
of O
the O
substances O
, O
the O
types O
of O
interferences O
and O
the O
behaviour O
of O
the O
biological O
levels O
have O
been O
drawn O
up O
and O
proposed O
as O
a O
tool O
for O
easy O
consultation O
. O

Determinants O
of O
cellular O
sensitivity O
to O
topoisomerase B-GROUP
- I-GROUP
targeting I-GROUP
antitumor I-GROUP
drugs I-GROUP
. O
It O
is O
now O
clear O
that O
topoisomerase O
activity O
level O
is O
an O
important O
determinant O
of O
sensitivity O
to O
topo O
drugs O
. O
The O
regulation O
of O
topoisomerases O
is O
no O
doubt O
complex O
and O
multifaceted O
and O
is O
probably O
accomplished O
through O
redundancy O
at O
many O
control O
levels O
. O
The O
mechanism O
( O
s O
) O
of O
altered O
topo O
I O
expression O
in O
certain O
tumor O
types O
is O
unknown O
, O
but O
may O
be O
related O
to O
the O
central O
importance O
of O
topoisomerases O
in O
proliferating O
cell O
functions O
( O
transcription O
, O
replication O
, O
etc O
. O
) O
, O
and O
the O
aberrant O
and O
chronic O
activation O
of O
these O
functions O
as O
a O
result O
of O
specific O
tumorigenic O
alterations O
. O
Small O
differences O
in O
sensitivity O
to O
chemotherapy O
can O
have O
a O
dramatic O
effect O
on O
cure O
rates O
, O
and O
therefore O
subtle O
cell O
type O
- O
specific O
differences O
may O
be O
important O
determinants O
of O
drug O
sensitivity O
. O
Whether O
abnormal O
topoisomerase O
quantity O
and O
specific O
activity O
are O
associated O
with O
resistance O
or O
sensitivity O
to O
topoisomerase O
- O
targeted O
chemotherapy O
in O
the O
clinic O
is O
now O
being O
studied O
. O
Determinants O
downstream O
of O
cleavable O
complex O
formation O
that O
affect O
the O
sensitivity O
of O
tumor O
versus O
normal O
cells O
to O
topo O
drugs O
in O
particular O
and O
DNA O
- O
damaging O
agents O
in O
general O
are O
little O
known O
. O
The O
goal O
of O
enhancing O
selective O
tumor O
cell O
killing O
relative O
to O
the O
normal O
cells O
that O
are O
dose O
limiting O
may O
be O
achieved O
either O
by O
overcoming O
tumor O
cell O
resistance O
or O
by O
protecting O
normal O
cells O
. O
Both O
of O
these O
strategies O
will O
become O
more O
feasible O
as O
specific O
molecular O
differences O
between O
tumor O
and O
normal O
cells O
are O
being O
rapidly O
identified O
and O
new O
combination O
therapies O
that O
take O
advantage O
of O
these O
differences O
are O
being O
designed O
and O
tested O
. O

Acid O
- O
catalyzed O
ethanolysis O
of O
temazepam B-DRUG
in O
anhydrous O
and O
aqueous O
ethanol B-DRUG
solutions O
. O
The O
benzodiazepines B-GROUP
are O
a O
family O
of O
anxiolytic B-GROUP
and O
hypnotic B-GROUP
drugs I-GROUP
. O
When O
taken O
concurrently O
with O
ethanol B-DRUG
, O
a O
pharmacological O
interaction O
may O
occur O
, O
potentiating O
the O
central O
nervous O
system O
depression O
produced O
by O
either O
drug O
. O
In O
addition O
to O
this O
pharmacological O
interaction O
, O
this O
report O
describes O
a O
novel O
chemical O
reaction O
between O
temazepam B-DRUG
( O
a O
benzodiazepine B-GROUP
) O
and O
ethanol B-DRUG
under O
acidic O
conditions O
similar O
to O
those O
found O
in O
vivo O
, O
resulting O
in O
a O
3 O
- O
ethoxylated O
product O
. O
Optimal O
conditions O
, O
kinetics O
, O
equilibrium O
, O
and O
the O
mechanism O
of O
this O
acid O
- O
catalyzed O
ethanolysis O
are O
reported O
. O
The O
results O
raise O
the O
possibility O
that O
the O
ethanolysis O
reaction O
may O
occur O
in O
the O
stomach O
of O
people O
who O
consume O
alcohol B-DRUG
and O
3 B-GROUP
- I-GROUP
hydroxy I-GROUP
- I-GROUP
1 I-GROUP
, I-GROUP
4 I-GROUP
- I-GROUP
benzodiazepine I-GROUP
on O
a O
regular O
basis O
. O
The O
acid O
- O
catalyzed O
ethanol B-DRUG
- O
drug O
reaction O
is O
a O
relatively O
unexplored O
area O
and O
may O
alter O
the O
pharmacological O
action O
of O
some O
drugs O
. O

